olfaction	O
in	O
neurodegenerative	O
disorder	O

there	O
has	O
been	O
an	O
increase	O
of	O
interest	O
in	O
olfactory	O
dysfunction	O
since	O
it	O
was	O
realised	O
that	O
anosmia	B-OLFACTORY
was	O
a	O
common	O
feature	O
of	O
idiopathic	O
parkinsons	O
disease	O
pd	O
and	O
alzheimertype	O
dementia	B-NEURODEGENERATIVE
ad	I-NEURODEGENERATIVE

it	O
is	O
an	O
intriguing	O
possibility	O
that	O
the	O
first	O
sign	O
of	O
a	O
disorder	O
hitherto	O
regarded	O
as	O
one	O
of	O
movement	O
or	O
cognition	O
may	O
be	O
that	O
of	O
disturbed	O
smell	O
sense	O

in	O
this	O
review	O
of	O
pd	O
parkinsonian	O
syndromes	O
essential	O
tremor	O
ad	B-NEURODEGENERATIVE
motor	O
neurone	O
disease	O
mnd	O
and	O
huntingtons	O
chorea	O
hc	O
the	O
following	O
observations	O
are	O
made	O
1	O

olfactory	O
dysfunction	O
is	O
frequent	O
and	O
often	O
severe	O
in	O
pd	O
and	O
ad	B-NEURODEGENERATIVE
2	O

normal	O
smell	O
identification	O
in	O
pd	O
is	O
rare	O
and	O
should	O
prompt	O
review	O
of	O
diagnosis	O
unless	O
the	O
patient	B-PERCIEVER
is	O
female	B-PERCIEVER
with	O
tremordominant	O
disease	O
3	O

anosmia	B-OLFACTORY
in	O
suspected	O
progressive	O
supranuclear	O
palsy	O
and	O
corticobasal	O
degeneration	O
is	O
atypical	O
and	O
should	O
likewise	O
provoke	O
diagnostic	O
review	O
4	O

hyposmia	B-OLFACTORY
is	O
an	O
early	O
feature	O
of	O
pd	O
and	O
ad	B-NEURODEGENERATIVE
and	O
may	O
precede	O
motor	O
and	O
cognitive	O
signs	O
respectively	O
5	O

subjects	B-PERCIEVER
with	O
anosmia	B-OLFACTORY
and	O
one	O
apoe4	O
allele	O
have	O
an	O
approximate	O
5fold	O
increased	O
risk	O
of	O
later	O
ad	B-NEURODEGENERATIVE
6	O

impaired	O
smell	O
sense	O
is	O
seen	O
in	O
some	O
patients	B-PERCIEVER
at	O
50	O
risk	O
of	O
parkinsonism	O
7	O

smell	O
testing	O
in	O
hc	O
and	O
mnd	O
where	O
abnormality	O
may	O
be	O
found	O
is	O
not	O
likely	O
to	O
be	O
of	O
clinical	O
value	O
and	O
8	O

biopsy	O
of	O
olfactory	O
nasal	O
neurons	O
shows	O
nonspecific	O
changes	O
in	O
pd	O
and	O
ad	B-NEURODEGENERATIVE
and	O
at	O
present	O
will	O
not	O
aid	O
diagnosis	O

olfaction	O
in	O
neurodegenerative	O
disorder	O

there	O
has	O
been	O
gradual	O
increase	O
of	O
interest	O
in	O
olfactory	O
dysfunction	O
since	O
it	O
was	O
realised	O
that	O
anosmia	B-OLFACTORY
was	O
a	O
common	O
feature	O
of	O
idiopathic	O
parkinsons	O
disease	O
ipd	O
and	O
alzheimertype	O
dementia	B-NEURODEGENERATIVE

it	O
is	O
an	O
intriguing	O
observation	O
that	O
a	O
premonitory	O
sign	O
of	O
a	O
disorder	O
hitherto	O
regarded	O
as	O
one	O
of	O
movement	O
or	O
cognition	O
may	O
be	O
that	O
of	O
disturbed	O
sense	O
of	O
smell	O

in	O
this	O
review	O
of	O
aging	O
ipd	O
parkinsonian	O
syndromes	O
tremor	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE
motor	O
neuron	O
disease	O
mnd	O
huntingtons	O
chorea	O
hc	O
and	O
inherited	O
ataxia	O
the	O
following	O
observations	O
are	O
made	O
1	O
olfactory	O
senescence	O
starts	O
at	O
about	O
the	O
age	O
of	O
36	O
years	O
in	O
both	O
sexes	O
and	O
accelerates	O
with	O
advancing	O
years	O
involving	O
pleasant	O
odours	O
preferentially	O
2	O
olfactory	O
dysfunction	O
is	O
nearuniversal	O
early	O
and	O
often	O
severe	O
in	O
ipd	O
and	O
ad	B-NEURODEGENERATIVE
developing	O
before	O
any	O
movement	O
or	O
cognitive	O
disorder	O
3	O
normal	O
smell	O
identification	O
in	O
ipd	O
is	O
rare	O
and	O
should	O
prompt	O
review	O
of	O
diagnosis	O
unless	O
the	O
patient	B-PERCIEVER
is	O
female	B-PERCIEVER
with	O
tremordominant	O
disease	O
4	O
anosmia	B-OLFACTORY
in	O
suspected	O
progressive	O
supranuclear	O
palsy	O
and	O
corticobasal	O
degeneration	O
is	O
atypical	O
and	O
should	O
likewise	O
provoke	O
diagnostic	O
review	O
5	O
subjects	B-PERCIEVER
with	O
hyposmia	B-OLFACTORY
and	O
one	O
apoe4	O
allele	O
have	O
an	O
approximate	O
5fold	O
increased	O
risk	O
of	O
later	O
ad	B-NEURODEGENERATIVE
6	O
impaired	O
sense	O
of	O
smell	O
may	O
be	O
seen	O
in	O
some	O
patients	B-PERCIEVER
at	O
50	O
risk	O
of	O
parkinsonism	O
and	O
possibly	O
in	O
patients	B-PERCIEVER
with	O
unexplained	O
hyposmia	B-OLFACTORY
7	O
smell	O
testing	O
in	O
hc	O
and	O
mnd	O
where	O
abnormality	O
may	O
be	O
found	O
is	O
not	O
likely	O
to	O
be	O
of	O
clinical	O
value	O
and	O
8	O
biopsy	O
of	O
olfactory	O
nasal	O
neurons	O
reveals	O
nonspecific	O
changes	O
in	O
ipd	O
and	O
ad	B-NEURODEGENERATIVE
and	O
at	O
present	O
will	O
not	O
aid	O
diagnosis	O

olfaction	O
deterioration	O
in	O
cognitive	O
disorders	O
in	O
the	O
elderly	O

background	O
parkinsons	O
and	O
alzheimers	O
diseases	O
are	O
widespread	O
neurodegenerative	O
pathologies	O

parkinsons	O
disease	O
affects	O
about	O
1	O
of	O
the	O
population	O
over	O
the	O
age	O
of	O
65	O
years	O
while	O
alzheimer	O
is	O
considered	O
the	O
most	O
common	O
cause	O
of	O
dementia	B-NEURODEGENERATIVE
with	O
an	O
annual	O
incidence	O
of	O
1	O
in	O
persons	O
aged	O
65	O
years	O

it	O
has	O
been	O
demonstrated	O
that	O
both	O
these	O
neurodegenerative	O
diseases	O
are	O
associated	O
with	O
smell	O
dysfunction	O

aim	O
the	O
aim	O
of	O
the	O
present	O
review	O
is	O
to	O
describe	O
briefly	O
modern	O
olfactory	O
evaluation	O
tools	O
as	O
well	O
as	O
the	O
importance	O
of	O
olfactory	O
sensitivity	O
screening	O
in	O
the	O
elderly	O
especially	O
where	O
cognitive	O
disorders	O
such	O
as	O
alzheimers	O
or	O
parkinsons	O
diseases	O
are	O
suspected	O

methods	O
a	O
brief	O
literature	O
review	O
focusing	O
on	O
the	O
basic	O
principle	O
of	O
smell	O
tests	O
is	O
illustrated	O
together	O
with	O
their	O
application	O
in	O
elderly	O
patients	B-PERCIEVER
affected	O
by	O
cognitive	O
disorders	O
in	O
particular	O
parkinsons	O
and	O
alzheimers	O
diseases	O

resultsconclusions	O
alzheimers	O
and	O
parkinsons	O
diseases	O
are	O
both	O
neurodegenerative	O
disorders	O
typically	O
found	O
in	O
the	O
elderly	O

as	O
both	O
diseases	O
are	O
characterized	O
by	O
the	O
early	O
presence	O
of	O
dysosmia	O
simple	O
validated	O
smell	O
tests	O
could	O
very	O
well	O
help	O
clinicians	O
in	O
the	O
early	O
diagnosis	O
of	O
these	O
neuropathological	O
conditions	O

elderly	O
patients	B-PERCIEVER
complaining	O
of	O
smell	O
loss	O
and	O
found	O
to	O
be	O
dysosmic	O
by	O
means	O
of	O
validated	O
olfactory	O
tests	O
should	O
be	O
neurologically	O
evaluated	O
as	O
early	O
as	O
possible	O
to	O
detect	O
slight	O
motor	O
abnormalities	O
in	O
an	O
atrisk	O
population	O

anosmia	B-OLFACTORY
and	O
ageusia	O
in	O
parkinsons	O
disease	O

anosmia	B-OLFACTORY
the	O
loss	O
of	O
sense	O
of	O
smell	O
is	O
a	O
common	O
nonmotor	O
feature	O
of	O
parkinsons	O
disease	O
pd	O

ageusia	O
the	O
loss	O
of	O
sense	O
of	O
taste	O
is	O
additionally	O
an	O
underappreciated	O
nonmotor	O
feature	O
of	O
pd	O

the	O
olfactory	O
tract	O
is	O
involved	O
early	O
in	O
pd	O
as	O
indicated	O
by	O
frequent	O
occurrence	O
of	O
hyposmia	B-OLFACTORY
or	O
anosmia	B-OLFACTORY
years	O
or	O
decades	O
before	O
motor	O
symptoms	O
and	O
by	O
autopsy	O
studies	O
showing	O
early	O
synuclein	O
pathology	O
in	O
the	O
olfactory	O
tract	O
and	O
anterior	O
olfactory	O
nucleus	O
even	O
in	O
the	O
early	O
stages	O
of	O
pd	O

testing	O
for	O
olfaction	O
consists	O
of	O
evaluation	O
of	O
olfactory	O
thresholds	O
smell	O
identification	O
and	O
discrimination	O
and	O
olfactory	O
memory	O

testing	O
for	O
gustation	O
involves	O
evaluating	O
thresholds	O
and	O
discrimination	O
of	O
five	O
basic	O
tastes	O
salty	O
sweet	O
bitter	O
sour	O
and	O
umami	O

the	O
presence	O
of	O
a	O
specific	O
pattern	O
of	O
loss	O
in	O
both	O
olfaction	O
and	O
gustation	O
in	O
pd	O
has	O
been	O
proposed	O
but	O
this	O
has	O
not	O
yet	O
been	O
confirmed	O

within	O
pd	O
olfactory	O
loss	O
is	O
strongly	O
tied	O
with	O
cognitive	O
status	O
though	O
links	O
to	O
other	O
features	O
of	O
pd	O
or	O
a	O
particular	O
pd	O
phenotype	O
is	O
debated	O

hyposmia	B-OLFACTORY
is	O
more	O
often	O
present	O
and	O
typically	O
more	O
severe	O
in	O
pd	O
patients	B-PERCIEVER
than	O
other	O
parkinsonian	O
syndromes	O
making	O
it	O
a	O
potentially	O
useful	O
biomarker	O
for	O
the	O
disease	O

olfactory	O
identification	O
among	O
various	O
subtypes	O
of	O
parkinson	O
disease	O

introduction	O
this	O
study	O
is	O
aimed	O
at	O
investigating	O
the	O
olfactory	O
function	O
among	O
different	O
subtypes	O
of	O
parkinson	O
disease	O
pd	O
and	O
the	O
impact	O
of	O
sex	O
on	O
smell	O
identification	O
test	O

methods	O
in	O
this	O
crosssectional	O
study	O
we	O
used	O
iransmell	O
identification	O
test	O
iransit	O

pd	O
severity	O
was	O
determined	O
using	O
a	O
hoehn	O
and	O
yahr	O
hampy	O
scale	O

we	O
used	O
analysis	O
of	O
covariance	O
ancova	O
to	O
compare	O
the	O
olfactory	O
function	O
among	O
different	O
pd	O
subtypes	O

all	O
analyses	O
were	O
performed	O
using	O
spss	O
software	O
version	O
160	O

results	O
in	O
total	O
66	O
males	O
and	O
38	O
females	O
participated	O
in	O
this	O
study	O

the	O
most	O
common	O
pd	O
subtype	O
was	O
postural	O
instability	O
and	O
gait	O
difficulty	O
385	O

severe	O
hyposmia	B-OLFACTORY
and	O
anosmia	B-OLFACTORY
were	O
found	O
in	O
446	O
and	O
196	O
of	O
participants	B-PERCIEVER
respectively	O

women	B-PERCIEVER
had	O
a	O
higher	O
score	O
in	O
olfactory	O
function	O
than	O
men	B-PERCIEVER
p	O
044	O

the	O
score	O
of	O
subjects	B-PERCIEVER
with	O
stage	O
1	O
in	O
the	O
hampy	O
scale	O
was	O
about	O
3	O
points	O
higher	O
than	O
the	O
score	O
with	O
stage	O
4	O

the	O
ancova	O
showed	O
a	O
statistically	O
significant	O
effect	O
of	O
subtypes	O
pd	O
on	O
iransit	O
score	O
after	O
controlling	O
for	O
the	O
effects	O
of	O
covariates	O
p	O
003	O

there	O
is	O
a	O
significant	O
difference	O
between	O
tremordominant	O
parkinson	O
disease	O
tdpd	O
and	O
other	O
subtypes	O
of	O
pd	O
p	O
005	O

however	O
iransit	O
scores	O
failed	O
to	O
show	O
a	O
significant	O
difference	O
between	O
men	B-PERCIEVER
and	O
women	B-PERCIEVER
p	O
013	O

discussionconclusion	O
our	O
results	O
confirmed	O
that	O
pd	O
is	O
heterogeneous	O
and	O
there	O
is	O
significant	O
variability	O
in	O
odor	O
identification	O
ability	O
in	O
these	O
patients	B-PERCIEVER

we	O
observed	O
more	O
olfactory	O
impairment	O
in	O
tdpd	O
and	O
subjects	B-PERCIEVER
with	O
higher	O
hampy	O
stage	O

we	O
recommended	O
future	O
studies	O
with	O
repeated	O
measurements	O
of	O
different	O
aspects	O
of	O
smell	O
function	O
to	O
characterize	O
the	O
temporal	O
relationship	O
of	O
olfactory	O
dysfunction	O
with	O
pd	O

neurological	O
features	O
and	O
outcome	O
in	O
covid19	O
dementia	B-NEURODEGENERATIVE
can	O
predict	O
severe	O
disease	O

the	O
covid19	O
pandemic	O
has	O
infected	O
more	O
than	O
22	O
million	O
people	O
worldwide	O

although	O
much	O
has	O
been	O
learned	O
about	O
covid19	O
we	O
do	O
not	O
know	O
much	O
about	O
its	O
neurological	O
features	O
and	O
their	O
outcome	O

this	O
observational	O
study	O
was	O
conducted	O
on	O
the	O
patients	B-PERCIEVER
of	O
imam	O
hossein	O
hospital	O
and	O
361	O
adult	O
patients	B-PERCIEVER
214	O
males	O
with	O
confirmed	O
diagnosis	O
of	O
covid19	O
from	O
march	O
5	O
2020	O
to	O
april	O
3	O
2020	O
were	O
enrolled	O

data	O
was	O
gathered	O
on	O
age	O
sex	O
comorbidities	O
initial	O
symptoms	O
symptoms	O
during	O
the	O
disease	O
course	O
neurological	O
symptoms	O
and	O
outcome	O

the	O
mean	O
age	O
of	O
the	O
patients	B-PERCIEVER
was	O
6190	O
1676	O
years	O

the	O
most	O
common	O
initial	O
symptoms	O
were	O
cough	O
fever	O
and	O
dyspnea	O

in	O
21	O
patients	B-PERCIEVER
58	O
the	O
initial	O
symptom	O
was	O
neurological	O

history	O
of	O
dementia	B-NEURODEGENERATIVE
was	O
associated	O
with	O
severe	O
covid19	O
disease	O
odds	O
ratio	O
128	O

during	O
the	O
course	O
of	O
the	O
disease	O
186	O
patients	B-PERCIEVER
5152	O
had	O
at	O
least	O
one	O
neurological	O
symptom	O
the	O
most	O
common	O
being	O
headache	O
109	O
302	O
followed	O
by	O
anosmiaageusia	O
69	O
191	O
and	O
dizziness	O
54	O
15	O

also	O
31	O
patients	B-PERCIEVER
had	O
neurological	O
complications	O
858	O

anosmia	B-OLFACTORY
ageusia	O
dizziness	O
and	O
headache	O
were	O
associated	O
with	O
favorable	O
outcome	O
p	O
0001	O
while	O
altered	O
mental	O
status	O
and	O
hemiparesis	O
were	O
associated	O
with	O
poor	O
outcome	O

the	O
mortality	O
rate	O
of	O
patients	B-PERCIEVER
who	O
had	O
neurological	O
complications	O
was	O
more	O
than	O
twice	O
than	O
that	O
of	O
patients	B-PERCIEVER
without	O
neurological	O
complication	O
p	O
0008	O

almost	O
half	O
of	O
the	O
patients	B-PERCIEVER
experienced	O
at	O
least	O
one	O
neurological	O
symptom	O
which	O
may	O
be	O
the	O
initial	O
presentation	O
of	O
covid19	O

dementia	B-NEURODEGENERATIVE
appears	O
to	O
be	O
associated	O
with	O
severe	O
covid19	O

mortality	O
was	O
higher	O
in	O
patients	B-PERCIEVER
with	O
neurological	O
complications	O
and	O
these	O
patients	B-PERCIEVER
needed	O
more	O
intensive	O
care	O

is	O
either	O
anosmia	B-OLFACTORY
or	O
constipation	O
associated	O
with	O
cognitive	O
dysfunction	O
in	O
parkinsons	O
disease	O

objective	O
to	O
clarify	O
the	O
association	O
of	O
anosmia	B-OLFACTORY
or	O
constipation	O
with	O
cognitive	O
dysfunction	O
and	O
disease	O
severity	O
in	O
patients	B-PERCIEVER
with	O
parkinsons	O
disease	O
pd	O

methods	O
newly	O
diagnosed	O
patients	B-PERCIEVER
with	O
pd	O
less	O
than	O
5	O
years	O
without	O
a	O
clinical	O
diagnosis	O
of	O
dementia	B-NEURODEGENERATIVE
were	O
included	O
from	O
february	O
2017	O
to	O
august	O
2018	O

the	O
subjects	B-PERCIEVER
were	O
further	O
divided	O
into	O
subgroups	O
based	O
on	O
whether	O
anosmia	B-OLFACTORY
occurred	O
and	O
the	O
grade	O
of	O
constipation	O

the	O
severity	O
of	O
pd	O
motor	O
symptoms	O
was	O
rated	O
using	O
the	O
movement	O
disorder	O
societysponsored	O
revision	O
of	O
the	O
unified	O
parkinsons	O
disease	O
rating	O
scale	O
mdsupdrs	O
and	O
cognitive	O
functions	O
were	O
evaluated	O
by	O
montreal	O
cognitive	O
assessment	O
moca	O

statistical	O
analyses	O
including	O
ttests	O
chisquare	O
tests	O
multiple	O
linear	O
regression	O
and	O
binary	O
logistic	O
regression	O
were	O
used	O
to	O
determine	O
statistical	O
significance	O

results	O
a	O
total	O
of	O
107	O
newly	O
diagnosed	O
pd	O
patients	B-PERCIEVER
were	O
included	O
in	O
this	O
study	O

the	O
moca	O
score	O
was	O
significantly	O
lower	O
in	O
the	O
anosmia	B-OLFACTORY
group	O
p	O
0001	O

constipation	O
was	O
associated	O
with	O
impaired	O
olfaction	O
in	O
a	O
posthoc	O
test	O

the	O
correlation	O
coefficient	O
between	O
moca	O
and	O
upsit	B-SMELL_TEST
score	O
was	O
041	O
p	O
0001	O

total	O
anosmia	B-OLFACTORY
and	O
age	O
were	O
associated	O
with	O
cognitive	O
dysfunction	O
moca	O
26	O
odds	O
ratio	O
263	O
p	O
0003	O
110	O
p	O
0001	O
respectively	O

the	O
anosmia	B-OLFACTORY
group	O
had	O
a	O
higher	O
mdsupdrs	O
part	O
3	O
score	O
with	O
beta	O
coefficient	O
of	O
730	O
p	O
002	O

furthermore	O
grade	O
3	O
constipation	O
was	O
associated	O
with	O
a	O
higher	O
mdsupdrs	O
total	O
score	O
with	O
beta	O
coefficient	O
of	O
1488	O
p	O
002	O

conclusions	O
anosmia	B-OLFACTORY
but	O
not	O
constipation	O
was	O
associated	O
with	O
cognitive	O
impairment	O
in	O
pd	O
patients	B-PERCIEVER

nevertheless	O
severe	O
constipation	O
was	O
associated	O
with	O
impaired	O
olfaction	O
and	O
pd	O
disease	O
severity	O

we	O
suggest	O
that	O
the	O
propagation	O
of	O
alphasynuclein	O
from	O
the	O
olfactory	O
route	O
is	O
distinct	O
from	O
the	O
enteric	O
nervous	O
system	O
but	O
the	O
intercommunication	O
between	O
these	O
two	O
routes	O
is	O
complex	O

olfactory	O
dysfunction	O
in	O
aging	O
and	O
neurodegenerative	O
diseases	O

alterations	O
in	O
olfactory	O
functions	O
are	O
proposed	O
to	O
be	O
early	O
biomarkers	O
for	O
neurodegeneration	O

many	O
neurodegenerative	O
diseases	O
are	O
agerelated	O
including	O
two	O
of	O
the	O
most	O
common	O
parkinsons	O
disease	O
pd	O
and	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE

the	O
establishment	O
of	O
biomarkers	O
that	O
promote	O
early	O
risk	O
identification	O
is	O
critical	O
for	O
the	O
implementation	O
of	O
early	O
treatment	O
to	O
postpone	O
or	O
avert	O
pathological	O
development	O

olfactory	O
dysfunction	O
od	O
is	O
seen	O
in	O
90	O
of	O
earlystage	O
pd	O
patients	B-PERCIEVER
and	O
85	O
of	O
patients	B-PERCIEVER
with	O
earlystage	O
ad	B-NEURODEGENERATIVE
which	O
makes	O
it	O
an	O
attractive	O
biomarker	O
for	O
early	O
diagnosis	O
of	O
these	O
diseases	O

here	O
we	O
systematically	O
review	O
widely	O
applied	O
smelling	O
tests	O
available	O
for	O
humans	O
as	O
well	O
as	O
olfaction	O
assessments	O
performed	O
in	O
some	O
animal	O
models	O
and	O
the	O
relationships	O
between	O
od	O
and	O
normal	O
aging	O
pd	O
ad	B-NEURODEGENERATIVE
and	O
other	O
conditions	O

the	O
utility	O
of	O
od	O
as	O
a	O
biomarker	O
for	O
neurodegenerative	O
disease	O
diagnosis	O
and	O
future	O
research	O
directions	O
are	O
also	O
discussed	O

olfaction	O
and	O
apathy	O
in	O
early	O
idiopathic	O
parkinsons	O
disease	O

background	O
apathy	O
remains	O
a	O
disabling	O
symptom	O
in	O
parkinsons	O
disease	O
pd	O
with	O
limited	O
therapeutic	O
success	O

processing	O
of	O
emotions	O
and	O
smell	O
share	O
neuroanatomical	O
and	O
evolutionary	O
pathways	O

objectives	O
to	O
explore	O
the	O
association	O
of	O
apathy	O
with	O
smell	O
dysfunction	O
sd	O
in	O
early	O
pd	O

methods	O
we	O
analyzed	O
patients	B-PERCIEVER
with	O
denovo	O
pd	O
with	O
followup	O
of	O
at	O
least	O
5	O
years	O
from	O
the	O
parkinsons	O
progression	O
markers	O
initiative	O

sd	O
and	O
apathy	O
were	O
defined	O
using	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
and	O
mdsupdrs	O
part	O
1a	O

odds	O
ratios	O
were	O
calculated	O
between	O
apathy	O
and	O
olfaction	O
groups	O

kaplanmeier	O
survival	O
analysis	O
was	O
grouped	O
by	O
presence	O
absence	O
of	O
smell	O
dysfunction	O

the	O
log	O
rank	O
test	O
was	O
used	O
to	O
compare	O
time	O
to	O
apathy	O

results	O
we	O
found	O
no	O
association	O
between	O
presence	O
of	O
apathy	O
in	O
patients	B-PERCIEVER
with	O
and	O
without	O
sd	O
or	O
101	O
049208	O

there	O
was	O
no	O
significant	O
difference	O
between	O
pd	O
patients	B-PERCIEVER
with	O
and	O
without	O
sd	O
in	O
time	O
to	O
apathy	O
p	O
072	O

conclusions	O
sd	O
does	O
not	O
portend	O
greater	O
risk	O
of	O
apathy	O
in	O
pd	O

covid19	O
and	O
olfactory	O
dysfunction	O
a	O
looming	O
wave	O
of	O
dementia	B-NEURODEGENERATIVE

olfactory	O
dysfunction	O
is	O
a	O
hallmark	O
symptom	O
of	O
covid19	O
disease	O
resulting	O
from	O
the	O
sarscov2	O
virus	O

the	O
cause	O
of	O
the	O
sudden	O
and	O
usually	O
temporary	O
anosmia	B-OLFACTORY
that	O
most	O
people	O
suffer	O
from	O
covid19	O
is	O
likely	O
entirely	O
peripheralinflammation	O
and	O
other	O
damage	O
caused	O
by	O
the	O
virus	O
in	O
the	O
sensory	O
epithelium	O
inside	O
the	O
upper	O
recesses	O
of	O
the	O
nasal	O
cavity	O
can	O
damage	O
or	O
prevent	O
chemicals	O
from	O
properly	O
activating	O
the	O
olfactory	O
sensory	O
neurons	O

however	O
persistent	O
olfactory	O
dysfunction	O
from	O
covid19	O
in	O
the	O
form	O
of	O
hyposmia	B-OLFACTORY
and	O
parosmia	B-OLFACTORY
decreased	O
or	O
altered	O
smell	O
may	O
affect	O
as	O
many	O
as	O
15	O
million	O
people	O
worldwide	O

this	O
epidemic	O
of	O
olfactory	O
dysfunction	O
is	O
thus	O
a	O
continuing	O
public	O
health	O
concern	O

mounting	O
evidence	O
suggests	O
that	O
the	O
sarscov2	O
virus	O
itself	O
or	O
inflammation	O
from	O
the	O
immune	O
response	O
in	O
the	O
nasal	O
sensory	O
epithelium	O
may	O
invade	O
the	O
olfactory	O
bulb	O
likely	O
via	O
nonneuronal	O
transmission	O

covid19related	O
longterm	O
olfactory	O
dysfunction	O
and	O
early	O
damage	O
to	O
olfactory	O
and	O
limbic	O
brain	O
regions	O
suggest	O
a	O
pattern	O
of	O
degeneration	O
similar	O
to	O
that	O
seen	O
in	O
early	O
stages	O
of	O
alzheimers	O
disease	O
parkinsons	O
disease	O
and	O
lewy	O
body	O
dementia	B-NEURODEGENERATIVE

thus	O
longterm	O
olfactory	O
dysfunction	O
coupled	O
with	O
cognitive	O
and	O
emotional	O
disturbance	O
from	O
covid19	O
may	O
be	O
the	O
first	O
signs	O
of	O
delayed	O
onset	O
dementia	B-NEURODEGENERATIVE
from	O
neurodegeneration	O

few	O
treatments	O
are	O
known	O
to	O
be	O
effective	O
to	O
prevent	O
further	O
degeneration	O
but	O
the	O
first	O
line	O
of	O
defense	O
against	O
degeneration	O
may	O
be	O
olfactory	O
and	O
environmental	O
enrichment	O

there	O
is	O
a	O
pressing	O
need	O
for	O
more	O
research	O
on	O
treatments	O
for	O
olfactory	O
dysfunction	O
and	O
longitudinal	O
studies	O
including	O
cognitive	O
and	O
olfactory	O
function	O
from	O
patients	B-PERCIEVER
who	O
have	O
recovered	O
from	O
even	O
mild	O
covid19new	O
noteworthy	O
more	O
than	O
15	O
million	O
people	O
worldwide	O
experience	O
persistent	O
covid19	O
olfactory	O
dysfunction	O
possibly	O
caused	O
by	O
olfactory	O
bulb	O
damage	O

sarscov2	O
can	O
cause	O
inflammation	O
and	O
viral	O
invasion	O
of	O
the	O
olfactory	O
bulb	O
initiating	O
a	O
cascade	O
of	O
degeneration	O
similar	O
to	O
alzheimers	O
disease	O
and	O
lewy	O
body	O
disease	O

people	O
who	O
have	O
had	O
even	O
mild	O
cases	O
of	O
covid19	O
show	O
signs	O
of	O
degeneration	O
in	O
cortical	O
areas	O
connected	O
with	O
the	O
olfactory	O
system	O

these	O
data	O
suggest	O
a	O
wave	O
of	O
postcovid	O
dementia	B-NEURODEGENERATIVE
in	O
the	O
coming	O
decades	O

anosmia	B-OLFACTORY
mild	O
cognitive	O
impairment	O
and	O
biomarkers	O
of	O
brain	O
aging	O
in	O
older	O
adults	O

olfactory	O
impairment	O
is	O
a	O
potential	O
marker	O
for	O
prodromal	O
dementia	B-NEURODEGENERATIVE
but	O
the	O
underlying	O
mechanisms	O
are	O
poorly	O
understood	O

this	O
populationbased	O
study	O
included	O
4214	O
dementiafree	O
participants	B-PERCIEVER
age	O
65	O
years	O

olfaction	O
was	O
assessed	O
using	O
the	O
16item	O
sniffin	O
sticks	O
identification	O
test	O

in	O
the	O
subsamples	O
we	O
measured	O
plasma	O
amyloid	O
beta	O
abeta40	O
abeta42	O
total	O
tau	O
and	O
neurofilament	O
light	O
chain	O
nfl	O
n	O
1054	O
and	O
quantified	O
hippocampal	O
entorhinal	O
cortex	O
and	O
white	O
matter	O
hyperintensity	O
wmh	O
volumes	O
and	O
alzheimers	O
disease	O
adsignature	O
cortical	O
thickness	O
n	O
917	O

data	O
were	O
analyzed	O
with	O
logistic	O
and	O
linear	O
regression	O
models	O

in	O
the	O
total	O
sample	O
mild	O
cognitive	O
impairment	O
mci	O
was	O
diagnosed	O
in	O
1102	O
persons	O
262	O
amnestic	O
mci	O
n	O
931	O
nonamnestic	O
mci	O
n	O
171	O

olfactory	O
impairment	O
was	O
significantly	O
associated	O
with	O
increased	O
likelihoods	O
of	O
mci	O
amnestic	O
mci	O
and	O
nonamnestic	O
mci	O

in	O
the	O
subsamples	O
anosmia	B-OLFACTORY
was	O
significantly	O
associated	O
with	O
higher	O
plasma	O
total	O
tau	O
and	O
nfl	O
concentrations	O
smaller	O
hippocampal	O
and	O
entorhinal	O
cortex	O
volumes	O
and	O
greater	O
wmh	O
volume	O
and	O
marginally	O
with	O
lower	O
adsignature	O
cortical	O
thickness	O

these	O
results	O
suggest	O
that	O
cerebral	O
neurodegenerative	O
and	O
microvascular	O
lesions	O
are	O
common	O
neuropathologies	O
linking	O
anosmia	B-OLFACTORY
with	O
mci	O
in	O
older	O
adults	O

widening	O
the	O
spectrum	O
of	O
risk	O
factors	O
comorbidities	O
and	O
prodromal	O
features	O
of	O
parkinson	O
disease	O

importance	O
the	O
prodromal	O
phase	O
of	O
parkinson	O
disease	O
pd	O
may	O
last	O
for	O
more	O
than	O
10	O
years	O

recognition	O
of	O
the	O
spectrum	O
and	O
occurrence	O
of	O
risk	O
factors	O
comorbidities	O
and	O
prodromal	O
features	O
of	O
pd	O
can	O
increase	O
understanding	O
of	O
the	O
causes	O
and	O
development	O
of	O
the	O
disease	O
and	O
help	O
identify	O
individuals	O
at	O
risk	O

objective	O
to	O
identify	O
the	O
association	O
of	O
a	O
subsequent	O
diagnosis	O
of	O
pd	O
with	O
a	O
range	O
of	O
risk	O
factors	O
and	O
prodromal	O
features	O
including	O
lifestyle	O
factors	O
comorbidities	O
and	O
potential	O
extracerebral	O
manifestations	O
of	O
pd	O

design	O
setting	O
and	O
participants	B-PERCIEVER
this	O
was	O
a	O
casecontrol	O
study	O
using	O
insurance	O
claims	O
of	O
outpatient	O
consultations	O
of	O
patients	B-PERCIEVER
with	O
german	O
statutory	O
health	O
insurance	O
between	O
january	O
1	O
2011	O
and	O
december	O
31	O
2020	O

included	O
were	O
patients	B-PERCIEVER
with	O
incident	O
diagnosis	O
of	O
pd	O
without	O
a	O
previous	O
diagnosis	O
of	O
parkinsonism	O
or	O
dementia	B-NEURODEGENERATIVE
and	O
controls	O
matched	O
12	O
for	O
age	O
sex	O
region	O
and	O
earliest	O
year	O
of	O
outpatient	O
encounter	O

exposures	O
exposures	O
were	O
selected	O
based	O
on	O
previous	O
systematic	O
reviews	O
casecontrol	O
and	O
cohort	O
studies	O
reporting	O
on	O
risk	O
factors	O
comorbidities	O
and	O
prodromal	O
features	O
of	O
pd	O

main	O
outcomes	O
and	O
measures	O
previously	O
postulated	O
risk	O
factors	O
and	O
prodromal	O
features	O
of	O
pd	O
using	O
the	O
international	O
statistical	O
classification	O
of	O
diseases	O
and	O
related	O
health	O
problems	O
tenth	O
revision	O
icd10	O
coding	O

results	O
a	O
total	O
of	O
138	O
345	O
patients	B-PERCIEVER
with	O
incident	O
pd	O
mean	O
sd	O
age	O
751	O
98	O
years	O
73	O
720	O
male	B-PERCIEVER
533	O
and	O
276	O
690	O
matched	O
controls	O
mean	O
sd	O
age	O
751	O
98	O
years	O
147	O
440	O
male	B-PERCIEVER
533	O
were	O
identified	O

study	O
participants	B-PERCIEVER
were	O
followed	O
up	O
for	O
a	O
mean	O
sd	O
of	O
60	O
20	O
years	O

consistent	O
with	O
previous	O
reports	O
risk	O
factors	O
and	O
prodromal	O
features	O
associated	O
with	O
pd	O
included	O
traumatic	O
brain	O
injury	O
odds	O
ratio	O
or	O
162	O
95	O
ci	O
136192	O
alcohol	O
misuse	O
or	O
132	O
95	O
ci	O
121144	O
hypertension	O
or	O
129	O
95	O
ci	O
126131	O
anosmia	B-OLFACTORY
or	O
216	O
95	O
ci	O
159293	O
and	O
parasomnias	O
including	O
rbd	O
or	O
162	O
95	O
ci	O
142184	O

in	O
addition	O
there	O
were	O
associations	O
with	O
restless	O
legs	O
syndrome	O
or	O
419	O
95	O
ci	O
391450	O
sleep	O
apnea	O
or	O
145	O
95	O
ci	O
137154	O
epilepsy	O
or	O
226	O
95	O
ci	O
207246	O
migraine	O
or	O
121	O
95	O
ci	O
112129	O
bipolar	O
disorder	O
or	O
381	O
95	O
ci	O
311467	O
and	O
schizophrenia	O
or	O
448	O
95	O
ci	O
382525	O

the	O
following	O
diagnoses	O
were	O
also	O
found	O
to	O
be	O
associated	O
with	O
pd	O
sensory	O
impairments	O
beyond	O
anosmia	B-OLFACTORY
such	O
as	O
hearing	O
loss	O
or	O
114	O
95	O
ci	O
109120	O
and	O
changes	O
of	O
skin	O
sensation	O
or	O
131	O
95	O
ci	O
121143	O

there	O
were	O
also	O
positive	O
associations	O
with	O
skin	O
disorders	O
eg	O
seborrheic	O
dermatitis	O
or	O
130	O
95	O
ci	O
115146	O
psoriasis	O
or	O
113	O
95	O
ci	O
105121	O
gastrointestinal	O
disorders	O
eg	O
gastroesophageal	O
reflux	O
or	O
129	O
95	O
ci	O
125133	O
gastritis	O
or	O
128	O
95	O
ci	O
124133	O
conditions	O
with	O
a	O
potential	O
inflammatory	O
component	O
eg	O
seronegative	O
osteoarthritis	O
or	O
121	O
95	O
ci	O
103143	O
and	O
diabetes	O
types	O
1	O
or	O
132	O
95	O
ci	O
121143	O
and	O
2	O
or	O
124	O
95	O
ci	O
120127	O

associations	O
even	O
5	O
to	O
10	O
years	O
before	O
diagnosis	O
included	O
tremor	O
odds	O
ratio	O
or	O
449	O
95	O
ci	O
398506	O
restless	O
legs	O
syndrome	O
or	O
373	O
95	O
ci	O
339409	O
bipolar	O
disorder	O
or	O
380	O
95	O
ci	O
282514	O
and	O
schizophrenia	O
or	O
400	O
95	O
ci	O
331485	O

conclusions	O
and	O
relevance	O
results	O
of	O
this	O
casecontrol	O
study	O
suggest	O
that	O
the	O
associations	O
found	O
between	O
pd	O
and	O
certain	O
risk	O
factors	O
comorbidities	O
and	O
prodromal	O
symptoms	O
in	O
a	O
representative	O
population	O
may	O
reflect	O
possible	O
early	O
extrastriatal	O
and	O
extracerebral	O
pathology	O
of	O
pd	O

this	O
may	O
be	O
due	O
to	O
shared	O
genetic	O
risk	O
with	O
pd	O
medication	O
exposure	O
or	O
direct	O
causation	O
or	O
represent	O
pathophysiologically	O
relevant	O
factors	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
pd	O

markers	O
of	O
olfactory	O
dysfunction	O
and	O
progression	O
to	O
dementia	B-NEURODEGENERATIVE
a	O
12year	O
populationbased	O
study	O

introduction	O
we	O
evaluated	O
markers	O
of	O
olfactory	O
dysfunction	O
od	O
for	O
estimating	O
hazard	O
of	O
dementia	B-NEURODEGENERATIVE
in	O
older	O
adults	O

methods	O
mild	O
hyposmia	B-OLFACTORY
and	O
severe	O
anosmia	B-OLFACTORY
od	O
was	O
classified	O
in	O
a	O
populationbased	O
study	O
of	O
dementiafree	O
persons	O
snack	O
n	O
2473	O
mean	O
age	O
70	O
years	O
using	O
the	O
sniffin	O
sticks	O
odor	O
identification	O
task	O

combined	O
variables	O
were	O
created	O
for	O
objective	O
and	O
subjective	O
od	O
and	O
for	O
od	O
and	O
apoe	O
status	O

hazard	O
of	O
dementia	B-NEURODEGENERATIVE
across	O
12	O
years	O
was	O
estimated	O
with	O
cox	O
regression	O

results	O
od	O
was	O
associated	O
with	O
increased	O
hazard	O
of	O
dementia	B-NEURODEGENERATIVE
201	O
95	O
confidence	O
interval	O
ci	O
160252	O
with	O
the	O
strongest	O
association	O
for	O
anosmia	B-OLFACTORY
292	O
95	O
ci	O
214398	O

results	O
remained	O
consistent	O
after	O
adjusting	O
for	O
potential	O
confounders	O
and	O
across	O
age	O
and	O
sex	O
subgroups	O

apoe	O
epsilon4	O
carriers	O
with	O
anosmia	B-OLFACTORY
had	O
the	O
highest	O
hazard	O
of	O
dementia	B-NEURODEGENERATIVE
epsilon4	O
695	O
95	O
ci	O
4161162	O
epsilon4epsilon4	O
1984	O
95	O
ci	O
6176378	O

discussion	O
od	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
dementia	B-NEURODEGENERATIVE
especially	O
severe	O
impairment	O
in	O
combination	O
with	O
genetic	O
risk	O
of	O
alzheimers	O
disease	O

humanderived	O
airliquid	O
interface	O
cultures	O
decipher	O
alzheimers	O
diseasesarscov2	O
crosstalk	O
in	O
the	O
olfactory	O
mucosa	O

background	O
the	O
neurological	O
effects	O
of	O
the	O
coronavirus	O
disease	O
of	O
2019	O
covid19	O
raise	O
concerns	O
about	O
potential	O
longterm	O
consequences	O
such	O
as	O
an	O
increased	O
risk	O
of	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE

neuroinflammation	O
and	O
other	O
adassociated	O
pathologies	O
are	O
also	O
suggested	O
to	O
increase	O
the	O
risk	O
of	O
serious	O
sarscov2	O
infection	O

anosmia	B-OLFACTORY
is	O
a	O
common	O
neurological	O
symptom	O
reported	O
in	O
covid19	O
and	O
in	O
early	O
ad	B-NEURODEGENERATIVE

the	O
olfactory	O
mucosa	O
om	O
is	O
important	O
for	O
the	O
perception	O
of	O
smell	O
and	O
a	O
proposed	O
site	O
of	O
viral	O
entry	O
to	O
the	O
brain	O

however	O
little	O
is	O
known	O
about	O
sarscov2	O
infection	O
at	O
the	O
om	O
of	O
individuals	O
with	O
ad	B-NEURODEGENERATIVE

methods	O
to	O
address	O
this	O
gap	O
we	O
established	O
a	O
3d	O
in	O
vitro	O
model	O
of	O
the	O
om	O
from	O
primary	O
cells	O
derived	O
from	O
cognitively	O
healthy	O
and	O
ad	B-NEURODEGENERATIVE
individuals	O

we	O
cultured	O
the	O
cells	O
at	O
the	O
airliquid	O
interface	O
ali	O
to	O
study	O
sarscov2	O
infection	O
under	O
controlled	O
experimental	O
conditions	O

primary	O
om	O
cells	O
in	O
ali	O
expressed	O
angiotensinconverting	O
enzyme	O
2	O
ace2	O
neuropilin1	O
nrp1	O
and	O
several	O
other	O
known	O
sarscov2	O
receptor	O
and	O
were	O
highly	O
vulnerable	O
to	O
infection	O

infection	O
was	O
determined	O
by	O
secreted	O
viral	O
rna	O
content	O
and	O
confirmed	O
with	O
sarscov2	O
nucleocapsid	O
protein	O
np	O
in	O
the	O
infected	O
cells	O
by	O
immunocytochemistry	O

differential	O
responses	O
of	O
healthy	O
and	O
ad	B-NEURODEGENERATIVE
individualsderived	O
om	O
cells	O
to	O
sarscov2	O
were	O
determined	O
by	O
rna	O
sequencing	O

results	O
results	O
indicate	O
that	O
cells	O
derived	O
from	O
cognitively	O
healthy	O
donors	O
and	O
individuals	O
with	O
ad	B-NEURODEGENERATIVE
do	O
not	O
differ	O
in	O
susceptibility	O
to	O
infection	O
with	O
the	O
wildtype	O
sarscov2	O
virus	O

however	O
transcriptomic	O
signatures	O
in	O
cells	O
from	O
individuals	O
with	O
ad	B-NEURODEGENERATIVE
are	O
highly	O
distinct	O

specifically	O
the	O
cells	O
from	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
that	O
were	O
infected	O
with	O
the	O
virus	O
showed	O
increased	O
levels	O
of	O
oxidative	O
stress	O
desensitized	O
inflammation	O
and	O
immune	O
responses	O
and	O
alterations	O
to	O
genes	O
associated	O
with	O
olfaction	O

these	O
results	O
imply	O
that	O
individuals	O
with	O
ad	B-NEURODEGENERATIVE
may	O
be	O
at	O
a	O
greater	O
risk	O
of	O
experiencing	O
severe	O
outcomes	O
from	O
the	O
infection	O
potentially	O
driven	O
by	O
preexisting	O
neuroinflammation	O

conclusions	O
the	O
study	O
sheds	O
light	O
on	O
the	O
interplay	O
between	O
ad	B-NEURODEGENERATIVE
pathology	O
and	O
sarscov2	O
infection	O

altered	O
transcriptomic	O
signatures	O
in	O
ad	B-NEURODEGENERATIVE
cells	O
may	O
contribute	O
to	O
unique	O
symptoms	O
and	O
a	O
more	O
severe	O
disease	O
course	O
with	O
a	O
notable	O
involvement	O
of	O
neuroinflammation	O

furthermore	O
the	O
research	O
emphasizes	O
the	O
need	O
for	O
targeted	O
interventions	O
to	O
enhance	O
outcomes	O
for	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
with	O
viral	O
infection	O

the	O
study	O
is	O
crucial	O
to	O
better	O
comprehend	O
the	O
relationship	O
between	O
ad	B-NEURODEGENERATIVE
covid19	O
and	O
anosmia	B-OLFACTORY

it	O
highlights	O
the	O
importance	O
of	O
ongoing	O
research	O
to	O
develop	O
more	O
effective	O
treatments	O
for	O
those	O
at	O
high	O
risk	O
of	O
severe	O
sarscov2	O
infection	O

longitudinal	O
brain	O
changes	O
in	O
parkinsons	O
disease	O
with	O
severe	O
olfactory	O
deficit	O

introduction	O
olfactory	O
dysfunction	O
and	O
rem	O
sleep	O
behavior	O
disorder	O
rbd	O
are	O
associated	O
with	O
distinct	O
cognitive	O
trajectories	O
in	O
the	O
course	O
of	O
parkinsons	O
disease	O
pd	O

the	O
underlying	O
neurobiology	O
for	O
this	O
relationship	O
remains	O
unclear	O
but	O
may	O
involve	O
distinct	O
patterns	O
of	O
neurodegeneration	O

this	O
study	O
aimed	O
to	O
examine	O
longitudinal	O
cortical	O
atrophy	O
and	O
thinning	O
in	O
earlystage	O
pd	O
with	O
severe	O
olfactory	O
deficit	O
anosmia	B-OLFACTORY
without	O
and	O
with	O
concurrent	O
probable	O
rbd	O

methods	O
longitudinal	O
mri	O
data	O
over	O
four	O
years	O
of	O
134	O
de	O
novo	O
pd	O
and	O
49	O
healthy	O
controls	O
hc	O
from	O
the	O
parkinson	O
progression	O
marker	O
initiative	O
ppmi	O
cohort	O
were	O
analyzed	O
using	O
a	O
linear	O
mixedeffects	O
model	O

patients	B-PERCIEVER
were	O
categorized	O
into	O
those	O
with	O
anosmia	B-OLFACTORY
by	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
score	O
18	O
ao	O
and	O
those	O
without	O
upsit	B-SMELL_TEST
score	O
18	O
ao	O

the	O
ao	O
group	O
was	O
further	O
subdivided	O
into	O
ao	O
with	O
probable	O
rbd	O
aorbd	O
and	O
without	O
aorbd	O
for	O
subanalysis	O

results	O
compared	O
to	O
subjects	B-PERCIEVER
without	O
baseline	O
anosmia	B-OLFACTORY
the	O
ao	O
group	O
exhibited	O
greater	O
longitudinal	O
declines	O
in	O
both	O
volume	O
and	O
thickness	O
in	O
the	O
bilateral	O
parahippocampal	O
gyri	O
and	O
right	O
transverse	O
temporal	O
gyrus	O

patients	B-PERCIEVER
with	O
concurrent	O
anosmia	B-OLFACTORY
and	O
rbd	O
showed	O
more	O
extensive	O
longitudinal	O
declines	O
in	O
cortical	O
volume	O
and	O
thickness	O
involving	O
additional	O
brain	O
regions	O
including	O
the	O
bilateral	O
precuneus	O
left	O
inferior	O
temporal	O
gyrus	O
right	O
paracentral	O
gyrus	O
and	O
right	O
precentral	O
gyrus	O

conclusions	O
the	O
atrophythinning	O
patterns	O
in	O
earlystage	O
pd	O
with	O
severe	O
olfactory	O
dysfunction	O
include	O
regions	O
that	O
are	O
critical	O
for	O
cognitive	O
function	O
and	O
could	O
provide	O
a	O
structural	O
basis	O
for	O
previously	O
reported	O
associations	O
between	O
severe	O
olfactory	O
deficit	O
and	O
cognitive	O
decline	O
in	O
pd	O

concurrent	O
rbd	O
might	O
enhance	O
the	O
dynamics	O
of	O
cortical	O
changes	O

is	O
parkinsons	O
disease	O
a	O
primary	O
olfactory	O
disorder	O

it	O
has	O
been	O
known	O
for	O
over	O
30	O
years	O
that	O
olfactory	O
function	O
is	O
disordered	O
in	O
idiopathic	O
parkinsons	O
disease	O
ipd	O

the	O
severity	O
and	O
partial	O
specificity	O
of	O
anosmia	B-OLFACTORY
was	O
not	O
realized	O
until	O
recently	O
with	O
the	O
advent	O
of	O
more	O
detailed	O
analysis	O
and	O
sophisticated	O
measurement	O

the	O
olfactory	O
vector	O
hypothesis	O
suggests	O
that	O
the	O
causative	O
agent	O
for	O
ipd	O
enters	O
the	O
brain	O
via	O
the	O
nasal	O
route	O
but	O
the	O
reason	O
for	O
olfactory	O
dysfunction	O
may	O
be	O
more	O
subtle	O

evidence	O
for	O
olfactory	O
disturbance	O
is	O
reviewed	O
from	O
pathological	O
psychological	O
neurophysiological	O
and	O
genetic	O
standpoints	O

it	O
is	O
proposed	O
that	O
the	O
initial	O
causative	O
event	O
in	O
ipd	O
may	O
start	O
in	O
the	O
rhinencephalon	O
olfactory	O
brain	O
prior	O
to	O
damage	O
in	O
the	O
basal	O
ganglia	O

olfactory	O
deficits	O
induce	O
neurofilament	O
hyperphosphorylation	O

olfactory	O
dysfunction	O
including	O
structural	O
abnormalities	O
of	O
the	O
olfactory	O
epithelium	O
the	O
olfactory	O
bulb	O
and	O
the	O
central	O
olfactory	O
cortices	O
is	O
recognized	O
as	O
an	O
early	O
feature	O
of	O
alzheimer	O
disease	O
ad	B-NEURODEGENERATIVE
the	O
most	O
prevalent	O
neurodegenerative	O
disease	O
in	O
aged	O
population	O
characterized	O
by	O
intracellular	O
neurofibrillary	O
tangles	O
nfts	O

how	O
olfactory	O
deficits	O
are	O
linked	O
with	O
adlike	O
neuropathological	O
changes	O
is	O
still	O
unknown	O

here	O
by	O
using	O
two	O
anosmia	B-OLFACTORY
animal	O
models	O
bilateral	O
olfactory	O
bulbectomy	O
obx	O
rats	O
and	O
cnga2y	O
mice	O
which	O
lack	O
intact	O
olfactory	O
cng	O
channels	O
we	O
found	O
the	O
immunoreactivity	O
of	O
phosphorylated	O
neurofilament	O
nf	O
are	O
highly	O
increased	O
in	O
the	O
neurites	O
at	O
both	O
the	O
hippocampus	O
and	O
the	O
cortex	O

as	O
hyperphosphorylated	O
nf	O
is	O
one	O
of	O
the	O
main	O
components	O
of	O
nfts	O
our	O
study	O
strongly	O
suggested	O
the	O
underlying	O
correlation	O
of	O
olfactory	O
deficits	O
with	O
adlike	O
pathological	O
impairments	O

olfactory	O
identification	O
deficit	O
predicts	O
white	O
matter	O
tract	O
impairment	O
in	O
alzheimers	O
disease	O

olfactory	O
identification	O
deficit	O
oid	O
has	O
been	O
associated	O
with	O
both	O
aging	O
and	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE

in	O
the	O
context	O
of	O
an	O
amnestic	O
disorders	O
oid	O
predicts	O
conversion	O
to	O
ad	B-NEURODEGENERATIVE

neuroanatomical	O
correlates	O
could	O
increase	O
specificity	O
and	O
sensitivity	O
and	O
elucidate	O
the	O
mechanistic	O
differences	O
between	O
oid	O
in	O
ad	B-NEURODEGENERATIVE
and	O
aging	O

crosssectional	O
analysis	O
of	O
white	O
matter	O
microstructural	O
changes	O
was	O
performed	O
using	O
diffusion	O
tensor	O
imaging	O
dti	O
and	O
tractbasedspatialstatistics	O
in	O
amnestic	O
mild	O
cognitive	O
impairment	O
amci	O
ad	B-NEURODEGENERATIVE
and	O
normal	O
controls	O
nc	O
in	O
66	O
subjects	B-PERCIEVER
26	O
ad	B-NEURODEGENERATIVE
15	O
amci	O
25	O
nc	O

dti	O
3tesla	O
mri	O
scans	O
were	O
analyzed	O
and	O
subject	O
level	O
means	O
for	O
fractional	O
anisotropy	O
fa	O
mean	O
diffusivity	O
md	O
radial	O
and	O
axial	O
diffusivity	O
lambda1d	O
and	O
lambda23d	O
were	O
calculated	O

linear	O
regression	O
models	O
were	O
applied	O
using	O
dti	O
markers	O
as	O
predictor	O
and	O
oid	O
as	O
outcome	O

oid	O
was	O
associated	O
with	O
increased	O
lambda1d	O
in	O
amci	O
and	O
increased	O
md	O
lambda1d	O
and	O
lambda23d	O
in	O
ad	B-NEURODEGENERATIVE

voxelwise	O
analyses	O
revealed	O
widespread	O
differences	O
in	O
all	O
markers	O
in	O
ad	B-NEURODEGENERATIVE

there	O
were	O
significant	O
differences	O
in	O
lambda1d	O
in	O
amci	O
particularly	O
in	O
the	O
olfactory	O
tract	O

oid	O
is	O
correlated	O
with	O
microstructural	O
white	O
matter	O
changes	O
as	O
early	O
as	O
in	O
amci	O

this	O
study	O
may	O
help	O
elucidate	O
the	O
biological	O
basis	O
for	O
olfactory	O
impairment	O
in	O
alzheimers	O
disease	O

neuroanatomical	O
correlates	O
could	O
help	O
distinguish	O
oid	O
associated	O
with	O
ad	B-NEURODEGENERATIVE
and	O
that	O
associated	O
with	O
aging	O

clinical	O
structural	O
and	O
neuropathological	O
features	O
of	O
olfactory	O
dysfunction	O
in	O
patients	B-PERCIEVER
with	O
alzheimers	O
disease	O

we	O
explored	O
changes	O
in	O
clinical	O
features	O
and	O
neuropathological	O
mechanisms	O
underlying	O
olfactory	O
dysfunction	O
od	O
in	O
60	O
patients	B-PERCIEVER
with	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE

olfactory	O
function	O
was	O
evaluated	O
using	O
the	O
sniffin	O
sticks	O
test	O
and	O
a	O
threshold	O
discrimination	O
identification	O
tdi	O
score	O

based	O
on	O
the	O
tdi	O
score	O
we	O
divided	O
patients	B-PERCIEVER
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
od	O
adod	O
and	O
adnod	O
respectively	O

cognitive	O
and	O
neuropsychiatric	O
symptoms	O
were	O
evaluated	O
by	O
a	O
series	O
of	O
rating	O
scales	O

the	O
volumes	O
and	O
cortical	O
thickness	O
of	O
the	O
thalamus	O
hippocampus	O
and	O
amygdala	O
were	O
measured	O
using	O
structural	O
magnetic	O
resonance	O
imaging	O

neuropathological	O
protein	O
levels	O
in	O
cerebrospinal	O
fluid	O
were	O
measured	O

the	O
frequency	O
of	O
od	O
was	O
50	O

tdi	O
scores	O
were	O
lower	O
in	O
the	O
adod	O
group	O
than	O
in	O
the	O
adnod	O
group	O
p	O
0001	O

compared	O
with	O
the	O
adnod	O
group	O
the	O
adod	O
group	O
showed	O
greater	O
cognitive	O
function	O
impairments	O
p	O
0001	O
and	O
daily	O
living	O
activities	O
were	O
more	O
severely	O
compromised	O
p	O
0019	O

the	O
adod	O
group	O
had	O
lower	O
hippocampal	O
and	O
amygdala	O
volumes	O
p	O
0025	O
p	O
0030	O
respectively	O
and	O
a	O
more	O
pronounced	O
reduction	O
in	O
cortical	O
thickness	O
p	O
0010	O

the	O
total	O
tau	O
level	O
was	O
lower	O
in	O
the	O
adod	O
group	O
than	O
the	O
adnod	O
group	O
p	O
0040	O

lower	O
minimental	O
state	O
examination	O
scores	O
and	O
thinner	O
adsignature	O
cortices	O
were	O
associated	O
with	O
lower	O
tdi	O
scores	O
or	O
0826	O
p	O
0001	O
or	O
1433	O
p	O
0008	O

overall	O
in	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
the	O
impairments	O
in	O
olfactory	O
discrimination	O
and	O
identification	O
seem	O
to	O
be	O
more	O
correlated	O
with	O
cognitive	O
levels	O

od	O
in	O
ad	B-NEURODEGENERATIVE
may	O
be	O
an	O
indicator	O
of	O
pathological	O
cognitive	O
decline	O
and	O
structural	O
changes	O

orthonasal	O
but	O
not	O
retronasal	O
olfaction	O
is	O
specifically	O
impaired	O
in	O
parkinsons	O
disease	O

olfactory	O
dysfunction	O
od	O
in	O
parkinsons	O
disease	O
pd	O
appears	O
several	O
years	O
before	O
the	O
presence	O
of	O
motor	O
disturbance	O

olfactory	O
testing	O
has	O
the	O
potential	O
to	O
serve	O
as	O
a	O
tool	O
for	O
early	O
detection	O
of	O
pd	O
but	O
od	O
is	O
not	O
specific	O
to	O
pd	O
as	O
it	O
affects	O
up	O
to	O
20	O
of	O
the	O
general	O
population	O

olfaction	O
includes	O
an	O
orthonasal	O
and	O
a	O
retronasal	O
components	O
in	O
some	O
forms	O
of	O
od	O
retronasal	O
olfactory	O
function	O
is	O
preserved	O

we	O
aimed	O
to	O
evaluate	O
whether	O
combined	O
testing	O
components	O
allows	O
for	O
discriminating	O
between	O
pdrelated	O
od	O
and	O
nonparkinsonian	O
od	O
npod	O

the	O
objective	O
of	O
this	O
study	O
is	O
to	O
orthonasal	O
and	O
retronasal	O
olfactory	O
function	O
in	O
pd	O
patients	B-PERCIEVER
and	O
compare	O
them	O
to	O
a	O
npod	O
group	O
and	O
to	O
healthy	O
controls	O

we	O
hypothesized	O
that	O
this	O
combined	O
testing	O
allows	O
to	O
distinguish	O
pd	O
patients	B-PERCIEVER
from	O
both	O
other	O
groups	O

we	O
included	O
32	O
pd	O
patients	B-PERCIEVER
25	O
npod	O
patients	B-PERCIEVER
and	O
15	O
healthy	O
controls	O

both	O
olfactory	O
components	O
were	O
impaired	O
in	O
pd	O
and	O
npod	O
patients	B-PERCIEVER
compared	O
with	O
controls	O
however	O
npod	O
patients	B-PERCIEVER
had	O
significantly	O
better	O
orthonasal	O
scores	O
than	O
pd	O
patients	B-PERCIEVER

furthermore	O
the	O
ratio	O
of	O
retronasalorthonasal	O
score	O
was	O
higher	O
in	O
pd	O
than	O
in	O
both	O
other	O
groups	O

in	O
the	O
npod	O
group	O
orthonasal	O
and	O
retronasal	O
scores	O
were	O
significantly	O
correlated	O
no	O
such	O
correlation	O
could	O
be	O
observed	O
in	O
pd	O
patients	B-PERCIEVER

in	O
summary	O
pd	O
patients	B-PERCIEVER
seem	O
to	O
rely	O
on	O
compensatory	O
mechanisms	O
for	O
flavor	O
perception	O

combined	O
orthonasal	O
and	O
retronasal	O
olfactory	O
testing	O
may	O
contribute	O
to	O
differentiate	O
pd	O
patients	B-PERCIEVER
from	O
patients	B-PERCIEVER
with	O
npod	O

olfaction	O
in	O
lrrk2	O
linked	O
parkinsons	O
disease	O
is	O
it	O
different	O
from	O
idiopathic	O
parkinsons	O
disease	O

background	O
studies	O
on	O
olfaction	O
in	O
lrrk2associated	O
parkinsons	O
disease	O
lrrk2pd	O
have	O
yielded	O
variable	O
results	O

the	O
impact	O
of	O
smell	O
dysfunction	O
upon	O
daily	O
life	O
activities	O
have	O
been	O
rarely	O
assessed	O
in	O
pd	O

objective	O
to	O
characterize	O
the	O
olfactory	O
deficit	O
in	O
lrrk2pd	O
and	O
its	O
impact	O
on	O
daily	O
life	O
activities	O

methods	O
twentyfour	O
lrrk2pd	O
40	O
idiopathic	O
pd	O
ipd	O
and	O
49	O
agesexmatched	O
controls	O
were	O
interviewed	O
about	O
olfactory	O
characteristics	O
and	O
the	O
impact	O
of	O
smell	O
on	O
daily	O
life	O
activities	O

the	O
barcelona	O
smell	O
identification	O
test	O
bast24	O
and	O
the	O
spanishversion	O
of	O
the	O
40item	O
university	O
of	O
pennsylvania	O
smell	O
test	O
upsit	B-SMELL_TEST
were	O
applied	O

results	O
nineteen	O
792	O
lrrk2pd	O
patients	B-PERCIEVER
reported	O
subjective	O
smell	O
impairment	O
with	O
a	O
low	O
impact	O
upon	O
daily	O
living	O
activities	O

upsit	B-SMELL_TEST
score	O
was	O
higher	O
in	O
lrrk2pd	O
than	O
in	O
ipd	O
2254798	O
vs	O
1884603	O
p	O
0042	O

all	O
ipd	O
and	O
958	O
lrrk2pd	O
patients	B-PERCIEVER
had	O
hyposmiaanosmia	O
assessed	O
by	O
means	O
of	O
the	O
upsit	B-SMELL_TEST

no	O
differences	O
were	O
found	O
between	O
lrrk2pd	O
and	O
ipd	O
regarding	O
smell	O
detection	O
memory	O
or	O
forcedchoice	O
identification	O

conclusion	O
most	O
lrrk2pd	O
patients	B-PERCIEVER
reported	O
subjective	O
smell	O
impairment	O
and	O
presented	O
hyposmia	B-OLFACTORY
according	O
to	O
validated	O
smell	O
tests	O
with	O
a	O
low	O
impact	O
of	O
the	O
smell	O
dysfunction	O
on	O
daily	O
life	O
activities	O

is	O
there	O
a	O
close	O
association	O
of	O
depression	O
with	O
either	O
constipation	O
or	O
dysosmia	O
in	O
parkinsons	O
disease	O

a	O
possible	O
association	O
between	O
depression	O
and	O
either	O
the	O
severity	O
of	O
constipation	O
or	O
dysosmia	O
in	O
parkinsons	O
disease	O
pd	O
patients	B-PERCIEVER
was	O
investigated	O
in	O
this	O
crosssectional	O
study	O

onehundred	O
six	O
patients	B-PERCIEVER
who	O
had	O
the	O
history	O
of	O
pd	O
for	O
less	O
than	O
5	O
years	O
were	O
recruited	O

depression	O
was	O
measured	O
using	O
the	O
beck	O
depression	O
inventoryii	O
bdiii	O
and	O
our	O
patients	B-PERCIEVER
were	O
divided	O
into	O
depressive	O
and	O
nondepressive	O
groups	O
dp	O
bdiii	O
14	O
n	O
22	O
and	O
ndp	O
bdiii	O
14	O
n	O
84	O

olfactory	O
dysfunction	O
was	O
assessed	O
by	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST

constipation	O
severity	O
was	O
defined	O
by	O
stool	O
softener	O
dosage	O
and	O
amount	O

statistical	O
analyses	O
with	O
onetailed	O
t	O
or	O
chisquared	O
test	O
odds	O
ratios	O
or	O
and	O
betacoefficient	O
were	O
used	O
to	O
determine	O
significant	O
differences	O

total	O
scores	O
based	O
on	O
the	O
unified	O
parkinsons	O
disease	O
rating	O
scale	O
updrs	O
were	O
significantly	O
higher	O
in	O
the	O
dp	O
group	O

a	O
significant	O
relationship	O
was	O
observed	O
between	O
pd	O
patients	B-PERCIEVER
with	O
depression	O
and	O
severe	O
constipation	O
pd	O
patients	B-PERCIEVER
with	O
depression	O
were	O
more	O
likely	O
to	O
present	O
with	O
severe	O
constipation	O
or	O
581	O
95	O
ci	O
1242729	O
p	O
0026	O
adjusted	O
for	O
age	O
and	O
gender	O
but	O
the	O
significance	O
became	O
marginal	O
after	O
adjusted	O
for	O
age	O
gender	O
and	O
updrs	O
part	O
3	O
or	O
446	O
95	O
ci	O
0932133	O
p	O
0061	O

however	O
no	O
association	O
between	O
olfactory	O
dysfunction	O
and	O
depression	O
was	O
detected	O

there	O
were	O
significant	O
positive	O
correlations	O
between	O
bdiii	O
scores	O
and	O
severe	O
constipation	O
beta	O
se	O
765	O
202	O
p	O
0001	O
adjusted	O
for	O
age	O
and	O
gender	O
beta	O
se	O
706	O
204	O
p	O
0001	O
adjusted	O
for	O
age	O
gender	O
and	O
updrs3	O

besides	O
we	O
detected	O
a	O
marginally	O
significant	O
correlation	O
that	O
pd	O
patients	B-PERCIEVER
with	O
higher	O
bdiii	O
scores	O
tended	O
to	O
present	O
more	O
severe	O
motor	O
symptoms	O

olfactory	O
dysfunction	O
seemed	O
to	O
be	O
less	O
relevant	O
to	O
bdiii	O
scores	O

based	O
on	O
our	O
findings	O
we	O
speculate	O
that	O
depression	O
may	O
be	O
more	O
closely	O
related	O
to	O
brainstem	O
nuclei	O
than	O
to	O
the	O
limbic	O
pathway	O

relationship	O
between	O
cognitive	O
impairment	O
and	O
olfactory	O
function	O
among	O
older	O
adults	O
with	O
olfactory	O
impairment	O

objective	O
understanding	O
the	O
relationships	O
among	O
aging	O
cognitive	O
function	O
and	O
olfaction	O
may	O
be	O
useful	O
for	O
diagnosing	O
olfactory	O
decline	O
in	O
older	O
adults	O

olfactory	O
function	O
declines	O
in	O
the	O
early	O
stage	O
of	O
neurodegenerative	O
diseases	O
including	O
alzheimers	O
and	O
parkinsons	O
diseases	O

aging	O
and	O
cognitive	O
impairment	O
are	O
associated	O
with	O
olfactory	O
decline	O

moreover	O
the	O
assessment	O
of	O
hyposmia	B-OLFACTORY
and	O
anosmia	B-OLFACTORY
is	O
paramount	O
to	O
the	O
diagnosis	O
of	O
neurodegenerative	O
diseases	O

we	O
aimed	O
to	O
assess	O
the	O
relationships	O
among	O
aging	O
cognitive	O
function	O
and	O
olfaction	O
in	O
patients	B-PERCIEVER
with	O
olfactory	O
impairment	O

methods	O
this	O
observational	O
study	O
included	O
141	O
patients	B-PERCIEVER
with	O
olfactory	O
deterioration	O
who	O
presented	O
with	O
dementia	B-NEURODEGENERATIVE
mild	O
cognitive	O
impairment	O
mci	O
agerelated	O
hyposmia	B-OLFACTORY
or	O
postviral	O
olfactory	O
dysfunction	O
pvod	O

the	O
patients	B-PERCIEVER
underwent	O
tt	O
olfactometry	O
a	O
selfadministered	O
odor	O
questionnaire	O
saoq	O
a	O
visual	O
analog	O
scale	O
vas	O
and	O
a	O
minimental	O
state	O
examination	O

results	O
tt	O
odor	O
recognition	O
thresholds	O
decreased	O
with	O
aging	O
p	O
001	O
and	O
cognitive	O
impairment	O
p	O
008	O

the	O
average	O
tt	O
recognition	O
thresholds	O
were	O
514642	O
and	O
37	O
in	O
dementia	B-NEURODEGENERATIVE
mci	O
agerelated	O
hyposmia	B-OLFACTORY
and	O
pvod	O
respectively	O

moreover	O
the	O
average	O
differences	O
between	O
the	O
detection	O
and	O
recognition	O
thresholds	O
were	O
37	O
28	O
23	O
and	O
20	O
in	O
dementia	B-NEURODEGENERATIVE
mci	O
agerelated	O
hyposmia	B-OLFACTORY
and	O
pvod	O
respectively	O

hyposmia	B-OLFACTORY
with	O
dementia	B-NEURODEGENERATIVE
presented	O
the	O
highest	O
recognition	O
thresholds	O
p	O
005	O
and	O
the	O
largest	O
differences	O
between	O
the	O
tt	O
detection	O
and	O
recognition	O
thresholds	O
compared	O
with	O
agerelated	O
hyposmia	B-OLFACTORY
and	O
pvod	O
p	O
005	O

hyposmia	B-OLFACTORY
with	O
dementia	B-NEURODEGENERATIVE
had	O
the	O
highest	O
saoq	O
and	O
vas	O
scores	O
compared	O
with	O
the	O
other	O
groups	O
p	O
005	O

conclusion	O
the	O
possibility	O
of	O
dementia	B-NEURODEGENERATIVE
should	O
be	O
investigated	O
in	O
patients	B-PERCIEVER
with	O
hyposmia	B-OLFACTORY
including	O
those	O
with	O
high	O
tt	O
recognition	O
thresholds	O
a	O
large	O
difference	O
between	O
the	O
tt	O
detection	O
and	O
recognition	O
thresholds	O
and	O
high	O
saoq	O
and	O
vas	O
scores	O

could	O
covid19	O
anosmia	B-OLFACTORY
and	O
olfactory	O
dysfunction	O
trigger	O
an	O
increased	O
risk	O
of	O
future	O
dementia	B-NEURODEGENERATIVE
in	O
patients	B-PERCIEVER
with	O
apoe4	O

the	O
association	O
of	O
the	O
coronavirus	O
disease	O
2019	O
covid19	O
with	O
significant	O
neurological	O
and	O
neuropsychiatric	O
complications	O
has	O
been	O
increasingly	O
reported	O
both	O
during	O
the	O
acute	O
illness	O
and	O
in	O
its	O
aftermath	O

however	O
due	O
to	O
the	O
short	O
duration	O
of	O
patient	B-PERCIEVER
follow	O
up	O
until	O
now	O
it	O
is	O
not	O
clear	O
whether	O
this	O
infection	O
will	O
be	O
associated	O
with	O
longerterm	O
neurological	O
andor	O
neuropsychiatric	O
sequelae	O

in	O
particular	O
the	O
question	O
of	O
whether	O
covid19	O
will	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
and	O
rate	O
of	O
future	O
dementia	B-NEURODEGENERATIVE
remains	O
open	O
and	O
subject	O
to	O
speculation	O

during	O
the	O
course	O
of	O
the	O
covid19	O
pandemic	O
an	O
increasing	O
number	O
of	O
patients	B-PERCIEVER
have	O
reported	O
sudden	O
anosmia	B-OLFACTORY
or	O
other	O
olfactory	O
dysfunction	O
as	O
concurrent	O
symptoms	O

the	O
possibility	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
sarscov2	O
may	O
reach	O
the	O
brain	O
via	O
the	O
olfactory	O
nerve	O
or	O
an	O
upper	O
nasal	O
trancribrial	O
route	O
is	O
an	O
interesting	O
working	O
hypothesis	O

among	O
the	O
identified	O
genetic	O
risk	O
factors	O
for	O
lateonset	O
alzheimers	O
disease	O
load	O
apo	O
e4	O
is	O
one	O
of	O
the	O
strongest	O
and	O
most	O
frequent	O

people	O
carrying	O
one	O
or	O
two	O
copies	O
of	O
the	O
e4	O
allele	O
of	O
apo	O
e4	O
have	O
significant	O
odor	O
recognition	O
deficits	O
in	O
comparison	O
to	O
those	O
not	O
carrying	O
this	O
haplotype	O

the	O
hypothesis	O
invoked	O
in	O
this	O
paper	O
is	O
that	O
anosmiaolfactory	O
dysfunctions	O
induced	O
by	O
sarscov2	O
may	O
cause	O
an	O
increased	O
a	O
risk	O
of	O
future	O
neurodegenerative	O
dementia	B-NEURODEGENERATIVE
in	O
apoe4	O
carriers	O
and	O
that	O
this	O
risk	O
would	O
be	O
higher	O
than	O
in	O
apo	O
e4	O
carriers	O
affected	O
by	O
anosmia	B-OLFACTORY
not	O
induced	O
by	O
sarscov2	O

this	O
would	O
be	O
associated	O
with	O
virusinduced	O
chronic	O
modifications	O
in	O
the	O
central	O
nervous	O
system	O

it	O
is	O
proposed	O
that	O
covid19	O
patients	B-PERCIEVER
with	O
anosmia	B-OLFACTORY
and	O
no	O
other	O
serious	O
symptoms	O
should	O
be	O
followed	O
up	O
as	O
part	O
of	O
specifically	O
designed	O
and	O
approved	O
studies	O
in	O
order	O
to	O
identify	O
the	O
early	O
stages	O
of	O
dementia	B-NEURODEGENERATIVE
especially	O
load	O
and	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
thereby	O
improving	O
our	O
knowledge	O
of	O
the	O
mechanisms	O
involved	O
in	O
precognitive	O
stages	O
of	O
neurodegenerative	O
dementia	B-NEURODEGENERATIVE
and	O
making	O
best	O
use	O
of	O
any	O
available	O
therapies	O

this	O
latter	O
opportunity	O
is	O
unique	O
and	O
should	O
not	O
be	O
lost	O

using	O
the	O
chinese	O
smell	O
identification	O
test	O
to	O
explore	O
olfactory	O
function	O
in	O
parkinsons	O
disease	O

introduction	O
the	O
chinese	O
smell	O
identification	O
test	O
csit	O
was	O
developed	O
specifically	O
for	O
chinese	O
populations	O

this	O
work	O
investigated	O
the	O
utility	O
of	O
this	O
test	O
in	O
detecting	O
parkinsons	O
disease	O
pd	O

olfactory	O
dysfunction	O
is	O
a	O
common	O
nonmotor	O
symptom	O
of	O
pd	O

there	O
are	O
different	O
opinions	O
on	O
the	O
efficacy	O
of	O
drugs	O
for	O
anosmia	B-OLFACTORY
in	O
pdobjective	O
to	O
investigate	O
the	O
olfactory	O
function	O
of	O
chinese	O
pd	O
patients	B-PERCIEVER
verify	O
the	O
effectiveness	O
of	O
the	O
csit	O
and	O
further	O
detect	O
the	O
effects	O
of	O
dopaminergic	O
drugs	O
on	O
anosmiamethods	O
in	O
total	O
149	O
pd	O
patients	B-PERCIEVER
were	O
recruited	O
from	O
the	O
first	O
affiliated	O
hospital	O
of	O
anhui	O
medical	O
university	O
and	O
149	O
healthy	O
comparison	O
participants	B-PERCIEVER
hcp	O
were	O
recruited	O
from	O
the	O
institute	O
of	O
psychology	O
of	O
the	O
chinese	O
academy	O
of	O
sciences	O

the	O
csit	O
was	O
used	O
for	O
olfactory	O
function	O
testing	O
in	O
all	O
participantsresults	O
csit	O
scores	O
were	O
significantly	O
lower	O
in	O
the	O
pd	O
group	O
than	O
in	O
the	O
hcp	O
group	O
t296	O
12797	O
p	O
0001	O
d	O
148	O

receiver	O
operating	O
characteristic	O
curve	O
analysis	O
showed	O
that	O
the	O
optimal	O
threshold	O
value	O
for	O
the	O
olfactory	O
recognition	O
test	O
was	O
225	O
which	O
had	O
a	O
sensitivity	O
and	O
specificity	O
of	O
711	O
and	O
893	O
respectively	O
for	O
the	O
detection	O
of	O
parkinsons	O
disease	O

sex	O
showed	O
a	O
significant	O
influence	O
on	O
csit	O
score	O
t	O
3552	O
p	O
0001	O
with	O
males	O
being	O
more	O
likely	O
to	O
develop	O
olfactory	O
dysfunction	O

we	O
found	O
csit	O
scores	O
of	O
the	O
nonmedication	O
group	O
and	O
the	O
group	O
with	O
medication	O
were	O
lower	O
than	O
those	O
of	O
the	O
hcp	O
group	O
and	O
the	O
difference	O
was	O
statistically	O
significant	O
t82	O
7116	O
p	O
00167	O
d	O
159	O
t82	O
4907	O
p	O
00167	O
d	O
110	O

csit	O
scores	O
of	O
the	O
group	O
with	O
medication	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
nonmedication	O
group	O
t41	O
3067	O
p	O
00167	O
d	O
041conclusions	O
in	O
china	O
the	O
csit	O
is	O
recommended	O
to	O
improve	O
the	O
sensitivity	O
of	O
pd	O
detection	O

the	O
olfactory	O
function	O
of	O
pd	O
patients	B-PERCIEVER
was	O
improved	O
after	O
treatment	O
with	O
dopaminergic	O
drugs	O

covid19	O
and	O
parkinsons	O
disease	O
defects	O
in	O
neurogenesis	O
as	O
the	O
potential	O
cause	O
of	O
olfactory	O
system	O
impairments	O
and	O
anosmia	B-OLFACTORY

anosmia	B-OLFACTORY
a	O
neuropathogenic	O
condition	O
of	O
loss	O
of	O
smell	O
has	O
been	O
recognized	O
as	O
a	O
key	O
pathogenic	O
hallmark	O
of	O
the	O
current	O
pandemic	O
sarscov2	O
infection	O
responsible	O
for	O
covid19	O

while	O
the	O
anosmia	B-OLFACTORY
resulting	O
from	O
olfactory	O
bulb	O
ob	O
pathology	O
is	O
the	O
prominent	O
clinical	O
characteristic	O
of	O
parkinsons	O
disease	O
pd	O
sarscov2	O
infection	O
has	O
been	O
predicted	O
as	O
a	O
potential	O
risk	O
factor	O
for	O
developing	O
parkinsonismrelated	O
symptoms	O
in	O
a	O
significant	O
portion	O
of	O
covid19	O
patients	B-PERCIEVER
and	O
survivors	O

sarscov2	O
infection	O
appears	O
to	O
alter	O
the	O
dopamine	O
system	O
and	O
induce	O
the	O
loss	O
of	O
dopaminergic	O
neurons	O
that	O
have	O
been	O
known	O
to	O
be	O
the	O
cause	O
of	O
pd	O

however	O
the	O
underlying	O
biological	O
basis	O
of	O
anosmia	B-OLFACTORY
and	O
the	O
potential	O
link	O
between	O
covid19	O
and	O
pd	O
remains	O
obscure	O

ample	O
experimental	O
studies	O
in	O
rodents	O
suggest	O
that	O
the	O
occurrence	O
of	O
neural	O
stem	O
cell	O
nsc	O
mediated	O
neurogenesis	O
in	O
the	O
olfactory	O
epithelium	O
oe	O
and	O
ob	O
is	O
important	O
for	O
olfaction	O

though	O
the	O
occurrence	O
of	O
neurogenesis	O
in	O
the	O
human	B-PERCIEVER
forebrain	O
has	O
been	O
a	O
subject	O
of	O
debate	O
considerable	O
experimental	O
evidence	O
strongly	O
supports	O
the	O
incidence	O
of	O
neurogenesis	O
in	O
the	O
human	B-PERCIEVER
ob	O
in	O
adulthood	O

to	O
note	O
various	O
viral	O
infections	O
and	O
neuropathogenic	O
conditions	O
including	O
pd	O
with	O
olfactory	O
dysfunctions	O
have	O
been	O
characterized	O
by	O
impaired	O
neurogenesis	O
in	O
ob	O
and	O
oe	O

therefore	O
this	O
article	O
describes	O
and	O
examines	O
the	O
recent	O
reports	O
on	O
sarscov2	O
mediated	O
ob	O
dysfunctions	O
and	O
defects	O
in	O
the	O
dopaminergic	O
system	O
responsible	O
for	O
pd	O

further	O
the	O
article	O
emphasizes	O
that	O
covid19	O
and	O
pd	O
associated	O
anosmia	B-OLFACTORY
could	O
result	O
from	O
the	O
regenerative	O
failure	O
in	O
the	O
replenishment	O
of	O
the	O
dopaminergic	O
neurons	O
in	O
ob	O
and	O
olfactory	O
sensory	O
neurons	O
in	O
oe	O

the	O
nature	O
and	O
course	O
of	O
olfactory	O
deficits	O
in	O
alzheimers	O
disease	O

objective	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
specific	O
nature	O
and	O
course	O
of	O
olfactory	O
deficits	O
in	O
alzheimers	O
disease	O

previous	O
studies	O
had	O
noted	O
impaired	O
odor	O
identification	O
but	O
there	O
was	O
no	O
unanimity	O
about	O
the	O
presence	O
of	O
odor	O
detection	O
deficits	O

method	O
odor	O
identification	O
was	O
tested	O
in	O
55	O
patients	B-PERCIEVER
with	O
alzheimers	O
disease	O
and	O
57	O
elderly	O
control	O
subjects	B-PERCIEVER
by	O
using	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O

odor	O
detection	O
was	O
assessed	O
in	O
46	O
subjects	B-PERCIEVER
with	O
alzheimers	O
disease	O
and	O
40	O
control	O
subjects	B-PERCIEVER
by	O
using	O
a	O
forcedchoice	O
threshold	O
test	O
with	O
geraniol	O
as	O
the	O
odorant	B-SMELL_SOURCE

results	O
significant	O
deficits	O
in	O
olfactory	O
identification	O
were	O
present	O
in	O
subjects	B-PERCIEVER
who	O
were	O
in	O
the	O
earliest	O
stages	O
of	O
cognitive	O
impairment	O
and	O
these	O
deficits	O
increased	O
as	O
alzheimers	O
disease	O
progressed	O

there	O
was	O
some	O
overlap	O
in	O
individual	O
smell	O
identification	O
test	O
scores	O
between	O
cognitively	O
impaired	O
patients	B-PERCIEVER
and	O
normal	O
elderly	O
subjects	B-PERCIEVER

on	O
the	O
other	O
hand	O
odor	O
detection	O
deficits	O
did	O
not	O
appear	O
until	O
alzheimers	O
disease	O
was	O
relatively	O
advanced	O

smell	O
identification	O
test	O
scores	O
were	O
correlated	O
with	O
minimental	O
state	O
scores	O
but	O
geraniol	O
detection	O
was	O
not	O

conclusions	O
odor	O
identification	O
is	O
impaired	O
early	O
in	O
alzheimers	O
disease	O
and	O
may	O
be	O
more	O
influenced	O
by	O
cognitive	O
status	O
than	O
is	O
acuity	O
of	O
odor	O
detection	O
which	O
is	O
not	O
altered	O
until	O
later	O
in	O
the	O
disorder	O

the	O
pattern	O
of	O
hyposmia	B-OLFACTORY
in	O
alzheimers	O
disease	O
suggests	O
that	O
the	O
disorder	O
may	O
not	O
begin	O
in	O
the	O
nose	O
as	O
has	O
been	O
theorized	O
previously	O

further	O
refinement	O
of	O
olfactory	O
testing	O
may	O
be	O
useful	O
in	O
the	O
diagnostic	O
evaluation	O
of	O
early	O
dementia	B-NEURODEGENERATIVE

loss	O
of	O
olfactory	O
function	O
in	O
dementing	O
disease	O

alzheimers	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
show	O
neuropathological	O
changes	O
in	O
areas	O
of	O
the	O
brain	O
central	O
to	O
olfactory	O
processing	O
suggesting	O
the	O
theoretical	O
importance	O
and	O
potential	O
diagnostic	O
utility	O
of	O
investigating	O
functional	O
changes	O
in	O
olfaction	O
in	O
these	O
patients	B-PERCIEVER

persons	O
with	O
downs	O
syndrome	O
who	O
live	O
to	O
the	O
fourth	O
decade	O
develop	O
neuropathological	O
changes	O
in	O
the	O
brain	O
similar	O
to	O
those	O
found	O
in	O
ad	B-NEURODEGENERATIVE

a	O
series	O
of	O
investigations	O
have	O
been	O
conducted	O
to	O
assess	O
olfaction	O
function	O
in	O
both	O
patients	B-PERCIEVER
with	O
alzheimers	O
disease	O
and	O
persons	O
with	O
downs	O
syndrome	O

functional	O
testing	O
included	O
olfactory	O
threshold	O
odor	O
identification	O
odor	O
similarity	O
judgements	O
odor	O
recognition	O
memory	O
odor	O
recall	O
odor	O
fluency	O

both	O
alzheimers	O
patients	B-PERCIEVER
and	O
persons	O
with	O
downs	O
syndrome	O
showed	O
significant	O
impairment	O
in	O
olfactory	O
function	O
with	O
some	O
measures	O
showing	O
more	O
impairment	O
than	O
others	O
in	O
the	O
early	O
stages	O
of	O
the	O
disease	O
process	O

longitudinal	O
investigation	O
of	O
several	O
of	O
the	O
measures	O
indicated	O
decreased	O
function	O
over	O
time	O
consonant	O
with	O
falling	O
drs	O
scores	O

normal	O
controls	O
who	O
tested	O
positive	O
for	O
the	O
apoe4	O
allele	O
showed	O
impaired	O
odor	O
identification	O
compared	O
to	O
those	O
who	O
were	O
allele	O
negative	O

patients	B-PERCIEVER
with	O
huntingtons	O
disease	O
showed	O
olfactory	O
functional	O
impairments	O
although	O
the	O
degree	O
of	O
impairment	O
differed	O
from	O
the	O
cortical	O
dementias	O
for	O
some	O
of	O
these	O
tasks	O

the	O
sensitivity	O
and	O
specificity	O
of	O
these	O
assessments	O
will	O
be	O
discussed	O
in	O
relation	O
to	O
analogous	O
assessments	O
in	O
other	O
sensory	O
modalities	O

anosmia	B-OLFACTORY
in	O
dementia	B-NEURODEGENERATIVE
is	O
associated	O
with	O
lewy	O
bodies	O
rather	O
than	O
alzheimers	O
pathology	O

anosmia	B-OLFACTORY
is	O
very	O
common	O
in	O
the	O
lewy	O
body	O
variant	O
of	O
alzheimers	O
disease	O

background	O
olfactory	O
abnormalities	O
are	O
reported	O
in	O
alzheimers	O
disease	O
and	O
parkinsons	O
disease	O

anosmia	B-OLFACTORY
appears	O
to	O
be	O
common	O
in	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
but	O
not	O
in	O
pure	O
alzheimers	O
disease	O

objective	O
to	O
determine	O
whether	O
anosmia	B-OLFACTORY
improves	O
discrimination	O
between	O
the	O
lewy	O
body	O
variant	O
lbv	O
of	O
alzheimers	O
disease	O
and	O
pure	O
alzheimers	O
disease	O

methods	O
106	O
cases	O
of	O
necropsy	O
confirmed	O
pure	O
alzheimers	O
disease	O
n	O
89	O
or	O
lbv	O
n	O
17	O
were	O
reviewed	O

all	O
had	O
received	O
butanol	O
odour	O
threshold	O
testing	O

anosmia	B-OLFACTORY
was	O
defined	O
as	O
a	O
score	O
or	O
10	O
on	O
a	O
09	O
point	O
scale	O

logistic	O
regression	O
analysis	O
was	O
used	O
to	O
model	O
potential	O
predictors	O
for	O
example	O
parkinsonism	O
smoking	O
hallucinations	O
of	O
neuropathological	O
diagnosis	O
and	O
anosmia	B-OLFACTORY

results	O
lbv	O
cases	O
had	O
an	O
increased	O
prevalence	O
of	O
anosmia	B-OLFACTORY
65	O
compared	O
with	O
alzheimers	O
disease	O
23	O
odds	O
ratio	O
or	O
63	O
p	O
000045	O
or	O
normal	O
elderly	O
people	O
67	O

within	O
the	O
dementia	B-NEURODEGENERATIVE
cases	O
the	O
negative	O
predictive	O
value	O
92	O
and	O
specificity	O
78	O
of	O
anosmia	B-OLFACTORY
were	O
both	O
good	O
sensitivity	O
for	O
detecting	O
lbv	O
was	O
65	O
but	O
the	O
positive	O
predictive	O
value	O
ppv	O
was	O
only	O
35	O

logistic	O
regression	O
models	O
showed	O
anosmia	B-OLFACTORY
or	O
54	O
p	O
0005	O
and	O
visual	O
hallucinations	O
or	O
73	O
p	O
0007	O
were	O
strong	O
independent	O
predictors	O
of	O
lewy	O
body	O
pathology	O

when	O
anosmia	B-OLFACTORY
was	O
added	O
as	O
a	O
core	O
feature	O
to	O
consensus	O
diagnostic	O
criteria	O
for	O
probable	O
lewy	O
body	O
dementia	B-NEURODEGENERATIVE
five	O
additional	O
cases	O
of	O
lbv	O
were	O
detected	O
29	O
increased	O
sensitivity	O
but	O
with	O
four	O
additional	O
false	O
positives	O
1	O
increased	O
discrimination	O
4	O
decreased	O
specificity	O
33	O
decreased	O
ppv	O

conclusions	O
anosmia	B-OLFACTORY
is	O
very	O
common	O
in	O
lbv	O

adding	O
anosmia	B-OLFACTORY
as	O
a	O
core	O
feature	O
improved	O
sensitivity	O
for	O
detecting	O
lbv	O
but	O
did	O
not	O
improve	O
discrimination	O
between	O
alzheimers	O
disease	O
and	O
lbv	O
owing	O
to	O
a	O
concomitant	O
increase	O
in	O
false	O
positives	O

is	O
olfactory	O
impairment	O
in	O
parkinson	O
disease	O
related	O
to	O
phenotypic	O
or	O
genotypic	O
characteristics	O

objective	O
to	O
evaluate	O
the	O
relation	O
between	O
olfactory	O
impairment	O
oi	O
and	O
other	O
impairment	O
domains	O
in	O
parkinson	O
disease	O
pd	O
and	O
the	O
characteristics	O
of	O
oi	O
in	O
patients	B-PERCIEVER
with	O
certain	O
genotypic	O
characteristics	O

methods	O
in	O
295	O
nondemented	O
patients	B-PERCIEVER
with	O
pd	O
and	O
150	O
controls	O
with	O
a	O
similar	O
overall	O
age	O
and	O
sex	O
distribution	O
olfactory	O
function	O
was	O
evaluated	O
with	O
the	O
identification	O
id	O
and	O
discrimination	O
dis	O
tests	O
of	O
the	O
sniffin	O
sticks	O

in	O
patients	B-PERCIEVER
demographic	O
and	O
clinical	O
characteristics	O
were	O
evaluated	O
and	O
genetic	O
analyses	O
were	O
performed	O

results	O
of	O
all	O
patients	B-PERCIEVER
61	O
had	O
an	O
impaired	O
id	O
and	O
43	O
had	O
an	O
impaired	O
dis	O

no	O
significant	O
correlations	O
04	O
were	O
found	O
between	O
olfactory	O
scores	O
and	O
other	O
demographic	O
or	O
clinical	O
variables	O

age	O
and	O
sex	O
accounted	O
for	O
the	O
22	O
explained	O
variance	O
of	O
the	O
id	O
score	O
regression	O
model	O
whereas	O
age	O
sex	O
and	O
disease	O
duration	O
accounted	O
for	O
the	O
15	O
explained	O
variance	O
of	O
the	O
dis	O
score	O
regression	O
model	O

parkin	O
and	O
dj1	O
mutation	O
carriers	O
homozygous	O
or	O
heterozygous	O
compound	O
n	O
6	O
had	O
normal	O
id	O
scores	O

apoe	O
epsilon2	O
or	O
apoe	O
epsilon4	O
carriers	O
had	O
no	O
significantly	O
different	O
olfactory	O
scores	O
than	O
noncarriers	O

the	O
allele	O
distribution	O
of	O
the	O
alphasynuclein	O
sncarep1	O
polymorphism	O
in	O
groups	O
with	O
an	O
impaired	O
or	O
normal	O
id	O
or	O
dis	O
was	O
comparable	O

conclusions	O
olfactory	O
impairment	O
oi	O
in	O
parkinson	O
disease	O
pd	O
may	O
be	O
unrelated	O
to	O
other	O
impairment	O
domains	O
of	O
the	O
disease	O
which	O
may	O
indicate	O
that	O
olfaction	O
is	O
an	O
independent	O
feature	O
of	O
pd	O

parkin	O
and	O
dj1	O
mutation	O
carriers	O
had	O
normal	O
identification	O
scores	O
but	O
the	O
number	O
of	O
mutation	O
carriers	O
is	O
too	O
small	O
to	O
draw	O
conclusions	O

the	O
apoe	O
genotype	O
apoe	O
epsilon2	O
or	O
apoe	O
epsilon4	O
alleles	O
and	O
sncarep1	O
polymorphism	O
do	O
not	O
seem	O
to	O
influence	O
olfaction	O
in	O
pd	O

ageing	O
neurodegeneration	O
and	O
olfactory	O
and	O
gustatory	O
loss	O

olfactory	O
and	O
gustatory	O
disorders	O
increase	O
with	O
advancing	O
age	O

moreover	O
olfactory	O
disorders	O
are	O
common	O
in	O
neurodegenerative	O
disorders	O
especially	O
in	O
idiopathic	O
parkinsons	O
disease	O
ipd	O
and	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE

since	O
the	O
decrease	O
in	O
olfactory	O
function	O
is	O
usually	O
gradual	O
it	O
often	O
remains	O
undetected	O

given	O
the	O
poor	O
selfassessment	O
of	O
olfactory	O
function	O
olfactory	O
testing	O
is	O
mandatory	O
in	O
suspected	O
cases	O
to	O
establish	O
the	O
diagnosis	O
of	O
hyposmia	B-OLFACTORY
or	O
anosmia	B-OLFACTORY

the	O
high	O
rate	O
of	O
anosmia	B-OLFACTORY
over	O
the	O
age	O
of	O
70	O
is	O
suspected	O
to	O
be	O
due	O
to	O
several	O
factors	O
such	O
as	O
changes	O
in	O
the	O
olfactory	O
epithelium	O
reduced	O
mucus	O
secretion	O
hormonal	O
changes	O
changes	O
in	O
epithelial	O
thickness	O
for	O
example	O
and	O
the	O
reduced	O
neuroregeneration	O
rate	O
in	O
olfactory	O
receptor	O
cells	O
themselves	O

there	O
is	O
no	O
known	O
adequate	O
treatment	O
for	O
stopping	O
or	O
reversing	O
this	O
agerelated	O
decline	O
in	O
olfaction	O

in	O
ipd	O
olfactory	O
impairment	O
precedes	O
motor	O
symptoms	O
by	O
years	O
and	O
is	O
independent	O
of	O
dopaminergic	O
loss	O

using	O
fmri	O
altered	O
neuronal	O
activity	O
in	O
the	O
amygdaloid	O
complex	O
and	O
hippocampal	O
formation	O
during	O
olfactory	O
stimulation	O
have	O
been	O
demonstrated	O
as	O
has	O
a	O
link	O
between	O
the	O
expression	O
of	O
olfactory	O
eventrelated	O
potentials	O
and	O
olfactoryinduced	O
brain	O
activity	O

in	O
adby	O
contrast	O
with	O
ipdthe	O
severity	O
of	O
the	O
disease	O
and	O
the	O
olfactory	O
disorder	O
correlate	O

the	O
olfactory	O
disorders	O
alone	O
however	O
cannot	O
distinguish	O
between	O
ad	B-NEURODEGENERATIVE
and	O
ipd	O

a	O
complete	O
loss	O
of	O
gustatory	O
function	O
is	O
rare	O
while	O
dysgeusia	O
is	O
common	O
especially	O
with	O
increasing	O
age	O

there	O
are	O
multiple	O
possible	O
explanations	O
including	O
concomitant	O
disease	O
and	O
the	O
sideeffects	O
of	O
medication	O

these	O
need	O
to	O
be	O
established	O
on	O
the	O
basis	O
of	O
exact	O
history	O
and	O
examination	O

treatment	O
remains	O
difficult	O

trigeminal	O
system	O
in	O
parkinsons	O
disease	O
a	O
potential	O
avenue	O
to	O
detect	O
parkinsonspecific	O
olfactory	O
dysfunction	O

background	O
olfactory	O
dysfunction	O
od	O
is	O
very	O
frequent	O
in	O
parkinsons	O
disease	O
pd	O
and	O
observed	O
years	O
before	O
diagnosis	O

the	O
trigeminal	O
system	O
a	O
chemosensory	O
system	O
allowing	O
for	O
the	O
perception	O
of	O
spiciness	O
freshness	O
etc	O
is	O
intimately	O
connected	O
to	O
the	O
olfactory	O
system	O
and	O
although	O
usually	O
reduced	O
in	O
od	O
the	O
trigeminal	O
system	O
is	O
not	O
well	O
characterized	O
in	O
pd	O

we	O
hypothesize	O
that	O
measuring	O
trigeminal	O
sensitivity	O
potentially	O
allows	O
to	O
discriminate	O
between	O
od	O
due	O
to	O
pd	O
and	O
od	O
due	O
to	O
other	O
causes	O
to	O
potentially	O
help	O
the	O
development	O
of	O
an	O
early	O
diagnostic	O
tool	O

objective	O
to	O
evaluate	O
olfactory	O
and	O
trigeminal	O
sensitivity	O
and	O
perception	O
in	O
pd	O
patients	B-PERCIEVER
and	O
compare	O
them	O
to	O
participants	B-PERCIEVER
with	O
nonparkinsonian	O
od	O
npod	O
and	O
to	O
healthy	O
controls	O

methods	O
we	O
assessed	O
olfactory	O
function	O
using	O
sniffin	O
sticks	O
test	O
and	O
trigeminal	O
function	O
with	O
the	O
localization	O
task	O
in	O
28	O
pd	O
patients	B-PERCIEVER
27	O
healthy	O
controls	O
and	O
21	O
patients	B-PERCIEVER
with	O
od	O
unrelated	O
to	O
pd	O

results	O
pd	O
patients	B-PERCIEVER
exhibited	O
significantly	O
higher	O
trigeminal	O
sensitivity	O
than	O
npod	O
patients	B-PERCIEVER
p	O
0002	O
and	O
performed	O
similar	O
to	O
healthy	O
controls	O

in	O
contrast	O
pd	O
and	O
npod	O
patients	B-PERCIEVER
had	O
both	O
similar	O
olfactory	O
scores	O
significantly	O
below	O
healthy	O
controls	O

conclusion	O
the	O
trigeminal	O
system	O
seems	O
not	O
to	O
be	O
impaired	O
in	O
pd	O
patients	B-PERCIEVER
even	O
in	O
the	O
presence	O
of	O
od	O

measuring	O
trigeminal	O
sensitivity	O
may	O
therefore	O
allow	O
to	O
differentiate	O
pdrelated	O
od	O
from	O
other	O
forms	O
of	O
od	O

olfactory	O
phenotypes	O
differentiate	O
cognitively	O
unimpaired	O
seniors	O
from	O
alzheimers	O
disease	O
and	O
mild	O
cognitive	O
impairment	O
a	O
combined	O
machine	O
learning	O
and	O
traditional	O
statistical	O
approach	O

background	O
olfactory	O
dysfunction	O
od	O
is	O
an	O
early	O
symptom	O
of	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE

however	O
olfactory	O
testing	O
is	O
not	O
commonly	O
performed	O
to	O
test	O
od	O
in	O
the	O
setting	O
of	O
ad	B-NEURODEGENERATIVE

objective	O
this	O
work	O
investigates	O
objective	O
od	O
as	O
a	O
noninvasive	O
biomarker	O
for	O
accurately	O
classifying	O
subjects	B-PERCIEVER
as	O
cognitively	O
unimpaired	O
cu	O
mild	O
cognitive	O
impairment	O
mci	O
and	O
ad	B-NEURODEGENERATIVE

methods	O
patients	B-PERCIEVER
with	O
mci	O
n	O
24	O
and	O
ad	B-NEURODEGENERATIVE
n	O
24	O
and	O
cu	O
n	O
33	O
controls	O
completed	O
two	O
objective	O
tests	O
of	O
olfaction	O
affordable	O
rapid	O
olfactory	O
measurement	O
array	O
aroma	O
sniffin	O
sticks	O
screening	O
12	O
test	O
sst12	O

demographic	O
and	O
subjective	O
sinonasal	O
and	O
olfaction	O
symptom	O
information	O
was	O
also	O
obtained	O

analyses	O
utilized	O
traditional	O
statistics	O
and	O
machine	O
learning	O
to	O
determine	O
olfactory	O
variables	O
and	O
combinations	O
of	O
variables	O
of	O
importance	O
for	O
differentiating	O
normal	O
and	O
disease	O
states	O

results	O
inability	O
to	O
correctly	O
identify	O
a	O
scent	O
after	O
detection	O
was	O
a	O
hallmark	O
of	O
mciad	O

aroma	O
was	O
superior	O
to	O
sst12	O
for	O
differentiating	O
mci	O
from	O
ad	B-NEURODEGENERATIVE

performance	O
on	O
the	O
clove	B-SMELL_SOURCE
scent	O
was	O
significantly	O
different	O
between	O
all	O
three	O
groups	O

aroma	O
regression	O
modeling	O
yielded	O
six	O
scents	O
with	O
auc	O
of	O
the	O
roc	O
of	O
0890	O
p	O
0001	O

random	O
forest	O
model	O
machine	O
learning	O
algorithms	O
considering	O
aroma	O
olfactory	O
data	O
successfully	O
predicted	O
mci	O
versus	O
ad	B-NEURODEGENERATIVE
disease	O
state	O

considering	O
only	O
aroma	O
data	O
machine	O
learning	O
algorithms	O
were	O
875accurate	O
95ci	O
04735	O
09968	O

sensitivity	O
and	O
specificity	O
were	O
100and	O
75	O
respectively	O
with	O
roc	O
of	O
0875	O

when	O
considering	O
aroma	O
and	O
subject	O
demographic	O
and	O
subjective	O
data	O
the	O
auc	O
of	O
the	O
roc	O
increased	O
to	O
09375	O

conclusion	O
od	O
differentiates	O
cus	O
from	O
those	O
with	O
mci	O
and	O
ad	B-NEURODEGENERATIVE
and	O
can	O
accurately	O
predict	O
mci	O
versus	O
ad	B-NEURODEGENERATIVE

leveraging	O
od	O
data	O
may	O
meaningfully	O
guide	O
management	O
and	O
research	O
decisions	O

slow	O
motion	O
analysis	O
of	O
repetitive	O
tapping	O
smart	O
test	O
measuring	O
bradykinesia	O
in	O
recently	O
diagnosed	O
parkinsons	O
disease	O
and	O
idiopathic	O
anosmia	B-OLFACTORY

background	O
bradykinesia	O
is	O
the	O
defining	O
motor	O
feature	O
of	O
parkinsons	O
disease	O
pd	O

there	O
are	O
limitations	O
to	O
its	O
assessment	O
using	O
standard	O
clinical	O
rating	O
scales	O
especially	O
in	O
the	O
early	O
stages	O
of	O
pd	O
when	O
a	O
floor	O
effect	O
may	O
be	O
observed	O

objective	O
to	O
develop	O
a	O
quantitative	O
method	O
to	O
track	O
repetitive	O
tapping	O
movements	O
and	O
to	O
compare	O
people	O
in	O
the	O
early	O
stages	O
of	O
pd	O
healthy	O
controls	O
and	O
individuals	O
with	O
idiopathic	O
anosmia	B-OLFACTORY

methods	O
this	O
was	O
a	O
crosssectional	O
study	O
of	O
99	O
participants	B-PERCIEVER
earlystage	O
pd	O
26	O
controls	O
64	O
idiopathic	O
anosmia	B-OLFACTORY
9	O

for	O
each	O
participant	O
repetitive	O
finger	O
tapping	O
was	O
recorded	O
over	O
20	O
seconds	O
using	O
a	O
smartphone	O
at	O
240	O
frames	O
per	O
second	O

from	O
each	O
video	O
amplitude	O
between	O
fingers	O
frequency	O
number	O
of	O
taps	O
per	O
second	O
and	O
velocity	O
distance	O
travelled	O
per	O
second	O
was	O
extracted	O

clinical	O
assessment	O
was	O
based	O
on	O
the	O
motor	O
section	O
of	O
the	O
mdsupdrs	O

results	O
people	O
in	O
the	O
early	O
stage	O
of	O
pd	O
performed	O
the	O
task	O
with	O
slower	O
velocity	O
p	O
0001	O
and	O
with	O
greater	O
frequency	O
slope	O
than	O
controls	O
p	O
0003	O

the	O
combination	O
of	O
reduced	O
velocity	O
and	O
greater	O
frequency	O
slope	O
obtained	O
the	O
best	O
accuracy	O
to	O
separate	O
earlystage	O
pd	O
from	O
controls	O
based	O
on	O
metric	O
thresholds	O
alone	O
auc	O
088	O

individuals	O
with	O
anosmia	B-OLFACTORY
exhibited	O
slower	O
velocity	O
p	O
0001	O
and	O
smaller	O
amplitude	O
p	O
0001	O
compared	O
with	O
controls	O

conclusion	O
we	O
present	O
a	O
simple	O
proofofconcept	O
method	O
to	O
detect	O
early	O
motor	O
dysfunction	O
in	O
pd	O

mean	O
tap	O
velocity	O
appeared	O
to	O
be	O
the	O
best	O
parameter	O
to	O
differentiate	O
patients	B-PERCIEVER
with	O
pd	O
from	O
controls	O

patients	B-PERCIEVER
with	O
anosmia	B-OLFACTORY
also	O
showed	O
detectable	O
differences	O
in	O
motor	O
performance	O
compared	O
with	O
controls	O
which	O
may	O
suggest	O
that	O
some	O
were	O
in	O
the	O
prodromal	O
phase	O
of	O
pd	O

odor	O
identification	O
predicts	O
the	O
transition	O
of	O
patients	B-PERCIEVER
with	O
isolated	O
rbd	O
a	O
retrospective	O
study	O

introduction	O
to	O
determine	O
if	O
the	O
severity	O
of	O
olfactory	O
dysfunction	O
in	O
isolated	O
rem	O
sleep	O
behavior	O
disorder	O
irbd	O
predicts	O
conversion	O
to	O
parkinsons	O
disease	O
pd	O
or	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
dlb	O

methods	O
olfaction	O
was	O
tested	O
using	O
the	O
japanese	O
version	O
of	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsitj	O
in	O
155	O
consecutive	O
patients	B-PERCIEVER
with	O
polysomnographyconfirmed	O
irbd	O
and	O
34	O
healthy	O
controls	O

irbd	O
patients	B-PERCIEVER
were	O
followed	O
up	O
for	O
58	O
32	O
range	O
0211	O
years	O

thirtyeight	O
patients	B-PERCIEVER
underwent	O
repeat	O
upsitj	O
evaluation	O
at	O
27	O
13	O
years	O
after	O
the	O
baseline	O
test	O

results	O
upsitj	O
score	O
was	O
lower	O
in	O
irbd	O
patients	B-PERCIEVER
than	O
in	O
age	O
and	O
sexmatched	O
controls	O

the	O
receiver	O
operating	O
characteristic	O
curve	O
analysis	O
showed	O
that	O
the	O
optimal	O
cutoff	O
score	O
of	O
225	O
in	O
upsitj	O
discriminated	O
between	O
irbd	O
patients	B-PERCIEVER
and	O
controls	O
with	O
a	O
sensitivity	O
of	O
943	O
and	O
specificity	O
of	O
818	O

anosmia	B-OLFACTORY
upsitj	O
score	O
19	O
was	O
present	O
in	O
542	O
of	O
irbd	O
patients	B-PERCIEVER

in	O
total	O
42	O
patients	B-PERCIEVER
developed	O
a	O
neurodegenerative	O
disease	O
of	O
whom	O
17	O
had	O
pd	O
22	O
dlb	O
and	O
3	O
msa	O

kaplanmeier	O
analysis	O
showed	O
that	O
the	O
shortterm	O
risk	O
of	O
lewy	O
body	O
disease	O
lbd	O
was	O
higher	O
in	O
patients	B-PERCIEVER
with	O
anosmia	B-OLFACTORY
than	O
in	O
those	O
without	O
anosmia	B-OLFACTORY

at	O
baseline	O
the	O
upsitj	O
score	O
was	O
similar	O
between	O
patients	B-PERCIEVER
who	O
developed	O
pd	O
and	O
dlb	O
p	O
0136	O

all	O
three	O
irbd	O
patients	B-PERCIEVER
100	O
who	O
developed	O
msa	O
did	O
not	O
have	O
anosmia	B-OLFACTORY

conclusions	O
in	O
irbd	O
patients	B-PERCIEVER
anosmia	B-OLFACTORY
predicts	O
a	O
higher	O
shortterm	O
risk	O
of	O
transition	O
to	O
lbd	O
but	O
cannot	O
distinguish	O
between	O
pd	O
and	O
dlb	O

at	O
baseline	O
preserved	O
odor	O
identification	O
may	O
occur	O
in	O
latent	O
msa	O

future	O
irbd	O
neuroprotective	O
trials	O
should	O
evaluate	O
anosmia	B-OLFACTORY
as	O
a	O
marker	O
of	O
prodromal	O
lbd	O

identifying	O
the	O
potential	O
role	O
of	O
serum	O
mir20a	O
as	O
a	O
biomarker	O
for	O
olfactory	O
dysfunction	O
in	O
patients	B-PERCIEVER
with	O
parkinsons	O
disease	O

introduction	O
olfactory	O
dysfunction	O
od	O
one	O
of	O
the	O
most	O
common	O
nonmotor	O
symptoms	O
in	O
parkinsons	O
disease	O
pd	O
is	O
a	O
cardinal	O
prodromal	O
symptom	O
that	O
can	O
appear	O
years	O
before	O
the	O
onset	O
of	O
motor	O
symptoms	O

ongoing	O
studies	O
have	O
demonstrated	O
that	O
micrornas	O
mirnas	O
are	O
suitable	O
biomarkers	O
for	O
pd	O
while	O
there	O
is	O
a	O
lack	O
of	O
robust	O
mirnas	O
that	O
can	O
serve	O
as	O
markers	O
for	O
od	O
in	O
pd	O

methods	O
the	O
concordantly	O
differentially	O
expressed	O
mirnas	O
de	O
mirnas	O
in	O
the	O
damaged	O
olfactory	O
system	O
were	O
first	O
identified	O
in	O
2	O
odrelated	O
gene	O
expression	O
omnibus	O
geo	O
datasets	O

then	O
they	O
were	O
verified	O
in	O
another	O
pdrelated	O
geo	O
dataset	O
and	O
only	O
one	O
mirna	O
mir20a	O
was	O
found	O
to	O
be	O
significantly	O
altered	O

serum	O
levels	O
of	O
mir20a	O
were	O
further	O
measured	O
by	O
qpcr	O
in	O
79	O
pd	O
patients	B-PERCIEVER
with	O
od	O
pdod	O
52	O
pd	O
patients	B-PERCIEVER
without	O
od	O
pdnod	O
and	O
52	O
healthy	O
controls	O
hc	O

objective	O
measure	O
of	O
od	O
was	O
defined	O
by	O
16item	O
sniffin	O
sticks	O
odor	O
identification	O
test	O

all	O
the	O
participants	B-PERCIEVER
underwent	O
a	O
demographic	O
and	O
comprehensive	O
pdrelated	O
clinical	O
assessment	O

results	O
our	O
results	O
proved	O
that	O
mir20a	O
was	O
significantly	O
downregulated	O
in	O
pdod	O
compared	O
with	O
pdnod	O
and	O
the	O
area	O
under	O
curve	O
auc	O
for	O
od	O
detection	O
by	O
mir20a	O
was	O
0803	O
95	O
confidence	O
interval	O
07240883	O

in	O
addition	O
pdod	O
had	O
higher	O
scores	O
of	O
movement	O
disorder	O
societyunified	O
parkinsons	O
disease	O
rating	O
scale	O
updrs	O
ii	O
hoehn	O
and	O
yahr	O
stage	O
hy	O
nonmotor	O
symptoms	O
scale	O
nmss	O
3	O
nmss	O
5	O
nmss	O
9	O
hamilton	O
rating	O
scale	O
for	O
depression	O
hamd	O
hamilton	O
anxiety	O
scale	O
hama	O
activity	O
of	O
daily	O
living	O
adl	O
and	O
lower	O
scores	O
of	O
minimental	O
state	O
examination	O
mmse	O
and	O
39item	O
pd	O
quality	O
of	O
life	O
questionnaire	O
pdq39	O
than	O
pdnod	O

binary	O
regression	O
model	O
further	O
presented	O
that	O
lower	O
expressions	O
of	O
mir20a	O
and	O
poorer	O
cognitive	O
function	O
acted	O
as	O
promoting	O
factors	O
in	O
the	O
development	O
of	O
od	O

conclusion	O
our	O
results	O
suggest	O
that	O
mir20a	O
could	O
be	O
a	O
novel	O
biomarker	O
for	O
od	O
in	O
pd	O
and	O
pdod	O
patients	B-PERCIEVER
tend	O
to	O
have	O
higher	O
disease	O
stage	O
poorer	O
motor	O
aspects	O
of	O
experiences	O
of	O
daily	O
living	O
worse	O
cognitive	O
scores	O
and	O
inferior	O
quality	O
of	O
life	O
and	O
were	O
more	O
likely	O
to	O
have	O
mental	O
disorders	O

cognitive	O
function	O
in	O
particular	O
is	O
strongly	O
associated	O
with	O
od	O
in	O
pd	O
patients	B-PERCIEVER

olfactory	O
impairment	O
in	O
parkinsons	O
disease	O
and	O
white	O
matter	O
abnormalities	O
in	O
central	O
olfactory	O
areas	O
a	O
voxelbased	O
diffusion	O
tensor	O
imaging	O
study	O

olfactory	O
dysfunction	O
is	O
known	O
to	O
occur	O
before	O
the	O
appearance	O
of	O
the	O
classical	O
motor	O
signs	O
in	O
parkinsons	O
disease	O
pd	O
and	O
diffusion	O
tensor	O
imaging	O
dti	O
studies	O
in	O
pd	O
have	O
reported	O
fractional	O
anisotropy	O
fa	O
reductions	O
in	O
the	O
early	O
disease	O
stages	O

we	O
aimed	O
to	O
investigate	O
the	O
relationship	O
between	O
olfactory	O
dysfunction	O
and	O
white	O
matter	O
wm	O
fa	O
of	O
central	O
olfactory	O
areas	O
in	O
early	O
pd	O

twentyfour	O
patients	B-PERCIEVER
at	O
hoehn	O
and	O
yahr	O
stages	O
i	O
and	O
ii	O
and	O
24	O
healthy	O
controls	O
matched	O
by	O
age	O
gender	O
and	O
years	O
of	O
education	O
participated	O
in	O
this	O
study	O

dti	O
was	O
acquired	O
at	O
a	O
3	O
tesla	O
scanner	O
and	O
odor	O
identification	O
was	O
assessed	O
using	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST

we	O
performed	O
fa	O
voxelwise	O
group	O
comparisons	O
in	O
the	O
central	O
olfactory	O
structures	O
using	O
tractbased	O
spatial	O
statistics	O
tbss	O
and	O
correlation	O
analyses	O
between	O
fa	O
values	O
in	O
these	O
central	O
olfactory	O
areas	O
and	O
upsit	B-SMELL_TEST
scores	O

patients	B-PERCIEVER
with	O
severe	O
microsmia	O
upsit	B-SMELL_TEST
between	O
19	O
and	O
25	O
and	O
anosmia	B-OLFACTORY
upsit	B-SMELL_TEST
lower	O
or	O
equal	O
to	O
18	O
had	O
lower	O
fa	O
values	O
than	O
pd	O
patients	B-PERCIEVER
with	O
mildmoderate	O
or	O
no	O
olfactory	O
dysfunction	O
upsit	B-SMELL_TEST
between	O
26	O
and	O
40	O
and	O
healthy	O
controls	O
in	O
the	O
wm	O
adjacent	O
to	O
gyrus	O
rectus	O

in	O
addition	O
patients	B-PERCIEVER
with	O
anosmia	B-OLFACTORY
had	O
reduced	O
fa	O
in	O
the	O
wm	O
surrounding	O
primary	O
olfactory	O
areas	O
in	O
comparison	O
with	O
healthy	O
controls	O

fa	O
values	O
in	O
the	O
wm	O
adjacent	O
to	O
primary	O
olfactory	O
cortex	O
and	O
right	O
gyrus	O
rectus	O
correlated	O
with	O
upsit	B-SMELL_TEST
scores	O
in	O
the	O
pd	O
group	O

this	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
microstructural	O
wm	O
reductions	O
are	O
present	O
in	O
the	O
central	O
olfactory	O
system	O
of	O
early	O
stage	O
pd	O
patients	B-PERCIEVER
and	O
that	O
these	O
reductions	O
are	O
associated	O
with	O
reduced	O
ability	O
to	O
smell	O

colonic	O
neuropathology	O
is	O
independent	O
of	O
olfactory	O
dysfunction	O
in	O
parkinsons	O
disease	O

olfactory	O
dysfunction	O
od	O
and	O
constipation	O
are	O
two	O
frequent	O
and	O
early	O
nonmotor	O
features	O
of	O
parkinsons	O
disease	O
pd	O

colonic	O
pd	O
neuropathology	O
the	O
putative	O
cause	O
of	O
constipation	O
can	O
be	O
analyzed	O
and	O
quantified	O
using	O
routine	O
colonic	O
biopsies	O
and	O
parallels	O
disease	O
severity	O

the	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
whether	O
the	O
severity	O
of	O
neuropathology	O
in	O
the	O
colon	O
in	O
pd	O
is	O
related	O
to	O
od	O

twentysix	O
pd	O
patients	B-PERCIEVER
were	O
included	O

colonic	O
neuropathology	O
ie	O
the	O
density	O
of	O
lewy	O
pathology	O
and	O
the	O
number	O
of	O
submucosal	O
neurons	O
was	O
unrelated	O
to	O
od	O
as	O
assessed	O
using	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O

this	O
suggests	O
that	O
unlike	O
colonic	O
lewy	O
pathology	O
od	O
is	O
unrelated	O
to	O
disease	O
severity	O

sudden	O
intrabulbar	O
amyloid	O
increase	O
simultaneously	O
disrupts	O
olfactory	O
bulb	O
oscillations	O
and	O
odor	O
detection	O

there	O
seems	O
to	O
be	O
a	O
correlation	O
between	O
soluble	O
amyloid	O
beta	O
protein	O
abeta	O
accumulation	O
in	O
the	O
main	O
olfactory	O
bulb	O
ob	O
and	O
smell	O
deterioration	O
in	O
both	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
and	O
animal	O
models	O

moreover	O
this	O
loss	O
of	O
smell	O
appears	O
to	O
be	O
related	O
to	O
alterations	O
in	O
neural	O
network	O
activity	O
in	O
several	O
olfactoryrelated	O
circuits	O
including	O
the	O
ob	O
as	O
has	O
been	O
observed	O
in	O
anesthetized	O
animals	O
and	O
brain	O
slices	O

it	O
is	O
possible	O
that	O
there	O
is	O
a	O
correlation	O
between	O
these	O
two	O
pathological	O
phenomena	O
but	O
a	O
direct	O
and	O
simultaneous	O
evaluation	O
of	O
the	O
acute	O
and	O
direct	O
effect	O
of	O
abeta	O
on	O
ob	O
activity	O
while	O
animals	O
are	O
actually	O
smelling	O
has	O
not	O
been	O
performed	O

thus	O
here	O
we	O
tested	O
the	O
effects	O
of	O
acute	O
intrabulbar	O
injection	O
of	O
abeta	O
at	O
a	O
low	O
dose	O
200	O
pmol	O
on	O
the	O
ob	O
local	O
field	O
potential	O
before	O
and	O
during	O
the	O
presence	O
of	O
a	O
hidden	O
piece	O
of	O
smelly	O
food	O

our	O
results	O
show	O
that	O
abeta	O
decreases	O
the	O
power	O
of	O
ob	O
network	O
activity	O
while	O
impairing	O
the	O
animals	O
ability	O
to	O
reach	O
the	O
hidden	O
food	O

we	O
found	O
a	O
strong	O
relationship	O
between	O
the	O
power	O
of	O
the	O
ob	O
oscillations	O
and	O
the	O
correlation	O
between	O
obs	O
and	O
the	O
olfactory	O
detection	O
test	O
scores	O

these	O
findings	O
provide	O
a	O
direct	O
link	O
between	O
abetainduced	O
ob	O
network	O
dysfunction	O
and	O
smell	O
loss	O
in	O
rodents	O
which	O
could	O
be	O
extrapolated	O
to	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER

impaired	O
olfactory	O
identification	O
in	O
dementiafree	O
individuals	O
is	O
associated	O
with	O
the	O
functional	O
abnormality	O
of	O
the	O
precuneus	O

objective	O
olfactory	O
dysfunction	O
indicates	O
a	O
higher	O
risk	O
of	O
developing	O
dementia	B-NEURODEGENERATIVE

however	O
the	O
potential	O
structural	O
and	O
functional	O
changes	O
are	O
still	O
largely	O
unknown	O

methods	O
a	O
total	O
of	O
236	O
participants	B-PERCIEVER
were	O
enrolled	O
including	O
45	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE
individuals	O
and	O
191dementiafree	O
individuals	O

detailed	O
study	O
methods	O
comprising	O
neuropsychological	O
assessment	O
and	O
olfactory	O
identification	O
test	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
as	O
well	O
as	O
structural	O
and	O
functional	O
magnetic	O
resonance	O
imaging	O
mri	O
were	O
applied	O
in	O
this	O
research	O

the	O
dementiafree	O
individuals	O
were	O
divided	O
into	O
two	O
subgroups	O
based	O
on	O
olfactory	O
score	O
dementiafree	O
with	O
olfactory	O
dysfunction	O
dfod	O
subgroup	O
and	O
dementiafree	O
without	O
olfactory	O
dysfunction	O
dfnod	O
subgroup	O

the	O
results	O
were	O
analyzed	O
for	O
subsequent	O
intergroup	O
comparisons	O
and	O
correlations	O

the	O
cognitive	O
assessment	O
was	O
conducted	O
again	O
three	O
years	O
later	O

results	O
i	O
at	O
dementiafree	O
stage	O
there	O
was	O
a	O
positive	O
correlation	O
between	O
olfactory	O
score	O
and	O
cognitive	O
function	O

ii	O
in	O
dementiafree	O
group	O
the	O
volume	O
of	O
crucial	O
brain	O
structures	O
involved	O
in	O
olfactory	O
recognition	O
and	O
processing	O
such	O
as	O
amygdala	O
entorhinal	O
cortex	O
and	O
basal	O
forebrain	O
volumes	O
are	O
positively	O
associated	O
with	O
olfactory	O
score	O

iii	O
compared	O
to	O
the	O
dfnod	O
group	O
the	O
dfod	O
group	O
showed	O
a	O
significant	O
reduction	O
in	O
olfactory	O
network	O
on	O
function	O

iv	O
compared	O
to	O
dfnod	O
group	O
there	O
were	O
significant	O
functional	O
connectivity	O
fc	O
decline	O
between	O
pcun_lr_4_1	O
in	O
the	O
precuneus	O
of	O
posterior	O
default	O
mode	O
network	O
pdmn	O
and	O
the	O
salience	O
network	O
sn	O
in	O
dfod	O
group	O
and	O
the	O
fc	O
values	O
decreased	O
with	O
falling	O
olfactory	O
scores	O

moreover	O
in	O
dfod	O
group	O
the	O
noteworthy	O
reduction	O
in	O
fc	O
were	O
observed	O
between	O
pcun_lr_4_1	O
and	O
amygdala	O
which	O
was	O
a	O
crucial	O
component	O
of	O
on	O

v	O
the	O
ad	B-NEURODEGENERATIVE
conversion	O
rate	O
of	O
dfod	O
was	O
2941	O
while	O
the	O
dfnod	O
group	O
was	O
1250	O

the	O
structural	O
and	O
functional	O
changes	O
in	O
the	O
precuneus	O
were	O
also	O
observed	O
in	O
ad	B-NEURODEGENERATIVE
and	O
were	O
more	O
severe	O

conclusions	O
in	O
addition	O
to	O
the	O
olfactory	O
circuit	O
the	O
precuneus	O
is	O
a	O
critical	O
structure	O
in	O
the	O
odor	O
identification	O
process	O
whose	O
abnormal	O
function	O
underlies	O
the	O
olfactory	O
identification	O
impairment	O
of	O
dementiafree	O
individuals	O

alphasynuclein	O
pathology	O
in	O
the	O
olfactory	O
pathways	O
of	O
dementia	B-NEURODEGENERATIVE
patients	B-PERCIEVER

lewytype	O
pathology	O
is	O
a	O
characteristic	O
of	O
a	O
number	O
of	O
neurodegenerative	O
disorders	O
including	O
parkinsons	O
disease	O
and	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O

thus	O
far	O
the	O
definitive	O
diagnosis	O
of	O
these	O
dementias	O
can	O
only	O
be	O
confirmed	O
at	O
postmortem	O

however	O
it	O
is	O
known	O
that	O
the	O
loss	O
of	O
smell	O
anosmia	B-OLFACTORY
is	O
an	O
early	O
symptom	O
in	O
patients	B-PERCIEVER
who	O
develop	O
dementia	B-NEURODEGENERATIVE
and	O
the	O
use	O
of	O
the	O
smell	O
test	O
has	O
been	O
proposed	O
as	O
an	O
early	O
diagnostic	O
procedure	O

the	O
aim	O
of	O
this	O
study	O
was	O
to	O
understand	O
further	O
the	O
extent	O
of	O
lewy	O
pathology	O
in	O
the	O
olfactory	O
system	O
of	O
patients	B-PERCIEVER
with	O
neurodegenerative	O
disorders	O

postmortem	O
tissue	O
from	O
250	O
subjects	B-PERCIEVER
was	O
obtained	O
from	O
the	O
optima	O
brain	O
bank	O

five	O
areas	O
of	O
the	O
olfactory	O
pathway	O
were	O
examined	O
by	O
immunolabelling	O
for	O
alphasynuclein	O
a	O
major	O
component	O
of	O
lewy	O
pathology	O
the	O
olfactory	O
tractbulb	O
n	O
79	O
the	O
anterior	O
olfactory	O
nucleus	O
in	O
the	O
lateral	O
olfactory	O
gyrus	O
n	O
193	O
the	O
region	O
of	O
olfactory	O
projection	O
to	O
the	O
orbitofrontal	O
cortex	O
n	O
225	O
the	O
hippocampus	O
n	O
236	O
and	O
the	O
amygdala	O
n	O
201	O

results	O
show	O
that	O
lewy	O
pathology	O
affects	O
different	O
parts	O
of	O
the	O
olfactory	O
pathways	O
differentially	O
suggesting	O
a	O
specific	O
pattern	O
of	O
development	O
of	O
pathology	O

clinical	O
parkinsons	O
disease	O
is	O
most	O
likely	O
to	O
be	O
identified	O
if	O
the	O
orbitofrontal	O
cortex	O
is	O
affected	O
while	O
the	O
diagnosis	O
is	O
less	O
likely	O
if	O
the	O
pathology	O
is	O
restricted	O
to	O
the	O
olfactory	O
bulb	O
or	O
tract	O

these	O
results	O
suggest	O
that	O
pathology	O
in	O
the	O
olfactory	O
bulb	O
and	O
tract	O
occurs	O
prior	O
to	O
clinical	O
signs	O
of	O
parkinsons	O
disease	O

furthermore	O
the	O
results	O
presented	O
here	O
provide	O
further	O
evidence	O
supporting	O
the	O
possible	O
value	O
of	O
a	O
smell	O
test	O
to	O
aid	O
the	O
clinical	O
diagnosis	O
of	O
neurodegenerative	O
diseases	O

olfactory	O
impairment	O
is	O
more	O
marked	O
in	O
patients	B-PERCIEVER
with	O
mild	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
than	O
those	O
with	O
mild	O
alzheimer	O
disease	O

background	O
dementia	B-NEURODEGENERATIVE
patients	B-PERCIEVER
with	O
anosmia	B-OLFACTORY
are	O
more	O
likely	O
to	O
have	O
lewy	O
body	O
pathology	O
at	O
postmortem	O
but	O
clinicopathological	O
studies	O
have	O
only	O
assessed	O
olfaction	O
in	O
moderate	O
dementia	B-NEURODEGENERATIVE
or	O
an	O
average	O
of	O
5	O
years	O
before	O
death	O

it	O
is	O
not	O
known	O
whether	O
in	O
patients	B-PERCIEVER
with	O
mild	O
dementia	B-NEURODEGENERATIVE
mmse	O
score	O
over	O
20	O
olfactory	O
function	O
is	O
more	O
impaired	O
in	O
alzheimer	O
disease	O
ad	B-NEURODEGENERATIVE
than	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
dlb	O

methods	O
patients	B-PERCIEVER
with	O
mild	O
dlb	O
n	O
21	O
mild	O
ad	B-NEURODEGENERATIVE
n	O
27	O
mild	O
cognitive	O
impairment	O
mci	O
n	O
21	O
and	O
controls	O
n	O
47	O
were	O
assessed	O
using	O
a	O
16item	O
olfactory	O
identification	O
test	O
and	O
an	O
olfactory	O
threshold	O
test	O
which	O
used	O
sticks	O
impregnated	O
with	O
differing	O
concentrations	O
of	O
butanol	O

results	O
patients	B-PERCIEVER
with	O
mild	O
dlb	O
had	O
impaired	O
olfactory	O
identification	O
ability	O
compared	O
with	O
those	O
with	O
mild	O
ad	B-NEURODEGENERATIVE
or	O
mci	O
independent	O
of	O
age	O
cognitive	O
function	O
and	O
sex	O

the	O
sensitivity	O
of	O
a	O
cutoff	O
score	O
of	O
seven	O
correct	O
responses	O
out	O
of	O
16	O
was	O
081	O
for	O
distinguishing	O
mild	O
dlb	O
from	O
mild	O
ad	B-NEURODEGENERATIVE
auc	O
0682	O

the	O
specificity	O
positive	O
predictive	O
value	O
and	O
negative	O
predictive	O
value	O
for	O
the	O
same	O
cutoff	O
score	O
were	O
041	O
048	O
and	O
073	O
respectively	O

the	O
olfactory	O
threshold	O
was	O
not	O
different	O
in	O
the	O
ad	B-NEURODEGENERATIVE
and	O
dlb	O
groups	O

conclusions	O
simple	O
bedside	O
tests	O
of	O
olfactory	O
identification	O
merit	O
further	O
examination	O
for	O
their	O
potential	O
to	O
improve	O
the	O
identification	O
of	O
patients	B-PERCIEVER
with	O
dlb	O
when	O
used	O
alongside	O
existing	O
criteria	O

they	O
are	O
insufficiently	O
specific	O
for	O
use	O
in	O
screening	O

relationship	O
between	O
the	O
regional	O
cerebral	O
blood	O
flow	O
and	O
the	O
cognitive	O
function	O
and	O
anosmia	B-OLFACTORY
in	O
patients	B-PERCIEVER
with	O
parkinson	O
disease	O
and	O
alzheimer	O
disease	O

we	O
compared	O
the	O
relationship	O
between	O
regional	O
cerebral	O
blood	O
flow	O
rcbf	O
of	O
the	O
olfactory	O
area	O
and	O
the	O
cognitive	O
function	O
and	O
anosmia	B-OLFACTORY
in	O
patient	B-PERCIEVER
with	O
parkinson	O
disease	O
pd	O
and	O
in	O
those	O
with	O
alzheimer	O
disease	O
ad	B-NEURODEGENERATIVE

updrs	O
iii	O
mmse	O
hdsr	O
cdr	O
beck	O
depression	O
inventory	O
bdi	O
were	O
employed	O
in	O
this	O
study	O

the	O
subjects	B-PERCIEVER
included	O
56	O
pd	O
patients	B-PERCIEVER
average	O
age	O
714969	O
years	O
23	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
average	O
age	O
733712	O
years	O
12	O
patients	B-PERCIEVER
with	O
mild	O
cognitive	O
impairment	O
mci	O
average	O
age	O
725689	O
years	O
and	O
9	O
agematched	O
controls	O
nc	O
average	O
age	O
738661	O
years	O

next	O
we	O
intravenously	O
injected	O
1	O
ampule	O
of	O
thiamine	O
propyldisulphide	O
alinamin	O
and	O
confirmed	O
anosmia	B-OLFACTORY

in	O
addition	O
we	O
performed	O
123iimp	O
spect	O
see	O
methods	O
and	O
satistically	O
determined	O
rcbf	O
of	O
the	O
olfactory	O
area	O
based	O
on	O
the	O
basis	O
of	O
the	O
z	O
scores	O
of	O
the	O
interest	O
area	O

anosima	O
was	O
detected	O
in	O
approximately	O
40	O
of	O
the	O
pd	O
and	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER

the	O
hdsr	O
and	O
mmse	O
scores	O
were	O
significantly	O
higher	O
in	O
patients	B-PERCIEVER
with	O
anosima	O
than	O
in	O
those	O
without	O
anosima	O
the	O
cdr	O
scores	O
were	O
significantly	O
higher	O
in	O
the	O
former	O
than	O
in	O
the	O
latter	O

further	O
the	O
incidence	O
of	O
anosima	O
in	O
pd	O
patients	B-PERCIEVER
and	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
with	O
mci	O
increased	O
with	O
an	O
increase	O
in	O
the	O
cdr	O
scores	O

in	O
order	O
to	O
determine	O
the	O
rcbf	O
of	O
the	O
olfactory	O
area	O
of	O
the	O
pd	O
and	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER

as	O
to	O
rcbf	O
of	O
the	O
olfactory	O
area	O
we	O
examined	O
left	O
and	O
right	O
z	O
scores	O
of	O
hippocampus	O
parahippocampus	O
amygdala	O
and	O
uncus	O
at	O
talairach	O
level	O
3	O
and	O
the	O
scores	O
of	O
the	O
brodmann	O
area	O
28	O
34	O
35	O
and	O
36	O
at	O
talairach	O
level	O
5	O

in	O
patients	B-PERCIEVER
with	O
anosmia	B-OLFACTORY
the	O
z	O
scores	O
were	O
significantly	O
high	O
in	O
cases	O
with	O
anosmia	B-OLFACTORY
in	O
all	O
areas	O
except	O
the	O
right	O
brodmann	O
area	O
34	O
in	O
pd	O
patients	B-PERCIEVER
and	O
the	O
right	O
brodmann	O
area	O
28	O
and	O
bilateral	O
the	O
brodmann	O
area	O
34	O
of	O
both	O
sides	O
in	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER

some	O
parts	O
of	O
the	O
olfactory	O
area	O
are	O
closely	O
related	O
to	O
cognitive	O
function	O
and	O
it	O
appeares	O
that	O
a	O
reduced	O
rcbf	O
in	O
the	O
olfactory	O
areas	O
may	O
lead	O
to	O
a	O
functional	O
decline	O
in	O
these	O
regions	O
which	O
may	O
cause	O
anosmia	B-OLFACTORY
and	O
cognitive	O
decline	O
in	O
pd	O
and	O
ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER

olfaction	O
and	O
dementia	B-NEURODEGENERATIVE

preliminary	O
results	O
of	O
a	O
clinical	O
and	O
experimental	O
study	O
with	O
npropanol	O

various	O
reports	O
concerning	O
the	O
oroalimentary	O
ducts	O
of	O
dements	O
and	O
increasing	O
arguments	O
in	O
favour	O
of	O
a	O
new	O
etiopathogenic	O
hypothesis	O
for	O
picks	O
disease	O
involving	O
impaired	O
zinc	O
metabolism	O
and	O
histological	O
lesions	O
partly	O
linked	O
with	O
the	O
hodology	O
of	O
the	O
olfactory	O
system	O
lie	O
at	O
the	O
origin	O
of	O
our	O
present	O
clinical	O
interest	O
in	O
olfaction	O

in	O
a	O
first	O
stage	O
using	O
a	O
technique	O
based	O
on	O
dilution	O
with	O
npropanol	O
we	O
observed	O
certain	O
conditions	O
permitting	O
an	O
evaluation	O
of	O
the	O
olfactory	O
capacities	O
of	O
patients	B-PERCIEVER
with	O
picks	O
disease	O
senile	O
plaque	O
dementia	B-NEURODEGENERATIVE
and	O
neurofibrillary	O
degenerescense	O

there	O
does	O
not	O
seem	O
to	O
be	O
a	O
decline	O
in	O
olfaction	O
with	O
age	O

olfactory	O
capacities	O
in	O
the	O
two	O
forms	O
of	O
dementia	B-NEURODEGENERATIVE
studied	O
were	O
distinctly	O
inferior	O
to	O
those	O
of	O
nondements	O

olfactory	O
habituation	O
was	O
more	O
marked	O
especially	O
in	O
picks	O
disease	O
where	O
there	O
were	O
also	O
paradoxical	O
responses	O
which	O
seemed	O
to	O
form	O
part	O
of	O
a	O
more	O
general	O
change	O
in	O
reaction	O
to	O
stimulus	O

in	O
senile	O
plaque	O
dementia	B-NEURODEGENERATIVE
and	O
neurofibrillary	O
degenerescence	O
the	O
response	O
to	O
olfactory	O
stimulus	O
declines	O
with	O
dilution	O
of	O
npropanol	O
and	O
lesional	O
extension	O

observation	O
of	O
recorded	O
parameters	O
eeg	O
psychogalvanic	O
reflex	O
ocular	O
movement	O
breathing	O
is	O
useful	O
in	O
picks	O
disease	O
and	O
may	O
be	O
difficult	O
in	O
senile	O
plaque	O
dementia	B-NEURODEGENERATIVE
and	O
neurofibrillary	O
degenerescence	O

olfactory	O
capacities	O
appear	O
to	O
constitute	O
an	O
additional	O
criterion	O
on	O
which	O
to	O
base	O
a	O
diagnosis	O
of	O
dementia	B-NEURODEGENERATIVE

they	O
could	O
be	O
used	O
to	O
help	O
establish	O
the	O
neurobiological	O
bases	O
of	O
certain	O
types	O
of	O
demential	O
behaviour	O
and	O
to	O
observe	O
the	O
progress	O
of	O
tentative	O
therapies	O

anosmia	B-OLFACTORY
in	O
dementia	B-NEURODEGENERATIVE
is	O
associated	O
with	O
lewy	O
bodies	O
rather	O
than	O
alzheimers	O
pathology	O

objectives	O
to	O
assess	O
olfactory	O
function	O
of	O
patients	B-PERCIEVER
with	O
dementia	B-NEURODEGENERATIVE

odour	O
detection	O
ability	O
is	O
impaired	O
in	O
clinical	O
parkinsons	O
disease	O

evidence	O
of	O
impaired	O
detection	O
in	O
patients	B-PERCIEVER
with	O
clinically	O
diagnosed	O
alzheimers	O
disease	O
is	O
inconsistent	O

no	O
studies	O
of	O
olfaction	O
have	O
been	O
neuropathologically	O
validated	O

methods	O
the	O
olfactory	O
function	O
of	O
92	O
patients	B-PERCIEVER
with	O
dementia	B-NEURODEGENERATIVE
and	O
94	O
controls	O
was	O
assessed	O
using	O
a	O
simple	O
bedside	O
test	O
as	O
part	O
of	O
the	O
oxford	O
project	O
to	O
investigate	O
memory	O
and	O
ageing	O
optima	O

neuropathological	O
assessment	O
was	O
made	O
of	O
cortical	O
lewy	O
bodies	O
and	O
substantia	O
nigra	O
sn	O
cell	O
counts	O
and	O
of	O
alzheimers	O
disease	O
in	O
all	O
92	O
patients	B-PERCIEVER
22	O
of	O
whom	O
had	O
sn	O
lewy	O
bodies	O
and	O
43	O
of	O
whom	O
had	O
only	O
alzheimers	O
disease	O

results	O
patients	B-PERCIEVER
with	O
lewy	O
bodies	O
were	O
more	O
likely	O
to	O
be	O
anosmic	O
than	O
those	O
with	O
alzheimers	O
disease	O
or	O
controls	O

patients	B-PERCIEVER
with	O
alzheimers	O
disease	O
were	O
not	O
more	O
likely	O
to	O
be	O
anosmic	O
than	O
controls	O

nor	O
was	O
anosmia	B-OLFACTORY
associated	O
with	O
degree	O
of	O
neurofibrillary	O
tangles	O
as	O
assessed	O
by	O
braak	O
stage	O

among	O
subjects	B-PERCIEVER
with	O
lewy	O
bodies	O
overall	O
cortical	O
lewy	O
body	O
scores	O
and	O
lewy	O
body	O
density	O
in	O
the	O
cingulate	O
were	O
higher	O
in	O
those	O
who	O
were	O
anosmic	O

consensus	O
clinical	O
criteria	O
for	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
had	O
a	O
sensitivity	O
of	O
64	O
and	O
specificity	O
of	O
89	O

in	O
the	O
absence	O
of	O
definite	O
alzheimers	O
disease	O
the	O
criteria	O
had	O
sensitivity	O
of	O
100	O

in	O
patients	B-PERCIEVER
with	O
definite	O
alzheimers	O
disease	O
anosmia	B-OLFACTORY
was	O
slightly	O
more	O
sensitive	O
55	O
than	O
the	O
consensus	O
criteria	O
33	O

however	O
the	O
addition	O
of	O
anosmia	B-OLFACTORY
to	O
the	O
consensus	O
criteria	O
did	O
not	O
improve	O
their	O
overall	O
performance	O

conclusion	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O
is	O
associated	O
with	O
impaired	O
odour	O
detection	O

misdiagnosis	O
may	O
have	O
accounted	O
for	O
some	O
previous	O
reports	O
of	O
impaired	O
odour	O
detection	O
in	O
alzheimers	O
disease	O

simple	O
but	O
more	O
sensitive	O
tests	O
of	O
anosmia	B-OLFACTORY
are	O
required	O
if	O
they	O
are	O
to	O
be	O
clinically	O
useful	O
in	O
identifying	O
patients	B-PERCIEVER
with	O
dementia	B-NEURODEGENERATIVE
with	O
lewy	O
bodies	O

severe	O
dysosmia	O
is	O
specifically	O
associated	O
with	O
alzheimerlike	O
memory	O
deficits	O
in	O
nondemented	O
elderly	O
retirees	O

objectives	O
to	O
determine	O
whether	O
or	O
not	O
1	O
impaired	O
olfactory	O
function	O
is	O
associated	O
with	O
impaired	O
memory	O
on	O
neuropsychological	O
testing	O
in	O
healthy	O
retirees	O
and	O
if	O
so	O
then	O
2	O
whether	O
memory	O
impairment	O
is	O
most	O
consistent	O
with	O
a	O
mesiotemporal	O
rather	O
than	O
frontal	O
system	O
disorder	O

methods	O
173	O
independent	O
residents	O
of	O
a	O
continuing	O
care	O
retirement	O
community	O
were	O
studied	O

subjects	B-PERCIEVER
completed	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
and	O
a	O
battery	O
of	O
both	O
general	O
and	O
specific	O
cognitive	O
measures	O
that	O
included	O
the	O
minimental	O
state	O
examination	O
mmse	O
and	O
the	O
executive	O
interview	O
exit25	O

subjects	B-PERCIEVER
were	O
examined	O
twice	O
over	O
3	O
years	O

results	O
upsit	B-SMELL_TEST
performance	O
was	O
normal	O
in	O
21	O
and	O
in	O
the	O
anosmic	O
range	O
in	O
25	O
of	O
subjects	B-PERCIEVER

anosmic	O
upsit	B-SMELL_TEST
performance	O
was	O
associated	O
with	O
significantly	O
worse	O
performance	O
on	O
all	O
cognitive	O
tests	O

however	O
only	O
shortterm	O
verbal	O
memory	O
was	O
independently	O
associated	O
with	O
upsitdefined	O
anosmia	B-OLFACTORY

this	O
association	O
remained	O
significant	O
after	O
adjusting	O
for	O
the	O
other	O
cognitive	O
and	O
sociodemographic	O
variables	O

the	O
memory	O
deficits	O
of	O
anosmic	O
subjects	B-PERCIEVER
were	O
qualitatively	O
consistent	O
with	O
a	O
cortical	O
type	O
type	O
1	O
dementing	O
illness	O
such	O
as	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE

over	O
time	O
upsitdefined	O
anosmic	O
cases	O
suffered	O
significantly	O
greater	O
declines	O
on	O
both	O
the	O
mmse	O
and	O
the	O
exit25	O
independently	O
of	O
baseline	O
age	O
gender	O
and	O
mmse	O
score	O

conclusions	O
impaired	O
odor	O
identification	O
in	O
individuals	O
without	O
overt	O
dementia	B-NEURODEGENERATIVE
is	O
associated	O
with	O
an	O
adlike	O
memory	O
impairment	O
and	O
an	O
increased	O
rate	O
of	O
cognitive	O
decline	O

the	O
comorbid	O
association	O
of	O
these	O
deficits	O
is	O
consistent	O
with	O
the	O
known	O
hierarchical	O
spread	O
of	O
preclinical	O
ad	B-NEURODEGENERATIVE
pathology	O
and	O
may	O
be	O
a	O
specific	O
indicator	O
of	O
future	O
clinical	O
ad	B-NEURODEGENERATIVE
dementia	I-NEURODEGENERATIVE

association	O
of	O
anosmia	B-OLFACTORY
with	O
autonomic	O
failure	O
in	O
parkinson	O
disease	O

background	O
olfactory	O
dysfunction	O
and	O
autonomic	O
failure	O
are	O
gaining	O
recognition	O
as	O
nonmotor	O
manifestations	O
of	O
parkinson	O
disease	O
pd	O

this	O
observational	O
study	O
assessed	O
whether	O
in	O
pd	O
anosmia	B-OLFACTORY
and	O
autonomic	O
failure	O
are	O
related	O
to	O
each	O
other	O
or	O
to	O
neuroimaging	O
evidence	O
of	O
striatal	O
dopamine	O
deficiency	O

methods	O
olfactory	O
function	O
was	O
assessed	O
by	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
in	O
23	O
patients	B-PERCIEVER
with	O
sporadic	O
pd	O

baroreflexcardiovagal	O
gain	O
was	O
quantified	O
from	O
the	O
relationship	O
between	O
cardiac	O
interbeat	O
interval	O
and	O
systolic	O
pressure	O
during	O
the	O
valsalva	O
maneuver	O
and	O
baroreflexsympathoneural	O
function	O
by	O
responses	O
of	O
systolic	O
pressure	O
to	O
the	O
valsalva	O
maneuver	O
and	O
of	O
hemodynamics	O
and	O
plasma	O
norepinephrine	O
ne	O
and	O
dihydroxyphenylglycol	O
dhpg	O
levels	O
to	O
orthostasis	O

618ffluorodopamine	O
pet	O
and	O
plasma	O
and	O
skeletal	O
muscle	O
microdialysate	O
ne	O
and	O
dhpg	O
were	O
used	O
to	O
indicate	O
cardiac	O
and	O
extracardiac	O
noradrenergic	O
innervation	O
and	O
brain	O
618ffluorodopa	O
pet	O
to	O
indicate	O
striatal	O
dopaminergic	O
innervation	O

parkinsonism	O
was	O
assessed	O
by	O
updrs	O
scores	O

results	O
compared	O
to	O
patients	B-PERCIEVER
with	O
pd	O
and	O
normal	O
to	O
moderately	O
decreased	O
sense	O
of	O
smell	O
patients	B-PERCIEVER
with	O
anosmic	O
pd	O
had	O
lower	O
mean	O
baroreflexcardiovagal	O
gain	O
p	O
004	O
larger	O
falls	O
in	O
systolic	O
pressure	O
during	O
the	O
valsalva	O
maneuver	O
and	O
orthostasis	O
p	O
004	O
p	O
002	O
smaller	O
orthostatic	O
increments	O
in	O
plasma	O
ne	O
and	O
dhpg	O
p	O
0003	O
p	O
003	O
lower	O
cardiac	O
septalhepatic	O
and	O
renal	O
corticalhepatic	O
ratios	O
of	O
618ffluorodopaminederived	O
radioactivity	O
p	O
001	O
p	O
006	O
and	O
lower	O
microdialysate	O
ne	O
and	O
dhpg	O
p	O
001	O
p	O
0006	O

neither	O
clinical	O
severity	O
of	O
parkinsonism	O
nor	O
the	O
putamenoccipital	O
cortex	O
ratio	O
of	O
618ffluorodopaderived	O
radioactivity	O
was	O
related	O
to	O
the	O
upsit	B-SMELL_TEST
category	O

conclusions	O
in	O
parkinson	O
disease	O
anosmia	B-OLFACTORY
is	O
associated	O
with	O
baroreflex	O
failure	O
and	O
cardiac	O
and	O
organselective	O
extracardiac	O
noradrenergic	O
denervation	O
independently	O
of	O
parkinsonism	O
or	O
striatal	O
dopaminergic	O
denervation	O

olfactory	O
erps	O
in	O
an	O
odorvisual	O
congruency	O
task	O
differentiate	O
apoe	O
epsilon4	O
carriers	O
from	O
noncarriers	O

alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE
is	O
a	O
progressive	O
neurodegenerative	O
disorder	O
that	O
impairs	O
memory	O
and	O
semantic	O
processing	O

ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
and	O
mci	O
patients	B-PERCIEVER
at	O
risk	O
for	O
ad	B-NEURODEGENERATIVE
show	O
altered	O
n400	O
erp	O
responses	O
to	O
incongruent	O
visual	O
and	O
verbal	O
stimuli	O

ad	B-NEURODEGENERATIVE
patients	B-PERCIEVER
exhibit	O
neuropathology	O
in	O
olfactory	O
brain	O
areas	O
before	O
cognitive	O
symptoms	O
suggesting	O
the	O
potential	O
for	O
olfactory	O
processing	O
to	O
reflect	O
early	O
pathology	O

despite	O
this	O
odor	O
congruency	O
has	O
not	O
been	O
examined	O

we	O
investigated	O
odorimage	O
congruency	O
in	O
older	O
adults	O
at	O
genetic	O
risk	O
for	O
ad	B-NEURODEGENERATIVE

apoe	O
epsilon4	O
carriers	O
and	O
noncarriers	O
were	O
screened	O
for	O
anosmia	B-OLFACTORY
severe	O
hyposmia	B-OLFACTORY
and	O
dementia	B-NEURODEGENERATIVE

olfactory	O
erps	O
were	O
measured	O
6001300	O
ms	B-NEURODEGENERATIVE
following	O
odorimage	O
pairs	O

odors	O
were	O
each	O
presented	O
once	O
congruently	O
and	O
once	O
incongruently	O
via	O
an	O
olfactometer	O

pz	O
amplitude	O
significantly	O
decreased	O
on	O
incongruent	O
trials	O
in	O
e4	O
carriers	O

pz	O
amplitude	O
differences	O
on	O
congruous	O
and	O
incongruous	O
trials	O
were	O
larger	O
in	O
non	O
carriers	O

regression	O
indicated	O
that	O
congruency	O
showed	O
very	O
high	O
sensitivity	O
and	O
specificity	O
for	O
correctly	O
classifying	O
epsilon4	O
carriers	O
from	O
noncarriers	O

nicotine	O
increases	O
lifespan	O
and	O
rescues	O
olfactory	O
and	O
motor	O
deficits	O
in	O
a	O
drosophila	O
model	O
of	O
parkinsons	O
disease	O

drosophila	O
melanogaster	O
is	O
an	O
attractive	O
model	O
of	O
familial	O
parkinsons	O
disease	O
as	O
flies	O
with	O
lossoffunction	O
mutations	O
of	O
the	O
parkin	O
gene	O
exhibit	O
many	O
pathologies	O
observed	O
in	O
pd	O
patients	B-PERCIEVER

progressive	O
motor	O
deficits	O
found	O
in	O
homozygous	O
parkin	O
mutants	O
seem	O
to	O
result	O
from	O
mitochondrial	O
pathology	O
that	O
causes	O
indirect	O
flight	O
muscle	O
and	O
dopaminergic	O
neuronal	O
degeneration	O
12	O

we	O
have	O
found	O
that	O
heterozygous	O
parkin	O
mutants	O
have	O
decreased	O
lifespan	O
generally	O
progressive	O
motor	O
dysfunction	O
and	O
olfactory	O
deficits	O
compared	O
to	O
control	O
flies	O
suggesting	O
that	O
mutation	O
of	O
this	O
gene	O
produces	O
a	O
dominant	O
phenotype	O

tobacco	O
smokers	O
are	O
dosedependently	O
less	O
likely	O
to	O
develop	O
pd	O
34	O
subsequent	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
show	O
that	O
nicotine	O
is	O
protective	O
in	O
models	O
of	O
sporadic	O
pd	O
6	O

literature	O
addressing	O
the	O
potential	O
protection	O
by	O
nicotine	O
in	O
parkin	O
lossoffunction	O
models	O
spans	O
limited	O
concentrations	O
and	O
selected	O
time	O
points	O
in	O
the	O
organisms	O
lifespan	O

we	O
have	O
found	O
that	O
parkin	O
heterozygotes	O
have	O
lateonset	O
climbing	O
and	O
flying	O
deficits	O
as	O
well	O
as	O
decreased	O
viability	O
and	O
olfactory	O
deficits	O
that	O
precede	O
motor	O
defects	O

while	O
chronic	O
nicotine	O
exposure	O
decreases	O
lifespan	O
and	O
climbing	O
and	O
flying	O
abilities	O
in	O
control	O
flies	O
it	O
can	O
improve	O
viability	O
and	O
flying	O
capability	O
as	O
well	O
as	O
rescue	O
climbing	O
and	O
olfactory	O
deficits	O
in	O
parkin	O
heterozygotes	O

dopaminergic	O
neurons	O
are	O
spared	O
in	O
the	O
parkin	O
heterozygote	O
perhaps	O
because	O
this	O
phenotype	O
is	O
less	O
severe	O
than	O
in	O
the	O
homozygous	O
parkin	O
mutants	O

nicotine	O
pretreatment	O
may	O
be	O
protective	O
in	O
sporadic	O
pd	O
patients	B-PERCIEVER
and	O
models	O
however	O
timely	O
diagnosis	O
remains	O
to	O
be	O
an	O
obstacle	O

our	O
results	O
suggest	O
that	O
nicotine	O
also	O
may	O
be	O
protective	O
in	O
familial	O
pd	O
patients	B-PERCIEVER
who	O
can	O
be	O
easily	O
identified	O
before	O
motor	O
symptoms	O
occur	O

neuroimaging	O
biomarkers	O
and	O
impaired	O
olfaction	O
in	O
cognitively	O
normal	O
individuals	O

objective	O
there	O
is	O
a	O
need	O
for	O
inexpensive	O
noninvasive	O
tests	O
to	O
identify	O
older	O
healthy	O
persons	O
at	O
risk	O
for	O
alzheimer	O
disease	O
ad	B-NEURODEGENERATIVE
for	O
enrollment	O
in	O
ad	B-NEURODEGENERATIVE
prevention	O
trials	O

our	O
objective	O
was	O
to	O
examine	O
whether	O
abnormalities	O
in	O
neuroimaging	O
measures	O
of	O
amyloid	O
and	O
neurodegeneration	O
are	O
correlated	O
with	O
odor	O
identification	O
oi	O
in	O
the	O
populationbased	O
mayo	O
clinic	O
study	O
of	O
aging	O

methods	O
cognitively	O
normal	O
cn	O
participants	B-PERCIEVER
had	O
olfactory	O
function	O
assessed	O
using	O
the	O
brief	O
smell	O
identification	O
test	O
bsit	B-SMELL_TEST
underwent	O
magnetic	O
resonance	O
imaging	O
n	O
829	O
to	O
assess	O
a	O
composite	O
ad	B-NEURODEGENERATIVE
signature	O
cortical	O
thickness	O
and	O
hippocampal	O
volume	O
hva	O
and	O
underwent	O
11	O
cpittsburgh	O
compound	O
b	O
n	O
306	O
and	O
18	O
fluorodeoxyglucose	O
n	O
305	O
positron	O
emission	O
tomography	O
scanning	O
to	O
assess	O
amyloid	O
accumulation	O
and	O
brain	O
hypometabolism	O
respectively	O

the	O
association	O
of	O
neuroimaging	O
biomarkers	O
with	O
oi	O
was	O
examined	O
using	O
multinomial	O
logistic	O
regression	O
and	O
simple	O
linear	O
regression	O
models	O
adjusted	O
for	O
potential	O
confounders	O

results	O
among	O
829	O
cn	O
participants	B-PERCIEVER
mean	O
age	O
792	O
years	O
515	O
men	B-PERCIEVER
248	O
299	O
were	O
normosmic	O
and	O
78	O
94	O
had	O
anosmia	B-OLFACTORY
bsit	B-SMELL_TEST
score	O
6	O

abnormal	O
ad	B-NEURODEGENERATIVE
signature	O
cortical	O
thickness	O
and	O
reduced	O
hva	O
were	O
associated	O
with	O
decreased	O
oi	O
as	O
a	O
continuous	O
measure	O
slope	O
043	O
95	O
confidence	O
interval	O
ci	O
076	O
to	O
009	O
p	O
001	O
and	O
slope	O
072	O
95	O
ci	O
115	O
to	O
028	O
p	O
001	O
respectively	O

reduced	O
hva	O
decreased	O
ad	B-NEURODEGENERATIVE
signature	O
cortical	O
thickness	O
and	O
increased	O
amyloid	O
accumulation	O
were	O
significantly	O
associated	O
with	O
increased	O
odds	O
of	O
anosmia	B-OLFACTORY

interpretation	O
our	O
findings	O
suggest	O
that	O
oi	O
may	O
be	O
a	O
noninvasive	O
inexpensive	O
marker	O
for	O
risk	O
stratification	O
for	O
identifying	O
participants	B-PERCIEVER
at	O
the	O
preclinical	O
stage	O
of	O
ad	B-NEURODEGENERATIVE
who	O
may	O
be	O
at	O
risk	O
for	O
cognitive	O
impairment	O
and	O
eligible	O
for	O
inclusion	O
in	O
ad	B-NEURODEGENERATIVE
prevention	O
clinical	O
trials	O

these	O
crosssectional	O
findings	O
remain	O
to	O
be	O
validated	O
prospectively	O

ann	O
neurol	O
201781871882	O

multimodal	O
spatiotemporal	O
monitoring	O
of	O
basal	O
stem	O
cellderived	O
organoids	O
reveals	O
progression	O
of	O
olfactory	O
dysfunction	O
in	O
alzheimers	O
disease	O

olfactory	O
dysfunction	O
od	O
is	O
a	O
highly	O
prevalent	O
symptom	O
and	O
an	O
early	O
sign	O
of	O
neurodegenerative	O
diseases	O
in	O
humans	O

however	O
the	O
roles	O
of	O
peripheral	O
olfactory	O
system	O
in	O
disease	O
progression	O
and	O
the	O
mechanisms	O
behind	O
neurodegeneration	O
remain	O
to	O
be	O
studied	O

olfactory	O
epithelium	O
oe	O
organoid	O
is	O
an	O
ideal	O
model	O
to	O
study	O
pathophysiology	O
in	O
vitro	O
yet	O
the	O
reliance	O
on	O
3d	O
culture	O
condition	O
limits	O
continual	O
in	O
situ	O
monitoring	O
of	O
organoid	O
development	O

here	O
we	O
combined	O
impedance	O
biosensors	O
and	O
live	O
imaging	O
for	O
realtime	O
spatiotemporal	O
analysis	O
of	O
oe	O
organoids	O
morphological	O
and	O
physiological	O
features	O
during	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE
progression	O

the	O
impedance	O
measurements	O
showed	O
that	O
organoids	O
generated	O
from	O
basal	O
stem	O
cells	O
of	O
appps1	O
transgenic	O
mice	O
had	O
lower	O
proliferation	O
rate	O
than	O
that	O
from	O
wildtype	O
mice	O

in	O
concert	O
with	O
the	O
biosensor	O
measurements	O
live	O
imaging	O
enabled	O
to	O
visualize	O
the	O
spatial	O
and	O
temporal	O
dynamics	O
of	O
organoid	O
morphology	O

abnormal	O
protein	O
aggregation	O
and	O
accumulation	O
including	O
amyloid	O
plaques	O
and	O
neurofibrillary	O
tangles	O
was	O
found	O
in	O
ad	B-NEURODEGENERATIVE
organoids	O
and	O
increased	O
as	O
disease	O
progressed	O

this	O
multimodal	O
in	O
situ	O
bioelectrical	O
measurement	O
and	O
imaging	O
provide	O
a	O
new	O
platform	O
for	O
investigating	O
onset	O
mechanisms	O
of	O
od	O
which	O
would	O
shed	O
new	O
light	O
on	O
early	O
diagnosis	O
and	O
treatment	O
of	O
neurodegenerative	O
disease	O

clinical	O
features	O
and	O
neurobiochemical	O
mechanisms	O
of	O
olfactory	O
dysfunction	O
in	O
patients	B-PERCIEVER
with	O
parkinson	O
disease	O

this	O
study	O
aimed	O
to	O
investigate	O
clinical	O
features	O
influencing	O
factors	O
and	O
neurobiochemical	O
mechanisms	O
of	O
olfactory	O
dysfunction	O
od	O
in	O
parkinson	O
disease	O
pd	O

total	O
39	O
patients	B-PERCIEVER
were	O
divided	O
into	O
the	O
pd	O
with	O
od	O
pdod	O
and	O
pd	O
with	O
no	O
od	O
pdnod	O
groups	O
according	O
to	O
overall	O
olfactory	O
function	O
including	O
threshold	O
discrimination	O
and	O
identification	O
assessed	O
by	O
sniffin	O
sticks	O
test	O

motor	O
function	O
and	O
nonmotor	O
symptoms	O
were	O
rated	O
by	O
multiple	O
scales	O

dopamine	O
acetylcholine	O
norepinephrine	O
and	O
5hydroxytryptamine	O
levels	O
in	O
cerebrospinal	O
fluid	O
csf	O
were	O
measured	O

we	O
found	O
that	O
the	O
pdod	O
group	O
showed	O
significantly	O
lower	O
score	O
of	O
montreal	O
cognitive	O
assessment	O
scale	O
higher	O
scores	O
of	O
rapid	O
eye	O
movement	O
sleep	O
behavior	O
disorder	O
rbd	O
screening	O
questionnaire	O
and	O
epworth	O
sleepiness	O
scale	O
than	O
the	O
pdnod	O
group	O
p	O
005	O

rbd	O
screening	O
questionnaire	O
score	O
was	O
independently	O
associated	O
with	O
the	O
scores	O
of	O
overall	O
olfactory	O
function	O
and	O
discrimination	O
p	O
005	O

dopamine	O
and	O
acetylcholine	O
levels	O
in	O
csf	O
from	O
the	O
pdod	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
from	O
the	O
pdnod	O
group	O
p	O
005	O

dopamine	O
and	O
acetylcholine	O
levels	O
in	O
csf	O
were	O
significantly	O
and	O
positively	O
correlated	O
with	O
the	O
scores	O
of	O
overall	O
olfactory	O
function	O
threshold	O
discrimination	O
and	O
identification	O
in	O
pd	O
patients	B-PERCIEVER
p	O
005	O

rbd	O
screening	O
questionnaire	O
score	O
was	O
significantly	O
and	O
negatively	O
correlated	O
with	O
acetylcholine	O
level	O
in	O
csf	O
in	O
pd	O
patients	B-PERCIEVER
with	O
poor	O
olfactory	O
detection	O
p	O
005	O

this	O
investigation	O
reveals	O
that	O
pdod	O
is	O
associated	O
with	O
cognitive	O
impairment	O
probable	O
rbd	O
and	O
excessive	O
daytime	O
sleepiness	O

pdod	O
is	O
correlated	O
with	O
the	O
decreased	O
levels	O
of	O
dopamine	O
and	O
acetylcholine	O
in	O
csf	O

rbd	O
is	O
an	O
independent	O
influencing	O
factor	O
of	O
overall	O
olfactory	O
function	O
and	O
discrimination	O
and	O
the	O
decreased	O
acetylcholine	O
level	O
in	O
csf	O
may	O
be	O
the	O
common	O
neurobiochemical	O
basis	O
of	O
rbd	O
and	O
od	O
in	O
pd	O
patients	B-PERCIEVER

opportunities	O
and	O
pitfalls	O
of	O
rem	O
sleep	O
behavior	O
disorder	O
and	O
olfactory	O
dysfunction	O
as	O
early	O
markers	O
in	O
parkinsons	O
disease	O

during	O
its	O
premotor	O
stage	O
parkinsons	O
disease	O
pd	O
presents	O
itself	O
with	O
a	O
multitude	O
of	O
nonmotor	O
symptoms	O
with	O
different	O
degrees	O
of	O
specificity	O
and	O
sensitivity	O

the	O
most	O
important	O
among	O
them	O
are	O
rem	O
sleep	O
behavior	O
disorder	O
rbd	O
and	O
olfactory	O
dysfunction	O

rbd	O
is	O
a	O
parasomnia	O
characterized	O
by	O
the	O
loss	O
of	O
rem	O
sleep	O
muscle	O
atonia	O
and	O
dreamenacting	O
behaviors	O

olfactory	O
dysfunction	O
in	O
individuals	O
with	O
prodromal	O
pd	O
is	O
usually	O
described	O
as	O
hyposmia	B-OLFACTORY
reduced	O
sense	O
of	O
smell	O
or	O
anosmia	B-OLFACTORY
complete	O
loss	O
of	O
olfactory	O
function	O

these	O
symptoms	O
can	O
precede	O
the	O
full	O
expression	O
of	O
motor	O
symptoms	O
by	O
decades	O

a	O
close	O
comprehension	O
of	O
these	O
symptoms	O
and	O
the	O
underlying	O
mechanisms	O
may	O
enable	O
early	O
screening	O
as	O
well	O
as	O
interventions	O
to	O
improve	O
patients	B-PERCIEVER
quality	O
of	O
life	O

therefore	O
these	O
symptoms	O
have	O
unmatched	O
potential	O
for	O
identifying	O
pd	O
patients	B-PERCIEVER
in	O
prodromal	O
stages	O
not	O
only	O
allowing	O
early	O
diagnosis	O
but	O
potentially	O
opening	O
a	O
window	O
for	O
early	O
possibly	O
diseasemodifying	O
intervention	O

however	O
they	O
come	O
with	O
certain	O
challenges	O

this	O
review	O
addresses	O
some	O
of	O
the	O
key	O
opportunities	O
and	O
pitfalls	O
of	O
both	O
rbd	O
and	O
olfactory	O
dysfunction	O
as	O
early	O
markers	O
of	O
pd	O

phantosmias	O
and	O
parkinson	O
disease	O

background	O
impaired	O
olfaction	O
is	O
a	O
common	O
nonmotor	O
manifestation	O
of	O
parkinson	O
disease	O
pd	O

however	O
to	O
our	O
knowledge	O
qualitative	O
olfactory	O
disturbances	O
such	O
as	O
odor	O
distortions	O
have	O
not	O
been	O
extensively	O
reported	O
in	O
this	O
condition	O

objective	O
to	O
describe	O
2	O
patients	B-PERCIEVER
who	O
reported	O
positive	O
olfactory	O
symptoms	O
preceding	O
typical	O
pd	O
which	O
were	O
consistent	O
with	O
olfactory	O
hallucinations	O
phantosmias	O
in	O
the	O
absence	O
of	O
major	O
smell	O
deficit	O

design	O
case	O
series	O

setting	O
university	O
hospital	O

patients	B-PERCIEVER
we	O
describe	O
2	O
patients	B-PERCIEVER
both	O
seen	O
in	O
2007	O
who	O
reported	O
pleasant	O
olfactory	O
hallucinations	O
for	O
several	O
years	O

main	O
outcome	O
measures	O
iodine	O
i	O
123labeled	O
ioflupane	O
singlephoton	O
emission	O
computed	O
tomography	O
and	O
olfactometric	O
testing	O
results	O

results	O
the	O
123ilabeled	O
ioflupane	O
singlephoton	O
emission	O
computed	O
tomography	O
showed	O
reduced	O
radiotracer	O
uptake	O
in	O
both	O
striatum	O
more	O
marked	O
in	O
the	O
putamen	O
and	O
on	O
the	O
left	O
side	O
in	O
patient	B-PERCIEVER
1	O
and	O
reduced	O
radiotracer	O
uptake	O
in	O
both	O
putamen	O
more	O
marked	O
on	O
the	O
right	O
side	O
in	O
patient	B-PERCIEVER
2	O

olfactometric	O
testing	O
showed	O
mild	O
hyposmia	B-OLFACTORY
in	O
patient	B-PERCIEVER
1	O
and	O
normal	O
function	O
in	O
patient	B-PERCIEVER
2	O

the	O
disappearance	O
of	O
the	O
phantosmias	O
in	O
both	O
patients	B-PERCIEVER
coincided	O
with	O
the	O
development	O
of	O
typical	O
pd	O

conclusion	O
we	O
propose	O
phantosmia	B-OLFACTORY
as	O
a	O
new	O
premotor	O
manifestation	O
of	O
pd	O
and	O
suggest	O
that	O
qualitative	O
abnormalities	O
of	O
olfaction	O
rather	O
than	O
the	O
typical	O
smell	O
loss	O
demonstrated	O
in	O
this	O
condition	O
should	O
be	O
more	O
carefully	O
examined	O
in	O
the	O
prodromal	O
phase	O
of	O
pd	O

smell	O
and	O
preclinical	O
alzheimer	O
disease	O
study	O
of	O
29	O
patients	B-PERCIEVER
with	O
amnesic	O
mild	O
cognitive	O
impairment	O

objectives	O
to	O
evaluate	O
the	O
olfactory	O
function	O
in	O
patients	B-PERCIEVER
with	O
amnesic	O
mild	O
cognitive	O
impairment	O
amci	O
and	O
the	O
relationship	O
to	O
the	O
progression	O
from	O
amci	O
to	O
alzheimer	O
disease	O
ad	B-NEURODEGENERATIVE

design	O
cohort	O
prospective	O
study	O
on	O
amci	O
patients	B-PERCIEVER
at	O
the	O
first	O
evaluation	O
t0	O
and	O
at	O
the	O
18month	O
followup	O
t1	O

setting	O
alzheimer	O
unit	O
of	O
the	O
university	O
of	O
laquila	O
italy	O

methods	O
twentynine	O
amci	O
patients	B-PERCIEVER
were	O
enrolled	O
in	O
this	O
study	O

main	O
outcome	O
measures	O
olfactory	O
function	O
was	O
studied	O
with	O
the	O
sniffin	O
sticks	O
screening	O
test	O
ssst	O
and	O
the	O
sniffin	O
sticks	O
extended	O
test	O
sset	O

olfactory	O
functions	O
were	O
related	O
to	O
neurocognitive	O
functions	O
assessed	O
by	O
the	O
minimental	O
state	O
examination	O
mmse	O
and	O
the	O
mental	O
deterioration	O
battery	O
mdb	O

results	O
at	O
t0	O
amci	O
patients	B-PERCIEVER
showed	O
an	O
olfactory	O
impairment	O
and	O
all	O
of	O
the	O
amci	O
patients	B-PERCIEVER
had	O
lower	O
olfaction	O
scores	O
at	O
t1	O

at	O
t1	O
9	O
of	O
the	O
29	O
amci	O
patients	B-PERCIEVER
31	O
developed	O
ad	B-NEURODEGENERATIVE
and	O
had	O
lower	O
mean	O
ssst	O
and	O
sset	O
scores	O
than	O
20	O
amci	O
patients	B-PERCIEVER
who	O
did	O
not	O
develop	O
ad	B-NEURODEGENERATIVE

the	O
most	O
significant	O
relationship	O
was	O
found	O
between	O
olfactory	O
discrimination	O
and	O
visuospatial	O
ability	O
language	O
skill	O
and	O
the	O
rey	O
immediate	O
test	O
of	O
the	O
mdb	O
and	O
between	O
olfactory	O
identification	O
and	O
the	O
rey	O
delayed	O
test	O

conclusion	O
odour	O
discrimination	O
and	O
identification	O
performance	O
correlated	O
more	O
prominently	O
than	O
detection	O
thresholds	O
with	O
performance	O
on	O
neuropsychological	O
tests	O

we	O
concluded	O
that	O
the	O
olfactory	O
deficit	O
occurs	O
early	O
in	O
amci	O
so	O
we	O
suggest	O
introducing	O
the	O
clinical	O
routine	O
use	O
of	O
the	O
olfactory	O
test	O
for	O
early	O
identification	O
of	O
the	O
progression	O
of	O
the	O
decline	O
from	O
amci	O
to	O
ad	B-NEURODEGENERATIVE

olfactory	O
cortex	O
degeneration	O
in	O
alzheimers	O
disease	O
and	O
mild	O
cognitive	O
impairment	O

background	O
olfactory	O
deficits	O
are	O
prevalent	O
in	O
patients	B-PERCIEVER
with	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE
and	O
mild	O
cognitive	O
impairment	O
mci	O

these	O
symptoms	O
precede	O
clinical	O
onset	O
of	O
cognitive	O
and	O
memory	O
deficits	O
and	O
coincide	O
with	O
ad	B-NEURODEGENERATIVE
pathology	O
preferentially	O
in	O
the	O
central	O
olfactory	O
structures	O
suggesting	O
a	O
potential	O
biomarker	O
for	O
ad	B-NEURODEGENERATIVE
early	O
detection	O
and	O
progression	O

objective	O
therefore	O
we	O
tested	O
the	O
hypothesis	O
that	O
structural	O
degeneration	O
of	O
the	O
primary	O
olfactory	O
cortex	O
poc	O
could	O
be	O
detected	O
in	O
ad	B-NEURODEGENERATIVE
as	O
well	O
as	O
in	O
mci	O
patients	B-PERCIEVER
and	O
would	O
be	O
correlated	O
with	O
olfactory	O
functional	O
magnetic	O
resonance	O
imaging	O
fmri	O
alterations	O
reflecting	O
loss	O
of	O
olfactory	O
cortex	O
activity	O

methods	O
total	O
structural	O
volumes	O
and	O
fmri	O
activation	O
volumes	O
of	O
the	O
poc	O
and	O
hippocampus	O
were	O
measured	O
along	O
with	O
olfactory	O
and	O
cognitive	O
behavioral	O
tests	O
in	O
27	O
cognitively	O
normal	O
cn	O
21	O
mci	O
and	O
15	O
ad	B-NEURODEGENERATIVE
subjects	B-PERCIEVER

results	O
prominent	O
atrophy	O
in	O
the	O
poc	O
and	O
hippocampus	O
was	O
found	O
in	O
both	O
ad	B-NEURODEGENERATIVE
and	O
mci	O
subjects	B-PERCIEVER
and	O
correlated	O
with	O
behavioral	O
measurements	O

while	O
behavioral	O
and	O
volumetric	O
measurements	O
showed	O
a	O
gradual	O
decline	O
from	O
cn	O
to	O
mci	O
to	O
ad	B-NEURODEGENERATIVE
olfactory	O
activation	O
volume	O
in	O
the	O
poc	O
and	O
hippocampus	O
showed	O
a	O
steeper	O
decline	O
in	O
the	O
mci	O
group	O
compared	O
to	O
corresponding	O
tissue	O
volume	O
resembling	O
the	O
ad	B-NEURODEGENERATIVE
group	O

conclusions	O
decline	O
in	O
olfactory	O
activity	O
was	O
correlated	O
with	O
the	O
ad	B-NEURODEGENERATIVE
structural	O
degeneration	O
in	O
the	O
poc	O

a	O
more	O
prominent	O
olfactory	O
activity	O
deficit	O
than	O
that	O
of	O
behavioral	O
and	O
tissue	O
volume	O
measurements	O
was	O
shown	O
in	O
the	O
mci	O
stage	O

olfactory	O
fmri	O
may	O
thus	O
provide	O
an	O
earlier	O
and	O
more	O
sensitive	O
measure	O
of	O
functional	O
neurodegeneration	O
in	O
ad	B-NEURODEGENERATIVE
and	O
mci	O
patients	B-PERCIEVER

exploring	O
white	O
matter	O
microstructure	O
and	O
olfaction	O
dysfunction	O
in	O
early	O
parkinson	O
disease	O
diffusion	O
mri	O
reveals	O
new	O
insight	O

olfaction	O
dysfunction	O
is	O
considered	O
as	O
a	O
robust	O
marker	O
of	O
prodromal	O
parkinson	O
disease	O
pd	O

measurement	O
of	O
olfaction	O
function	O
as	O
a	O
screening	O
test	O
is	O
unsatisfactory	O
due	O
to	O
long	O
lead	O
time	O
interval	O
and	O
low	O
specificity	O
for	O
detection	O
of	O
pd	O

use	O
of	O
imaging	O
markers	O
might	O
yield	O
more	O
accurate	O
predictive	O
values	O
and	O
provide	O
bases	O
for	O
combined	O
use	O
of	O
imaging	O
and	O
clinical	O
markers	O
for	O
early	O
pd	O

diffusion	O
mri	O
connectometry	O
was	O
conducted	O
on	O
85	O
de	O
novo	O
pd	O
patients	B-PERCIEVER
in	O
and	O
36	O
healthy	O
controls	O
to	O
find	O
first	O
white	O
matter	O
tracts	O
with	O
significant	O
difference	O
in	O
quantitative	O
anisotropy	O
between	O
pd	O
groups	O
with	O
various	O
degrees	O
of	O
olfaction	O
dysfunction	O
and	O
second	O
second	O
fibers	O
with	O
correlation	O
with	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
score	O
in	O
each	O
group	O
using	O
a	O
multiple	O
regression	O
analysis	O
considering	O
age	O
sex	O
gds	O
and	O
moca	O
score	O

local	O
connectomes	O
were	O
determined	O
in	O
seven	O
of	O
all	O
the	O
possible	O
comparisons	O
correcting	O
for	O
false	O
discovery	O
rate	O
fdr	O

pd	O
patients	B-PERCIEVER
with	O
anosmia	B-OLFACTORY
and	O
normal	O
olfaction	O
had	O
the	O
highest	O
number	O
of	O
fibers	O
with	O
decreased	O
connectivity	O
in	O
left	O
inferior	O
longitudinal	O
fasciculus	O
bilateral	O
fornix	O
bilateral	O
middle	O
cerebellar	O
peduncle	O
mcp	O
bilateral	O
cingulum	O
bilateral	O
corticospinal	O
tract	O
cst	O
and	O
body	O
genu	O
and	O
splenium	O
of	O
corpus	O
callosum	O
cc	O
fdr	O
00013	O

in	O
multiple	O
regression	O
analysis	O
connectivity	O
in	O
the	O
body	O
genu	O
and	O
splenium	O
of	O
cc	O
and	O
bilateral	O
fornix	O
had	O
significant	O
negative	O
correlation	O
fdr	O
between	O
0019	O
and	O
0083	O
and	O
bilateral	O
cingulum	O
and	O
mcp	O
had	O
significant	O
positive	O
correlation	O
fdr	O
between	O
0022	O
and	O
0092	O
with	O
upsit	B-SMELL_TEST
score	O

white	O
matter	O
connectivity	O
in	O
healthy	O
controls	O
could	O
not	O
be	O
predicted	O
by	O
upsit	B-SMELL_TEST
score	O
using	O
the	O
same	O
model	O

the	O
results	O
of	O
this	O
study	O
provide	O
compelling	O
evidence	O
that	O
microstructural	O
degenerative	O
changes	O
in	O
these	O
areas	O
underlie	O
the	O
clinical	O
phenotype	O
of	O
prodromal	O
olfaction	O
dysfunction	O
in	O
pd	O
and	O
that	O
diffusion	O
parameters	O
of	O
these	O
areas	O
might	O
be	O
able	O
to	O
serve	O
as	O
signature	O
markers	O
for	O
early	O
detection	O
of	O
pd	O

this	O
is	O
the	O
first	O
report	O
that	O
confirms	O
a	O
discriminative	O
role	O
for	O
upsit	B-SMELL_TEST
score	O
in	O
identifying	O
pd	O
specific	O
changes	O
in	O
white	O
matter	O
microstructure	O

our	O
results	O
open	O
a	O
window	O
to	O
identify	O
microstructural	O
signatures	O
of	O
prodromal	O
pd	O
in	O
white	O
matter	O

diagnostic	O
accuracy	O
item	O
analysis	O
and	O
age	O
effects	O
of	O
the	O
upsit	B-SMELL_TEST
spanish	O
version	O
in	O
parkinsons	O
disease	O

objective	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
is	O
the	O
most	O
commonly	O
used	O
test	O
to	O
detect	O
olfactory	O
impairment	O
in	O
parkinsons	O
disease	O
pd	O
but	O
the	O
cutoff	O
score	O
for	O
clinical	O
purposes	O
is	O
often	O
difficult	O
to	O
establish	O
because	O
of	O
age	O
and	O
sex	O
effects	O

the	O
current	O
work	O
aims	O
to	O
study	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
upsit	B-SMELL_TEST
spanish	O
version	O
and	O
its	O
accuracy	O
in	O
discriminating	O
pd	O
patients	B-PERCIEVER
at	O
different	O
age	O
groups	O
from	O
healthy	O
controls	O
hc	O
and	O
to	O
perform	O
an	O
item	O
analysis	O

method	O
ninetyseven	O
nondemented	O
pd	O
patients	B-PERCIEVER
and	O
65	O
hc	O
were	O
assessed	O
with	O
the	O
upsit	B-SMELL_TEST
spanish	O
version	O

sensitivity	O
specificity	O
and	O
diagnostic	O
accuracy	O
for	O
pd	O
were	O
calculated	O

multiple	O
regression	O
analysis	O
was	O
used	O
to	O
define	O
predictors	O
of	O
upsit	B-SMELL_TEST
scores	O

results	O
using	O
the	O
normative	O
cutoff	O
score	O
for	O
anosmia	B-OLFACTORY
18	O
the	O
upsit	B-SMELL_TEST
showed	O
a	O
sensitivity	O
of	O
546	O
with	O
a	O
specificity	O
of	O
1000	O
for	O
pd	O

we	O
found	O
that	O
using	O
the	O
upsit	B-SMELL_TEST
cutoff	O
score	O
of	O
25	O
sensitivity	O
was	O
814	O
and	O
specificity	O
846	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
0908	O

diagnosis	O
and	O
age	O
were	O
good	O
predictors	O
of	O
upsit	B-SMELL_TEST
scores	O
b	O
10948	O
p	O
001	O
b	O
0203	O
p	O
001	O

when	O
optimal	O
cutoff	O
scores	O
were	O
considered	O
according	O
to	O
age	O
ranges	O
60	O
6170	O
and	O
71	O
sensitivity	O
and	O
specificity	O
values	O
were	O
800	O
for	O
all	O
age	O
groups	O

conclusions	O
in	O
the	O
spanish	O
upsit	B-SMELL_TEST
version	O
sensitivity	O
and	O
specificity	O
are	O
improved	O
when	O
specific	O
cutoff	O
scores	O
for	O
different	O
age	O
groups	O
are	O
computed	O

the	O
therapeutic	O
effect	O
of	O
deep	O
brain	O
stimulation	O
on	O
olfactory	O
functions	O
and	O
clinical	O
scores	O
in	O
parkinsons	O
disease	O

deep	O
brain	O
stimulation	O
dbs	O
is	O
still	O
a	O
highly	O
effective	O
treatment	O
option	O
that	O
significantly	O
improves	O
motor	O
function	O
in	O
advanced	O
pd	O

moreover	O
previous	O
findings	O
have	O
shown	O
that	O
olfactory	O
dysfunction	O
od	O
has	O
been	O
found	O
in	O
a	O
majority	O
of	O
patients	B-PERCIEVER
with	O
parkinsons	O
disease	O
pd	O

despite	O
this	O
the	O
effect	O
of	O
dbs	O
on	O
the	O
olfactory	O
function	O
is	O
not	O
fully	O
understood	O

here	O
we	O
aimed	O
to	O
determine	O
the	O
effect	O
of	O
stn	O
dbs	O
on	O
od	O
by	O
evaluating	O
the	O
olfactory	O
functions	O
in	O
the	O
preoperative	O
and	O
postoperative	O
early	O
stages	O
1st	O
and	O
3rd	O
months	O
in	O
fortyfive	O
pd	O
patients	B-PERCIEVER
and	O
40	O
healthy	O
controls	O

the	O
therapeutic	O
effect	O
of	O
dbs	O
on	O
the	O
improvement	O
of	O
motor	O
functions	O
was	O
parallelly	O
investigated	O

we	O
have	O
observed	O
that	O
there	O
was	O
a	O
significant	O
improvement	O
in	O
oi	O
in	O
the	O
1st	O
month	O
and	O
in	O
all	O
olfactory	O
parameters	O
ot	O
odi	O
oi	O
and	O
tdi	O
in	O
the	O
3rd	O
month	O

in	O
evaluating	O
the	O
motor	O
functional	O
scores	O
we	O
have	O
revealed	O
a	O
statistically	O
significant	O
p	O
0001	O
difference	O
between	O
preoperative	O
updrsmotor	O
score	O
23	O
73	O
and	O
the	O
postoperative	O
3rd	O
month	O
score	O
111	O
51	O

although	O
beck	O
depression	O
and	O
anxiety	O
scores	O
were	O
improved	O
to	O
a	O
certain	O
level	O
in	O
the	O
3rd	O
month	O
this	O
improvement	O
was	O
not	O
at	O
a	O
statistically	O
significant	O
level	O
p	O
005	O

as	O
a	O
conclusion	O
we	O
have	O
shown	O
that	O
stndbs	O
improves	O
the	O
smell	O
functions	O
in	O
pd	O
within	O
three	O
months	O
suggesting	O
that	O
the	O
therapeutic	O
effects	O
of	O
dbs	O
might	O
have	O
a	O
wide	O
range	O
of	O
therapeutic	O
spectrum	O

despite	O
some	O
limitations	O
ie	O
short	O
followup	O
period	O
our	O
study	O
gives	O
a	O
critical	O
message	O
that	O
future	O
studies	O
are	O
needed	O
to	O
evaluate	O
the	O
functional	O
correlates	O
of	O
stndbs	O
treatment	O
in	O
pd	O
patients	B-PERCIEVER

parkinsons	O
disease	O
affects	O
functional	O
connectivity	O
within	O
the	O
olfactorytrigeminal	O
network	O

background	O
olfactory	O
dysfunction	O
od	O
is	O
a	O
frequent	O
symptom	O
of	O
parkinsons	O
disease	O
pd	O
that	O
appears	O
years	O
prior	O
to	O
diagnosis	O

previous	O
studies	O
suggest	O
that	O
pdrelated	O
od	O
is	O
different	O
from	O
nonparkinsonian	O
forms	O
of	O
olfactory	O
dysfunction	O
npod	O
as	O
pd	O
patients	B-PERCIEVER
maintain	O
trigeminal	O
sensitivity	O
as	O
opposed	O
to	O
patients	B-PERCIEVER
with	O
npod	O
who	O
typically	O
exhibit	O
reduced	O
trigeminal	O
sensitivity	O

we	O
hypothesize	O
the	O
presence	O
of	O
a	O
specific	O
alteration	O
of	O
functional	O
connectivity	O
between	O
trigeminal	O
and	O
olfactory	O
processing	O
areas	O
in	O
pd	O

objective	O
we	O
aimed	O
to	O
assess	O
potential	O
differences	O
in	O
functional	O
connectivity	O
within	O
the	O
chemosensory	O
network	O
in	O
15	O
pd	O
patients	B-PERCIEVER
and	O
compared	O
them	O
to	O
15	O
npod	O
patients	B-PERCIEVER
and	O
to	O
15	O
controls	O

methods	O
functional	O
mri	O
scanning	O
session	O
included	O
restingstate	O
and	O
taskrelated	O
scans	O
where	O
participants	B-PERCIEVER
carried	O
out	O
an	O
olfactory	O
and	O
a	O
trigeminal	O
task	O

we	O
compared	O
functional	O
connectivity	O
using	O
a	O
seedbased	O
correlation	O
approach	O
and	O
brain	O
network	O
modularity	O
of	O
the	O
chemosensory	O
network	O

results	O
pd	O
patients	B-PERCIEVER
had	O
impaired	O
functional	O
connectivity	O
within	O
the	O
chemosensory	O
network	O
while	O
no	O
such	O
changes	O
were	O
observed	O
for	O
npod	O
patients	B-PERCIEVER

no	O
group	O
differences	O
we	O
found	O
in	O
modularity	O
of	O
the	O
identified	O
networks	O

both	O
patient	B-PERCIEVER
groups	O
exhibited	O
impaired	O
connectivity	O
when	O
executing	O
an	O
olfactory	O
task	O
while	O
network	O
modularity	O
was	O
significantly	O
weaker	O
for	O
pd	O
patients	B-PERCIEVER
than	O
both	O
other	O
groups	O

when	O
performing	O
a	O
trigeminal	O
task	O
no	O
changes	O
were	O
found	O
for	O
pd	O
patients	B-PERCIEVER
but	O
npod	O
patients	B-PERCIEVER
exhibited	O
impaired	O
connectivity	O

conversely	O
pd	O
patients	B-PERCIEVER
exhibited	O
a	O
significantly	O
higher	O
network	O
modularity	O
than	O
both	O
other	O
groups	O

conclusion	O
in	O
summary	O
the	O
specific	O
pattern	O
of	O
functional	O
connectivity	O
and	O
chemosensory	O
network	O
recruitment	O
in	O
pdrelated	O
od	O
may	O
explain	O
distinct	O
behavioral	O
chemosensory	O
features	O
in	O
pd	O
when	O
compared	O
to	O
npod	O
patients	B-PERCIEVER
and	O
healthy	O
controls	O

olfactory	O
testing	O
in	O
parkinson	O
disease	O
and	O
rem	O
behavior	O
disorder	O
a	O
machine	O
learning	O
approach	O

objective	O
we	O
sought	O
to	O
identify	O
an	O
abbreviated	O
test	O
of	O
impaired	O
olfaction	O
amenable	O
for	O
use	O
in	O
busy	O
clinical	O
environments	O
in	O
prodromal	O
isolated	O
rem	O
sleep	O
behavior	O
disorder	O
irbd	O
and	O
manifest	O
parkinson	O
disease	O
pd	O

methods	O
eight	O
hundred	O
ninety	O
individuals	O
with	O
pd	O
and	O
313	O
controls	O
in	O
the	O
discovery	O
cohort	O
study	O
underwent	O
sniffin	O
stick	O
odor	O
identification	O
assessment	O

random	O
forests	O
were	O
initially	O
trained	O
to	O
distinguish	O
individuals	O
with	O
poor	O
functional	O
anosmiahyposmia	O
and	O
good	O
normosmiasupersmeller	O
smell	O
ability	O
using	O
all	O
16	O
sniffin	O
sticks	O

models	O
were	O
retrained	O
using	O
the	O
top	O
3	O
sticks	O
ranked	O
by	O
order	O
of	O
predictor	O
importance	O

one	O
randomly	O
selected	O
3stick	O
model	O
was	O
tested	O
in	O
a	O
second	O
independent	O
pd	O
dataset	O
n	O
452	O
and	O
in	O
2	O
irbd	O
datasets	O
discovery	O
n	O
241	O
marburg	O
n	O
37	O
before	O
being	O
compared	O
to	O
previously	O
described	O
abbreviated	O
sniffin	O
stick	O
combinations	O

results	O
in	O
differentiating	O
poor	O
from	O
good	O
smell	O
ability	O
the	O
overall	O
area	O
under	O
the	O
curve	O
auc	O
value	O
associated	O
with	O
the	O
top	O
3	O
sticks	O
aniselicoricebanana	O
was	O
095	O
in	O
the	O
development	O
dataset	O
sensitivity	O
90	O
specificity	O
92	O
positive	O
predictive	O
value	O
92	O
negative	O
predictive	O
value	O
90	O

internal	O
and	O
external	O
validation	O
confirmed	O
aucs	O
090	O

the	O
combination	O
of	O
the	O
3stick	O
model	O
determined	O
poor	O
smell	O
and	O
an	O
rbd	O
screening	O
questionnaire	O
score	O
of	O
5	O
separated	O
those	O
with	O
irbd	O
from	O
controls	O
with	O
a	O
sensitivity	O
specificity	O
positive	O
predictive	O
value	O
and	O
negative	O
predictive	O
value	O
of	O
65	O
100	O
100	O
and	O
30	O

conclusions	O
our	O
3sniffinstick	O
model	O
holds	O
potential	O
utility	O
as	O
a	O
brief	O
screening	O
test	O
in	O
the	O
stratification	O
of	O
individuals	O
with	O
pd	O
and	O
irbd	O
according	O
to	O
olfactory	O
dysfunction	O

classification	O
of	O
evidence	O
this	O
study	O
provides	O
class	O
iii	O
evidence	O
that	O
a	O
3sniffinstick	O
model	O
distinguishes	O
individuals	O
with	O
poor	O
and	O
good	O
smell	O
ability	O
and	O
can	O
be	O
used	O
to	O
screen	O
for	O
individuals	O
with	O
irbd	O

olfactorytrigeminal	O
interactions	O
in	O
patients	B-PERCIEVER
with	O
parkinsons	O
disease	O

olfactory	O
dysfunction	O
od	O
is	O
a	O
highly	O
frequent	O
early	O
nonmotor	O
symptom	O
of	O
parkinsons	O
disease	O
pd	O

an	O
important	O
step	O
to	O
potentially	O
use	O
od	O
for	O
the	O
development	O
of	O
early	O
diagnostic	O
tools	O
of	O
pd	O
is	O
to	O
differentiate	O
pdrelated	O
od	O
from	O
other	O
forms	O
of	O
nonparkinsonian	O
od	O
npod	O
postviral	O
sinunasal	O
posttraumatic	O
and	O
idiopathic	O
od	O

measuring	O
nonolfactory	O
chemosensory	O
modalities	O
especially	O
the	O
trigeminal	O
system	O
may	O
allow	O
to	O
characterize	O
a	O
pdspecific	O
olfactory	O
profile	O

we	O
here	O
review	O
the	O
literature	O
on	O
pdspecific	O
chemosensory	O
alteration	O
patterns	O
compared	O
with	O
npod	O

specifically	O
we	O
focused	O
on	O
the	O
impact	O
of	O
pd	O
on	O
the	O
trigeminal	O
system	O
and	O
particularly	O
on	O
the	O
interaction	O
between	O
olfactory	O
and	O
trigeminal	O
systems	O

as	O
this	O
interaction	O
is	O
seemingly	O
affected	O
in	O
a	O
diseasespecific	O
manner	O
we	O
propose	O
a	O
model	O
of	O
interaction	O
between	O
both	O
chemosensory	O
systems	O
that	O
is	O
distinct	O
for	O
pdrelated	O
od	O
and	O
npod	O

these	O
patterns	O
of	O
chemosensory	O
impairment	O
still	O
need	O
to	O
be	O
confirmed	O
in	O
prodromal	O
pd	O
nevertheless	O
appropriate	O
chemosensory	O
tests	O
may	O
eventually	O
help	O
to	O
develop	O
diagnostic	O
tools	O
to	O
identify	O
individuals	O
at	O
risks	O
for	O
pd	O

olfactory	O
testing	O
does	O
not	O
predict	O
betaamyloid	O
mri	O
measures	O
of	O
neurodegeneration	O
or	O
vascular	O
pathology	O
in	O
the	O
british	O
1946	O
birth	O
cohort	O

objective	O
to	O
explore	O
the	O
value	O
of	O
olfactory	O
identification	O
deficits	O
as	O
a	O
predictor	O
of	O
cerebral	O
betaamyloid	O
status	O
and	O
other	O
markers	O
of	O
brain	O
health	O
in	O
cognitively	O
normal	O
adults	O
aged	O
70	O
years	O

methods	O
crosssectional	O
observational	O
cohort	O
study	O

389	O
largely	O
healthy	O
and	O
cognitively	O
normal	O
older	O
adults	O
were	O
recruited	O
from	O
the	O
mrc	O
national	O
survey	O
of	O
health	O
and	O
development	O
1946	O
british	O
birth	O
cohort	O
and	O
investigated	O
for	O
olfactory	O
identification	O
deficits	O
as	O
measured	O
by	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O

outcome	O
measures	O
were	O
imaging	O
markers	O
of	O
brain	O
health	O
derived	O
from	O
3	O
t	O
mri	O
scanning	O
cortical	O
thickness	O
entorhinal	O
cortex	O
thickness	O
white	O
matter	O
hyperintensity	O
volumes	O
18f	O
florbetapir	O
amyloidpet	O
scanning	O
and	O
cognitive	O
testing	O
results	O

participants	B-PERCIEVER
were	O
assessed	O
at	O
a	O
single	O
centre	O
between	O
march	O
2015	O
and	O
january	O
2018	O

results	O
mean	O
sd	O
age	O
was	O
706	O
07	O
years	O
508	O
were	O
female	B-PERCIEVER

645	O
had	O
hyposmia	B-OLFACTORY
and	O
26	O
anosmia	B-OLFACTORY

olfaction	O
showed	O
no	O
association	O
with	O
betaamyloid	O
status	O
hippocampal	O
volume	O
entorhinal	O
cortex	O
thickness	O
ad	B-NEURODEGENERATIVE
signature	O
cortical	O
thickness	O
white	O
matter	O
hyperintensity	O
volume	O
or	O
cognition	O

conclusion	O
and	O
relevance	O
in	O
the	O
early	O
70s	O
olfactory	O
function	O
is	O
not	O
a	O
reliable	O
predictor	O
of	O
a	O
range	O
of	O
imaging	O
and	O
cognitive	O
measures	O
of	O
preclinical	O
ad	B-NEURODEGENERATIVE

olfactory	O
identification	O
deficits	O
are	O
not	O
likely	O
to	O
be	O
a	O
useful	O
means	O
of	O
identifying	O
asymptomatic	O
amyloidosis	O

further	O
studies	O
are	O
required	O
to	O
assess	O
if	O
change	O
in	O
olfaction	O
may	O
be	O
a	O
proximity	O
marker	O
for	O
the	O
development	O
of	O
cognitive	O
impairment	O

selfreported	O
versus	O
objectively	O
assessed	O
olfaction	O
and	O
parkinsons	O
disease	O
risk	O

background	O
poor	O
olfaction	O
is	O
a	O
prodromal	O
symptom	O
of	O
parkinsons	O
disease	O
pd	O
however	O
selfreported	O
sense	O
of	O
smell	O
is	O
often	O
dismissed	O
as	O
unreliable	O

objective	O
to	O
assess	O
selfreported	O
and	O
objectively	O
assessed	O
sense	O
of	O
smell	O
independently	O
and	O
jointly	O
in	O
relation	O
to	O
future	O
risk	O
for	O
pd	O

methods	O
we	O
conducted	O
a	O
prospective	O
analysis	O
using	O
data	O
from	O
2424	O
participants	B-PERCIEVER
ages	O
7182	O
at	O
baseline	O
from	O
the	O
health	O
aging	O
and	O
body	O
composition	O
study	O

exposures	O
were	O
selfreported	O
poor	O
sense	O
of	O
smell	O
or	O
taste	O
and	O
the	O
objectively	O
measured	O
12item	O
brief	O
smell	O
identification	O
test	O
score	O

the	O
outcome	O
was	O
incident	O
pd	O
analyzed	O
using	O
cox	O
proportional	O
hazard	O
models	O
adjusted	O
for	O
age	O
sex	O
race	O
and	O
cognitive	O
function	O

results	O
after	O
approximately	O
10	O
years	O
of	O
followup	O
both	O
selfreported	O
and	O
objectively	O
tested	O
poor	O
sense	O
of	O
smell	O
were	O
independently	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
developing	O
pd	O
the	O
hazard	O
ratios	O
95	O
confidence	O
interval	O
were	O
28	O
13	O
59	O
and	O
40	O
21	O
75	O
respectively	O

when	O
analyzed	O
jointly	O
compared	O
with	O
participants	B-PERCIEVER
who	O
reported	O
and	O
tested	O
normal	O
the	O
hazard	O
ratio	O
was	O
22	O
10	O
46	O
for	O
those	O
reported	O
poor	O
sense	O
of	O
smell	O
but	O
tested	O
normal	O
36	O
19	O
69	O
for	O
reported	O
normal	O
but	O
tested	O
poor	O
and	O
78	O
32	O
194	O
for	O
both	O
reported	O
and	O
tested	O
poor	O

we	O
did	O
not	O
find	O
significant	O
interactions	O
between	O
selfreported	O
and	O
objectively	O
tested	O
sense	O
of	O
smell	O
in	O
predicting	O
pd	O
risk	O

conclusion	O
this	O
study	O
provides	O
preliminary	O
evidence	O
that	O
selfreported	O
poor	O
sense	O
of	O
smell	O
or	O
taste	O
should	O
not	O
be	O
simply	O
dismissed	O
as	O
useless	O
in	O
predicting	O
risk	O
of	O
pd	O

future	O
studies	O
should	O
confirm	O
our	O
finding	O
and	O
evaluate	O
whether	O
structured	O
questionnaires	O
may	O
further	O
improve	O
the	O
predictability	O

effects	O
of	O
bilateral	O
deep	O
brain	O
stimulation	O
of	O
the	O
subthalamic	O
nucleus	O
on	O
olfactory	O
function	O
in	O
parkinsons	O
disease	O
patients	B-PERCIEVER

objective	O
the	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
bilateral	O
deep	O
brain	O
stimulation	O
dbs	O
of	O
the	O
subthalamic	O
nucleus	O
stn	O
on	O
olfaction	O
in	O
patients	B-PERCIEVER
with	O
parkinsons	O
disease	O
pd	O

methods	O
15	O
patients	B-PERCIEVER
suffering	O
from	O
sporadic	O
pdrelated	O
dysosmia	O
were	O
implanted	O
with	O
bilateral	O
electrodes	O
aimed	O
at	O
the	O
stn	O

one	O
week	O
before	O
the	O
surgery	O
odor	O
detection	O
threshold	O
dt	O
and	O
identification	O
threshold	O
it	O
were	O
evaluated	O
in	O
all	O
patients	B-PERCIEVER
using	O
the	O
five	O
odor	O
olfactory	O
detection	O
arrays	O
in	O
both	O
medicationoff	O
and	O
medicationon	O
conditions	O

15	O
healthy	O
agematched	O
controls	O
also	O
received	O
the	O
same	O
olfactory	O
evaluation	O

patient	B-PERCIEVER
evaluations	O
were	O
repeated	O
at	O
6	O
and	O
12	O
months	O
postoperatively	O
in	O
a	O
medicationoffstimulatoron	O
or	O
medicationoffstimulatoroff	O
condition	O

odor	O
dt	O
and	O
it	O
scores	O
were	O
compared	O
pre	O
and	O
postoperatively	O
as	O
well	O
as	O
between	O
the	O
medicationoffstimulatoron	O
or	O
off	O
conditions	O

results	O
the	O
motor	O
symptoms	O
of	O
all	O
15	O
pd	O
patients	B-PERCIEVER
including	O
rigidity	O
tremor	O
bradykinesia	O
postural	O
instability	O
and	O
gait	O
were	O
significantly	O
improved	O
after	O
stimulator	O
implantation	O

the	O
updrs	O
motor	O
updrs	O
iii	O
scores	O
decreased	O
significantly	O
in	O
the	O
medicationoffstimulatoron	O
condition	O
p	O
001	O

the	O
odor	O
dt	O
and	O
it	O
scores	O
of	O
pd	O
patients	B-PERCIEVER
were	O
higher	O
than	O
those	O
of	O
healthy	O
controls	O
p	O
001	O

in	O
the	O
medicationoffstimulatoroff	O
condition	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
odor	O
dt	O
and	O
it	O
scores	O
in	O
pd	O
patients	B-PERCIEVER
pre	O
vs	O
postoperatively	O
p	O
005	O

notably	O
there	O
were	O
no	O
significant	O
alterations	O
to	O
dt	O
scores	O
in	O
the	O
stimulatoron	O
and	O
off	O
conditions	O
at	O
the	O
6	O
and	O
12month	O
followup	O
p	O
005	O
whereas	O
it	O
scores	O
were	O
significantly	O
improved	O
in	O
the	O
stimulationon	O
relative	O
to	O
the	O
stimulationoff	O
condition	O
at	O
the	O
6	O
and	O
12month	O
followup	O

conclusions	O
stn	O
dbs	O
can	O
significantly	O
improve	O
olfactory	O
cognitive	O
function	O
in	O
pd	O
patients	B-PERCIEVER

the	O
possible	O
mechanisms	O
include	O
an	O
improvement	O
in	O
striatal	O
metabolism	O
and	O
neuronal	O
activity	O
in	O
the	O
orbitofrontal	O
cortex	O
mediated	O
by	O
stn	O
dbs	O
as	O
well	O
as	O
increased	O
glucose	O
metabolism	O
in	O
the	O
striatum	O
midbrain	O
cingulate	O
gyrus	O
and	O
motor	O
and	O
higherorder	O
somatosensory	O
association	O
cortices	O

effects	O
of	O
caffeine	O
in	O
parkinsons	O
disease	O
from	O
neuroprotection	O
to	O
the	O
management	O
of	O
motor	O
and	O
nonmotor	O
symptoms	O

parkinsons	O
disease	O
pd	O
is	O
the	O
second	O
most	O
common	O
neurodegenerative	O
disorder	O
affecting	O
approximately	O
1	O
of	O
the	O
population	O
older	O
than	O
60	O
years	O

classically	O
pd	O
is	O
considered	O
to	O
be	O
a	O
motor	O
system	O
disease	O
and	O
its	O
diagnosis	O
is	O
based	O
on	O
the	O
presence	O
of	O
a	O
set	O
of	O
cardinal	O
motor	O
signs	O
rigidity	O
bradykinesia	O
rest	O
tremor	O
that	O
are	O
consequence	O
of	O
a	O
pronounced	O
death	O
of	O
dopaminergic	O
neurons	O
in	O
the	O
substantia	O
nigra	O
pars	O
compacta	O

nowadays	O
there	O
is	O
considerable	O
evidence	O
showing	O
that	O
nondopaminergic	O
degeneration	O
also	O
occurs	O
in	O
other	O
brain	O
areas	O
which	O
seems	O
to	O
be	O
responsible	O
for	O
the	O
deficits	O
in	O
olfactory	O
emotional	O
and	O
memory	O
functions	O
that	O
precede	O
the	O
classical	O
motor	O
symptoms	O
in	O
pd	O

the	O
present	O
review	O
attempts	O
to	O
examine	O
results	O
reported	O
in	O
epidemiological	O
clinical	O
and	O
animal	O
studies	O
to	O
provide	O
a	O
comprehensive	O
picture	O
of	O
the	O
antiparkinsonian	O
potential	O
of	O
caffeine	O

convergent	O
epidemiological	O
and	O
preclinical	O
data	O
suggest	O
that	O
caffeine	O
may	O
confer	O
neuroprotection	O
against	O
the	O
underlying	O
dopaminergic	O
neuron	O
degeneration	O
and	O
influence	O
the	O
onset	O
and	O
progression	O
of	O
pd	O

the	O
available	O
data	O
also	O
suggest	O
that	O
caffeine	O
can	O
improve	O
the	O
motor	O
deficits	O
of	O
pd	O
and	O
that	O
adenosine	O
a2a	O
receptor	O
antagonists	O
such	O
as	O
istradefylline	O
reduces	O
off	O
time	O
and	O
dyskinesia	O
associated	O
with	O
standard	O
dopamine	O
replacement	O
treatments	O

finally	O
recent	O
experimental	O
findings	O
have	O
indicated	O
the	O
potential	O
of	O
caffeine	O
in	O
the	O
management	O
of	O
nonmotor	O
symptoms	O
of	O
pd	O
which	O
do	O
not	O
improve	O
with	O
the	O
current	O
dopaminergic	O
drugs	O

altogether	O
the	O
studies	O
reviewed	O
provide	O
strong	O
evidence	O
that	O
caffeine	O
may	O
represent	O
a	O
promising	O
therapeutic	O
tool	O
in	O
pd	O
thus	O
being	O
the	O
first	O
compound	O
to	O
restore	O
both	O
motor	O
and	O
nonmotor	O
early	O
symptoms	O
of	O
pd	O
together	O
with	O
its	O
neuroprotective	O
potential	O

latent	O
cognitive	O
phenotypes	O
in	O
de	O
novo	O
parkinsons	O
disease	O
a	O
personcentered	O
approach	O

objectives	O
cognitive	O
impairment	O
is	O
an	O
important	O
aspect	O
of	O
parkinsons	O
disease	O
pd	O
but	O
there	O
is	O
considerable	O
heterogeneity	O
in	O
its	O
presentation	O

this	O
investigation	O
aims	O
to	O
identify	O
and	O
characterize	O
latent	O
cognitive	O
phenotypes	O
in	O
early	O
pd	O

methods	O
latent	O
class	O
analysis	O
a	O
datadriven	O
personcentered	O
cluster	O
analysis	O
was	O
performed	O
on	O
cognitive	O
data	O
from	O
the	O
parkinsons	O
progressive	O
markers	O
initiative	O
baseline	O
visit	O

this	O
analytic	O
method	O
facilitates	O
identification	O
of	O
naturally	O
occurring	O
endophenotypes	O

resulting	O
classes	O
were	O
compared	O
across	O
biomarker	O
symptom	O
and	O
demographic	O
data	O

results	O
six	O
cognitive	O
phenotypes	O
were	O
identified	O

three	O
demonstrated	O
consistent	O
performance	O
across	O
indicators	O
representing	O
poor	O
weakoverall	O
average	O
typicaloverall	O
and	O
strong	O
strongoverall	O
cognition	O

the	O
remaining	O
classes	O
demonstrated	O
unique	O
patterns	O
of	O
cognition	O
characterized	O
by	O
strongmemory	O
weakvisuospatial	O
and	O
amnestic	O
profiles	O

the	O
amnestic	O
class	O
evidenced	O
greater	O
tremor	O
severity	O
and	O
anosmia	B-OLFACTORY
but	O
was	O
unassociated	O
with	O
biomarkers	O
linked	O
with	O
alzheimers	O
disease	O

the	O
weakoverall	O
class	O
was	O
older	O
and	O
reported	O
more	O
nonmotor	O
features	O
associated	O
with	O
cognitive	O
decline	O
including	O
anxiety	O
depression	O
autonomic	O
dysfunction	O
anosmia	B-OLFACTORY
and	O
rem	O
sleep	O
behaviors	O

the	O
strongoverall	O
class	O
was	O
younger	O
more	O
female	B-PERCIEVER
and	O
reported	O
less	O
dysautonomia	O
and	O
anosmia	B-OLFACTORY

classes	O
were	O
unrelated	O
to	O
disease	O
duration	O
functional	O
independence	O
or	O
available	O
biomarkers	O

conclusions	O
latent	O
cognitive	O
phenotypes	O
with	O
focal	O
patterns	O
of	O
impairment	O
were	O
observed	O
in	O
recently	O
diagnosed	O
individuals	O
with	O
pd	O

cognitive	O
profiles	O
were	O
found	O
to	O
be	O
independent	O
of	O
traditional	O
biomarkers	O
and	O
motoric	O
indices	O
of	O
disease	O
progression	O

only	O
globally	O
impaired	O
class	O
was	O
associated	O
with	O
previously	O
reported	O
indicators	O
of	O
cognitive	O
decline	O
suggesting	O
this	O
group	O
may	O
drive	O
the	O
effects	O
reported	O
in	O
studies	O
using	O
variablebased	O
analysis	O

longitudinal	O
and	O
neuroanatomical	O
characterization	O
of	O
classes	O
will	O
yield	O
further	O
insight	O
into	O
the	O
evolution	O
of	O
cognitive	O
change	O
in	O
the	O
disease	O

jins	O
2017	O
23	O
551563	O

rbm24notch1	O
signaling	O
regulates	O
adult	O
neurogenesis	O
in	O
the	O
subventricular	O
zone	O
and	O
mediates	O
parkinsonassociated	O
olfactory	O
dysfunction	O

rationale	O
adult	O
neurogenesis	O
in	O
the	O
subventricular	O
zone	O
svz	O
is	O
essential	O
for	O
maintaining	O
neural	O
homeostasis	O
and	O
its	O
dysregulation	O
contributes	O
to	O
anosmia	B-OLFACTORY
and	O
delayed	O
tissue	O
healing	O
in	O
neurological	O
disorders	O
such	O
as	O
parkinsons	O
disease	O
pd	O

despite	O
intricate	O
regulatory	O
networks	O
identified	O
in	O
svz	O
neurogenesis	O
the	O
molecular	O
mechanisms	O
dynamically	O
maintaining	O
neural	O
stemprogenitor	O
cells	O
nspcs	O
in	O
response	O
to	O
physiological	O
and	O
pathological	O
stimuli	O
remain	O
incompletely	O
elucidated	O

methods	O
we	O
generated	O
an	O
rna	O
binding	O
motif	O
protein	O
24	O
rbm24	O
knockout	O
model	O
to	O
investigate	O
its	O
impact	O
on	O
adult	O
neurogenesis	O
in	O
the	O
svz	O
employing	O
immunofluorescence	O
immunoblot	O
electrophysiology	O
rnasequencing	O
and	O
in	O
vitro	O
experiments	O

further	O
investigations	O
utilized	O
a	O
pd	O
mouse	O
model	O
along	O
with	O
genetic	O
and	O
pharmacological	O
manipulations	O
to	O
elucidate	O
rbm24	O
involvement	O
in	O
pd	O
pathology	O

results	O
rbm24	O
a	O
multifaceted	O
posttranscriptional	O
regulator	O
of	O
cellular	O
homeostasis	O
exhibited	O
broad	O
expression	O
in	O
the	O
svz	O
from	O
development	O
to	O
aging	O

deletion	O
of	O
rbm24	O
significantly	O
impaired	O
nspc	O
proliferation	O
in	O
the	O
adult	O
svz	O
ultimately	O
resulting	O
in	O
collapsed	O
neurogenesis	O
in	O
the	O
olfactory	O
bulb	O

notably	O
rbm24	O
played	O
a	O
specific	O
role	O
in	O
maintaining	O
notch1	O
mrna	O
stability	O
in	O
adult	O
nspcs	O

the	O
rbm24notch1	O
signaling	O
axis	O
was	O
significantly	O
downregulated	O
in	O
the	O
svz	O
of	O
pd	O
mice	O

remarkably	O
overexpression	O
of	O
rbm24	O
rescued	O
disruption	O
of	O
adult	O
neurogenesis	O
and	O
olfactory	O
dysfunction	O
in	O
pd	O
mice	O
and	O
these	O
effects	O
were	O
hindered	O
by	O
dapt	O
a	O
potent	O
inhibitor	O
of	O
notch1	O

conclusions	O
our	O
findings	O
highlight	O
the	O
critical	O
role	O
of	O
the	O
rbm24notch1	O
signaling	O
axis	O
in	O
regulating	O
adult	O
svz	O
neurogenesis	O
under	O
physiological	O
and	O
pathological	O
circumstances	O

this	O
provides	O
valuable	O
insights	O
into	O
the	O
dynamic	O
regulation	O
of	O
nspc	O
homeostasis	O
and	O
offers	O
a	O
potential	O
targeted	O
intervention	O
for	O
pd	O
and	O
related	O
neurological	O
disorders	O

biopsies	O
of	O
olfactory	O
epithelium	O
in	O
patients	B-PERCIEVER
with	O
parkinsons	O
disease	O

parkinsons	O
disease	O
pd	O
is	O
a	O
neurodegenerative	O
disorder	O
involving	O
several	O
neuronal	O
systems	O

impaired	O
olfactory	O
function	O
may	O
constitute	O
one	O
of	O
the	O
earliest	O
symptoms	O
of	O
pd	O

however	O
it	O
is	O
still	O
unclear	O
to	O
what	O
degree	O
changes	O
of	O
the	O
olfactory	O
epithelium	O
may	O
contribute	O
to	O
dysosmia	O
and	O
if	O
these	O
changes	O
are	O
different	O
from	O
those	O
of	O
other	O
hyposmic	O
or	O
anosmic	O
patients	B-PERCIEVER

this	O
study	O
aimed	O
to	O
investigate	O
the	O
hypothesis	O
that	O
olfactory	O
loss	O
in	O
pd	O
is	O
a	O
consequence	O
of	O
specific	O
pdrelated	O
damage	O
of	O
olfactory	O
epithelium	O

biopsies	O
of	O
7	O
patients	B-PERCIEVER
diagnosed	O
with	O
pd	O
were	O
taken	O

six	O
patients	B-PERCIEVER
with	O
pd	O
were	O
hyposmic	O
one	O
anosmic	O

as	O
nonpd	O
controls	O
served	O
9	O
patients	B-PERCIEVER
with	O
hyposmia	B-OLFACTORY
9	O
with	O
anosmia	B-OLFACTORY
and	O
7	O
normosmic	O
individuals	O

further	O
nasal	O
mucosa	O
of	O
4	O
postmortem	O
individuals	O
was	O
investigated	O

immunohistochemical	O
examinations	O
were	O
performed	O
with	O
antibodies	O
against	O
olfactory	O
marker	O
protein	O
omp	O
protein	O
gene	O
product	O
95	O
pgp	O
95	O
betatubulin	O
bt	O
proliferationassociated	O
antigen	O
ki	O
67	O
the	O
stem	O
cell	O
marker	O
nestin	O
cytokeratin	O
p75ngfr	O
and	O
alphasynuclein	O

most	O
of	O
the	O
biopsy	O
specimens	O
exhibited	O
irregular	O
areas	O
of	O
olfactorylike	O
dysplastic	O
epithelium	O
positive	O
for	O
either	O
pgp	O
95	O
or	O
bt	O
but	O
negative	O
for	O
omp	O

no	O
major	O
histochemical	O
differences	O
in	O
either	O
the	O
expression	O
or	O
distribution	O
of	O
these	O
proteins	O
were	O
observed	O
in	O
the	O
olfactory	O
epithelium	O
of	O
patients	B-PERCIEVER
with	O
pd	O
compared	O
with	O
controls	O

reverse	O
transcription	O
pcr	O
rtpcr	O
data	O
indicated	O
mrna	O
for	O
omp	O
in	O
almost	O
all	O
subjects	B-PERCIEVER
independently	O
of	O
their	O
olfactory	O
performance	O

these	O
data	O
support	O
the	O
idea	O
that	O
olfactory	O
loss	O
in	O
parkinsons	O
disease	O
is	O
not	O
a	O
consequence	O
of	O
damage	O
to	O
the	O
olfactory	O
epithelium	O
but	O
rather	O
results	O
from	O
distinct	O
centralnervous	O
abnormalities	O

is	O
rhinorrhea	O
an	O
underrecognized	O
intrinsic	O
symptom	O
of	O
parkinson	O
disease	O

a	O
prospective	O
pilot	O
study	O

purpose	O
the	O
purpose	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
prevalence	O
of	O
idiopathic	O
rhinorrhea	O
in	O
pd	O
patients	B-PERCIEVER
versus	O
controls	O
to	O
determine	O
the	O
correlation	O
between	O
rhinorrhea	O
and	O
anosmia	B-OLFACTORY
and	O
the	O
factors	O
associated	O
with	O
rhinorrhea	O

scope	O
a	O
cohort	O
of	O
61	O
pd	O
patients	B-PERCIEVER
and	O
51	O
agematched	O
controls	O
completed	O
a	O
survey	O
about	O
rhinorrhea	O
and	O
underwent	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST

we	O
compared	O
the	O
prevalence	O
of	O
idiopathic	O
rhinorrhea	O
in	O
the	O
pd	O
patients	B-PERCIEVER
versus	O
controls	O
the	O
correlation	O
between	O
rhinorrhea	O
and	O
anosmia	B-OLFACTORY
in	O
pd	O
patients	B-PERCIEVER
and	O
the	O
factors	O
associated	O
with	O
rhinorrhea	O
in	O
the	O
pd	O
patients	B-PERCIEVER

the	O
results	O
of	O
the	O
study	O
are	O
that	O
6	O
of	O
controls	O
versus	O
24	O
of	O
pd	O
patients	B-PERCIEVER
had	O
rhinorrhea	O
p	O
03	O
moreover	O
only	O
2	O
of	O
controls	O
versus	O
15	O
of	O
pd	O
patients	B-PERCIEVER
had	O
severe	O
rhinorrhea	O

conclusion	O
rhinorrhea	O
is	O
more	O
prevalent	O
in	O
pd	O
patients	B-PERCIEVER
compared	O
to	O
controls	O
and	O
it	O
does	O
not	O
significantly	O
impact	O
performance	O
on	O
a	O
smell	O
test	O

olfactoryrelated	O
cortical	O
atrophy	O
is	O
associated	O
with	O
olfactory	O
dysfunction	O
in	O
parkinsons	O
disease	O

background	O
olfactory	O
dysfunction	O
is	O
often	O
associated	O
with	O
parkinsons	O
disease	O
pd	O
and	O
can	O
precede	O
characteristic	O
motor	O
symptoms	O
by	O
several	O
years	O

olfactoryrelated	O
cortical	O
atrophy	O
has	O
been	O
reported	O
in	O
pd	O
although	O
the	O
extent	O
and	O
association	O
between	O
cortical	O
atrophy	O
and	O
olfactory	O
dysfunction	O
have	O
been	O
controversial	O

the	O
present	O
study	O
examined	O
whether	O
olfactory	O
dysfunction	O
is	O
associated	O
with	O
gray	O
matter	O
gm	O
volume	O
in	O
brain	O
regions	O
subserving	O
primary	O
and	O
secondary	O
olfactory	O
processing	O

methods	O
highresolution	O
t1weighted	O
brain	O
mris	O
were	O
acquired	O
from	O
40	O
pd	O
without	O
dementia	B-NEURODEGENERATIVE
and	O
40	O
matched	O
controls	O
along	O
with	O
smell	O
identification	O
scores	O

brain	O
volumes	O
were	O
compared	O
using	O
voxelbased	O
morphometry	O

results	O
compared	O
to	O
controls	O
pd	O
patients	B-PERCIEVER
sustained	O
greater	O
gm	O
loss	O
localized	O
to	O
bilateral	O
piriform	O
cortex	O
pc	O
and	O
orbitofrontal	O
cortex	O
ofc	O

reduced	O
olfactory	O
performance	O
in	O
pd	O
was	O
significantly	O
associated	O
with	O
lower	O
gm	O
volumes	O
in	O
pc	O
and	O
ofc	O

conclusions	O
both	O
primary	O
and	O
secondary	O
olfactory	O
cortical	O
atrophy	O
occurred	O
in	O
pd	O
and	O
were	O
associated	O
with	O
olfactory	O
dysfunction	O

olfactory	O
dysfunction	O
is	O
associated	O
with	O
motor	O
function	O
only	O
in	O
tremordominant	O
parkinsons	O
disease	O

background	O
the	O
prevalence	O
of	O
olfactory	O
impairment	O
in	O
patients	B-PERCIEVER
with	O
parkinsons	O
disease	O
pd	O
is	O
5090	O
and	O
therefore	O
olfactory	O
dysfunction	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
nonmotor	O
symptoms	O
nmss	O
in	O
patients	B-PERCIEVER
with	O
pd	O

numerous	O
studies	O
have	O
evaluated	O
the	O
association	O
between	O
motor	O
and	O
nonmotor	O
symptoms	O
and	O
olfactory	O
dysfunction	O
in	O
pd	O

aim	O
in	O
this	O
study	O
we	O
investigated	O
the	O
relationship	O
between	O
olfactory	O
dysfunction	O
which	O
is	O
measured	O
using	O
the	O
upsit	B-SMELL_TEST
test	O
with	O
other	O
motor	O
and	O
nonmotor	O
symptoms	O
separately	O
in	O
three	O
motor	O
subtypes	O
of	O
pd	O
including	O
tremor	O
dominant	O
td	O
postural	O
instability	O
and	O
gait	O
difficulty	O
pigd	O
and	O
indeterminate	O
and	O
healthy	O
subjects	B-PERCIEVER

methods	O
we	O
recruited	O
487	O
earlystage	O
pd	O
patients	B-PERCIEVER
43	O
pigd	O
406	O
td	O
and	O
38	O
indeterminate	O
and	O
healthy	O
controls	O
hcs	O
n	O
197	O
from	O
the	O
parkinson	O
progression	O
markers	O
initiative	O
ppmi	O

all	O
participants	B-PERCIEVER
completed	O
motor	O
and	O
nonmotor	O
tests	O
at	O
baseline	O
visit	O
and	O
after	O
4	O
years	O
of	O
followup	O

subjects	B-PERCIEVER
underwent	O
common	O
pd	O
scaling	O
tests	O

results	O
olfactory	O
dysfunction	O
was	O
significantly	O
correlated	O
with	O
declined	O
motor	O
functions	O
only	O
in	O
the	O
td	O
subtype	O

also	O
significant	O
correlations	O
were	O
noticed	O
between	O
olfactory	O
dysfunction	O
and	O
speedattention	O
processing	O
and	O
executive	O
function	O
in	O
the	O
hcs	O
as	O
well	O

finally	O
no	O
significant	O
or	O
meaningful	O
association	O
was	O
observed	O
in	O
the	O
pigd	O
and	O
indeterminate	O
subtype	O

anosmia	B-OLFACTORY
and	O
hyposmia	B-OLFACTORY
subjects	B-PERCIEVER
in	O
the	O
td	O
group	O
had	O
the	O
worse	O
motor	O
and	O
nonmotor	O
scores	O
compared	O
to	O
normosmia	O
subjects	B-PERCIEVER
after	O
4	O
years	O

conclusion	O
olfactory	O
dysfunction	O
was	O
significantly	O
correlated	O
with	O
declined	O
motor	O
functions	O
in	O
the	O
td	O
subtype	O

this	O
is	O
indicating	O
that	O
olfactory	O
dysfunction	O
may	O
be	O
an	O
early	O
motor	O
and	O
nonmotor	O
biomarker	O
only	O
in	O
the	O
td	O
subtype	O

however	O
it	O
is	O
possible	O
that	O
the	O
involvement	O
of	O
olfactory	O
function	O
in	O
other	O
subtypes	O
is	O
not	O
strong	O
enough	O
to	O
make	O
it	O
a	O
useful	O
marker	O
of	O
diseases	O
progression	O

seedinduced	O
abeta	O
deposition	O
alters	O
neuronal	O
function	O
and	O
impairs	O
olfaction	O
in	O
a	O
mouse	O
model	O
of	O
alzheimers	O
disease	O

alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE
is	O
characterized	O
by	O
the	O
accumulation	O
of	O
amyloidbeta	O
abeta	O
which	O
ultimately	O
forms	O
plaques	O

these	O
abeta	O
deposits	O
can	O
be	O
induced	O
in	O
app	O
transgenic	O
mouse	O
models	O
by	O
prionlike	O
seeding	O

it	O
has	O
been	O
widely	O
accepted	O
that	O
anosmia	B-OLFACTORY
and	O
hyposmia	B-OLFACTORY
occur	O
during	O
the	O
early	O
stages	O
of	O
ad	B-NEURODEGENERATIVE
even	O
before	O
cognitive	O
deficits	O
are	O
present	O

in	O
order	O
to	O
determine	O
the	O
impact	O
of	O
seedinduced	O
abeta	O
deposits	O
on	O
olfaction	O
we	O
performed	O
intracerebral	O
injections	O
of	O
seedcompetent	O
brain	O
homogenate	O
into	O
the	O
olfactory	O
bulb	O
of	O
young	O
predepositing	O
app	O
transgenic	O
mice	O

remarkably	O
we	O
observed	O
a	O
dramatic	O
olfactory	O
impairment	O
in	O
those	O
mice	O

furthermore	O
the	O
number	O
of	O
newborn	O
neurons	O
as	O
well	O
as	O
the	O
activity	O
of	O
cells	O
in	O
the	O
mitral	O
cell	O
layer	O
was	O
decreased	O

notably	O
exposure	O
to	O
an	O
enriched	O
environment	O
reduced	O
abeta	O
seeding	O
vivified	O
neurogenesis	O
and	O
most	O
importantly	O
reversed	O
olfactory	O
deficits	O

based	O
on	O
our	O
findings	O
we	O
conclude	O
that	O
altered	O
neuronal	O
function	O
as	O
a	O
result	O
of	O
induced	O
abeta	O
pathology	O
might	O
contribute	O
to	O
olfactory	O
dysfunction	O
in	O
ad	B-NEURODEGENERATIVE

impact	O
of	O
deep	O
brain	O
stimulation	O
dbs	O
on	O
olfaction	O
in	O
parkinsons	O
disease	O
clinical	O
features	O
and	O
functional	O
hypotheses	O

deep	O
brain	O
stimulation	O
dbs	O
is	O
a	O
surgical	O
therapy	O
typically	O
applied	O
in	O
parkinsons	O
disease	O
pd	O

the	O
efficacity	O
of	O
dbs	O
on	O
the	O
control	O
of	O
motor	O
symptoms	O
in	O
pd	O
is	O
well	O
grounded	O
while	O
the	O
efficacity	O
on	O
nonmotor	O
symptoms	O
is	O
more	O
controversial	O
especially	O
on	O
olfactory	O
disorders	O
ods	O

the	O
present	O
review	O
shows	O
that	O
dbs	O
does	O
not	O
improve	O
hyposmia	B-OLFACTORY
but	O
can	O
affect	O
positively	O
identificationdiscrimination	O
scores	O
in	O
pd	O

the	O
functional	O
hypotheses	O
suggest	O
complex	O
mechanisms	O
in	O
terms	O
of	O
cerebral	O
connectivity	O
and	O
neurogenesis	O
process	O
which	O
could	O
act	O
indirectly	O
on	O
the	O
olfactory	O
bulb	O
and	O
olfactory	O
pathways	O
related	O
to	O
specific	O
cognitive	O
olfactory	O
tasks	O

the	O
functional	O
hypotheses	O
also	O
suggest	O
complex	O
mechanisms	O
of	O
cholinergic	O
neurotransmitter	O
interactions	O
involved	O
in	O
these	O
pathways	O

finally	O
the	O
impact	O
of	O
dbs	O
on	O
general	O
cognitive	O
functions	O
in	O
pd	O
could	O
also	O
be	O
beneficial	O
to	O
identificationdiscrimination	O
tasks	O
in	O
pd	O

potential	O
convergence	O
of	O
olfactory	O
dysfunction	O
in	O
parkinsons	O
disease	O
and	O
covid19	O
the	O
role	O
of	O
neuroinflammation	O

parkinsons	O
disease	O
pd	O
is	O
a	O
prevalent	O
neurodegenerative	O
disorder	O
that	O
affects	O
710	O
million	O
individuals	O
worldwide	O

a	O
common	O
early	O
symptom	O
of	O
pd	O
is	O
olfactory	O
dysfunction	O
od	O
and	O
more	O
than	O
90	O
of	O
pd	O
patients	B-PERCIEVER
suffer	O
from	O
od	O

recent	O
studies	O
have	O
highlighted	O
a	O
high	O
incidence	O
of	O
od	O
in	O
patients	B-PERCIEVER
with	O
sarscov2	O
infection	O

this	O
review	O
investigates	O
the	O
potential	O
convergence	O
of	O
od	O
in	O
pd	O
and	O
covid19	O
particularly	O
focusing	O
on	O
the	O
mechanisms	O
by	O
which	O
neuroinflammation	O
contributes	O
to	O
od	O
and	O
neurological	O
events	O

starting	O
from	O
our	O
fundamental	O
understanding	O
of	O
the	O
olfactory	O
bulb	O
we	O
summarize	O
the	O
clinical	O
features	O
of	O
od	O
and	O
pathological	O
features	O
of	O
the	O
olfactory	O
bulb	O
from	O
clinical	O
cases	O
and	O
autopsy	O
reports	O
in	O
pd	O
patients	B-PERCIEVER

we	O
then	O
examine	O
sarscov2induced	O
olfactory	O
bulb	O
neuropathology	O
and	O
od	O
and	O
emphasize	O
the	O
sarscov2induced	O
neuroinflammatory	O
cascades	O
potentially	O
leading	O
to	O
pd	O
manifestations	O

by	O
activating	O
microglia	O
and	O
astrocytes	O
as	O
well	O
as	O
facilitating	O
the	O
aggregation	O
of	O
alphasynuclein	O
sarscov2	O
could	O
contribute	O
to	O
the	O
onset	O
or	O
exacerbation	O
of	O
pd	O

we	O
also	O
discuss	O
the	O
possible	O
contributions	O
of	O
nfkappab	O
the	O
nlrp3	O
inflammasome	O
and	O
the	O
jakstat	O
p38	O
mapk	O
tlr4	O
il6jak2stat3	O
and	O
cgassting	O
signaling	O
pathways	O

although	O
olfactory	O
dysfunction	O
in	O
patients	B-PERCIEVER
with	O
covid19	O
may	O
be	O
reversible	O
it	O
is	O
challenging	O
to	O
restore	O
od	O
in	O
patients	B-PERCIEVER
with	O
pd	O

with	O
the	O
emergence	O
of	O
new	O
sarscov2	O
variants	O
and	O
the	O
recurrence	O
of	O
infections	O
we	O
call	O
for	O
continued	O
attention	O
to	O
the	O
intersection	O
between	O
pd	O
and	O
sarscov2	O
infection	O
especially	O
from	O
the	O
perspective	O
of	O
od	O

retronasal	O
olfactory	O
function	O
in	O
parkinsons	O
disease	O

objectiveshypothesis	O
orthonasal	O
olfaction	O
is	O
severely	O
altered	O
in	O
pd	O
patients	B-PERCIEVER

retronasal	O
olfactory	O
function	O
has	O
been	O
shown	O
to	O
be	O
preserved	O
under	O
certain	O
conditions	O
even	O
in	O
the	O
absence	O
of	O
orthonasal	O
function	O

this	O
study	O
was	O
undertaken	O
to	O
investigate	O
retronasal	O
versus	O
orthonasal	O
olfactory	O
function	O
in	O
parkinsons	O
disease	O
pd	O

study	O
design	O
prospective	O
study	O

methods	O
a	O
total	O
of	O
45	O
pd	O
patients	B-PERCIEVER
mean	O
age	O
61	O
years	O
range	O
2682	O
years	O
underwent	O
orthonasal	O
olfactory	O
testing	O
with	O
a	O
standardized	O
olfactory	O
test	O
sniffin	O
sticks	O
and	O
retronasal	O
olfactory	O
testing	O
with	O
a	O
10item	O
identification	O
kit	O
based	O
on	O
aromatized	O
powders	O

results	O
regarding	O
orthonasal	O
tests	O
all	O
pd	O
patients	B-PERCIEVER
scored	O
within	O
the	O
range	O
of	O
hyposmia	B-OLFACTORY
and	O
functional	O
anosmia	B-OLFACTORY

the	O
mean	O
correct	O
orthonasal	O
identification	O
score	O
for	O
pd	O
patients	B-PERCIEVER
was	O
56	O
26	O
and	O
the	O
mean	O
retronasal	O
identification	O
rate	O
was	O
60	O
3	O

there	O
was	O
no	O
significant	O
difference	O
between	O
ortho	O
and	O
retronasal	O
odor	O
identification	O
p	O
15	O

conclusions	O
the	O
present	O
study	O
shows	O
that	O
retronasal	O
and	O
orthonasal	O
olfactory	O
function	O
are	O
severely	O
impaired	O
in	O
pd	O
patients	B-PERCIEVER
and	O
this	O
impairment	O
is	O
of	O
similar	O
magnitude	O
for	O
both	O
functions	O

the	O
contribution	O
of	O
this	O
finding	O
to	O
the	O
foodintake	O
behavior	O
of	O
pd	O
patients	B-PERCIEVER
is	O
discussed	O

the	O
relationship	O
between	O
anosmia	B-OLFACTORY
constipation	O
and	O
orthostasis	O
and	O
parkinsons	O
disease	O
duration	O
results	O
of	O
a	O
pilot	O
study	O

autonomic	O
symptomatology	O
is	O
prevalent	O
in	O
parkinsons	O
disease	O
pd	O
and	O
impacts	O
quality	O
of	O
life	O
yet	O
little	O
data	O
exist	O
on	O
the	O
presentation	O
of	O
autonomic	O
dysregulation	O

this	O
study	O
measures	O
orthostasis	O
constipation	O
and	O
anosmia	B-OLFACTORY
in	O
58	O
pd	O
patients	B-PERCIEVER
and	O
51	O
agematched	O
controls	O
enrolled	O
in	O
the	O
university	O
of	O
floridas	O
movement	O
disorders	O
center	O

patients	B-PERCIEVER
had	O
their	O
blood	O
pressure	O
measured	O
while	O
seated	O
and	O
in	O
standing	O
position	O
performed	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
and	O
completed	O
a	O
constipation	O
survey	O

our	O
pd	O
patients	B-PERCIEVER
had	O
a	O
significantly	O
different	O
average	O
decrease	O
in	O
systolic	O
bp	O
from	O
a	O
seated	O
to	O
standing	O
position	O
compared	O
with	O
their	O
agematched	O
controls	O
590	O
mmhg	O
sd	O
1703	O
vs	O
26	O
mmhg	O
sd	O
1128	O
p	O
05	O

the	O
difference	O
in	O
heart	O
rate	O
from	O
seated	O
to	O
standing	O
positions	O
was	O
not	O
significant	O

reflexive	O
tachycardia	O
was	O
inversely	O
proportional	O
to	O
levodopa	O
equivalent	O
daily	O
dose	O
ledd	O
score	O
p	O
002	O

anosmia	B-OLFACTORY
occurred	O
in	O
964	O
of	O
the	O
pd	O
group	O
and	O
49	O
of	O
the	O
controls	O
p	O
001	O

constipation	O
was	O
also	O
more	O
prevalent	O
in	O
the	O
pd	O
population	O
than	O
in	O
the	O
controls	O
673	O
vs	O
216	O
p	O
001	O

both	O
anosmia	B-OLFACTORY
and	O
constipation	O
were	O
correlated	O
with	O
disease	O
duration	O
p	O
038	O
and	O
04	O
respectively	O

our	O
study	O
suggests	O
that	O
increasing	O
levels	O
of	O
dopaminergic	O
therapy	O
inhibits	O
reflexive	O
tachycardia	O

furthermore	O
our	O
study	O
suggests	O
that	O
anosmia	B-OLFACTORY
and	O
constipation	O
progress	O
with	O
the	O
primary	O
disease	O
process	O

predictive	O
value	O
of	O
olfactory	O
impairment	O
for	O
cognitive	O
decline	O
among	O
cognitively	O
normal	O
adults	O

objective	O
dementia	B-NEURODEGENERATIVE
affects	O
over	O
47	O
million	O
people	O
worldwide	O

olfactory	O
impairment	O
oi	O
is	O
a	O
wellestablished	O
predictive	O
marker	O
of	O
conversion	O
to	O
dementia	B-NEURODEGENERATIVE
among	O
those	O
with	O
mild	O
cognitive	O
impairment	O

this	O
systematic	O
review	O
aims	O
to	O
describe	O
the	O
predictive	O
value	O
of	O
oi	O
for	O
future	O
cognitive	O
decline	O
among	O
cognitively	O
normal	O
adults	O

methods	O
a	O
literature	O
search	O
encompassing	O
pubmed	O
embase	O
and	O
cochrane	O
for	O
longitudinal	O
cohort	O
studies	O
following	O
cognitively	O
normal	O
adults	O
with	O
baseline	O
oi	O
in	O
comparison	O
to	O
those	O
without	O
oi	O
reporting	O
incident	O
cognitive	O
impairment	O
or	O
dementia	B-NEURODEGENERATIVE
was	O
included	O

study	O
design	O
participant	O
demographics	O
olfactory	O
testing	O
method	O
and	O
incidence	O
of	O
cognitive	O
decline	O
or	O
dementia	B-NEURODEGENERATIVE
were	O
abstracted	O

two	O
investigators	O
independently	O
reviewed	O
all	O
articles	O

results	O
the	O
search	O
yielded	O
964	O
nonduplicate	O
abstracts	O
and	O
titles	O
from	O
which	O
19	O
fulltext	O
articles	O
were	O
reviewed	O
and	O
10	O
were	O
included	O

studies	O
included	O
were	O
all	O
good	O
quality	O
mean	O
score	O
87	O
of	O
9	O
and	O
all	O
studies	O
100	O
found	O
a	O
statistically	O
significant	O
association	O
between	O
baseline	O
oi	O
and	O
incident	O
cognitive	O
decline	O
compared	O
with	O
normosmic	O
controls	O

conclusion	O
the	O
existing	O
literature	O
suggests	O
that	O
oi	O
predicts	O
future	O
cognitive	O
decline	O
among	O
cognitively	O
normal	O
adults	O
supporting	O
olfactory	O
evaluation	O
as	O
a	O
lowcost	O
minimally	O
invasive	O
and	O
widely	O
available	O
screening	O
tool	O
to	O
be	O
used	O
in	O
combination	O
with	O
other	O
tests	O
to	O
identify	O
adults	O
at	O
early	O
risk	O
of	O
dementia	B-NEURODEGENERATIVE

level	O
of	O
evidence	O
na	O
laryngoscope	O
130840847	O
2020	O

nonvisual	O
hallucinations	O
in	O
parkinsons	O
disease	O
a	O
systematic	O
review	O

background	O
nonvisual	O
hallucinations	O
in	O
parkinsons	O
disease	O
pd	O
can	O
be	O
prevalent	O
and	O
distressing	O

most	O
existing	O
research	O
has	O
however	O
focused	O
on	O
visual	O
hallucinations	O
as	O
well	O
as	O
related	O
risk	O
factors	O

the	O
current	O
study	O
thus	O
conducted	O
a	O
systematic	O
review	O
to	O
collate	O
existing	O
evidence	O
on	O
nonvisual	O
hallucinations	O
in	O
pd	O
focusing	O
on	O
their	O
prevalence	O
phenomenology	O
and	O
clinicalcognitive	O
correlates	O

methods	O
ninetyone	O
relevant	O
studies	O
were	O
included	O
from	O
a	O
systematic	O
search	O
across	O
psycinfo	O
apa	O
pubmed	O
and	O
web	O
of	O
science	O
for	O
peerreviewed	O
publications	O
in	O
the	O
english	O
language	O
from	O
1970	O
to	O
the	O
present	O

these	O
comprised	O
a	O
mix	O
of	O
case	O
30	O
studies	O
n	O
56	O
and	O
group	O
design	O
62	O
studies	O
n	O
7346	O
studies	O
divided	O
into	O
three	O
somewhat	O
overlapping	O
collections	O
to	O
address	O
our	O
three	O
research	O
foci	O

results	O
prevalence	O
estimates	O
for	O
hallucinations	O
were	O
auditory	O
15720	O
olfactory	O
16210	O
somatictactile	O
04225	O
gustatory	O
10150	O
and	O
sensed	O
presence	O
09733	O

phenomenological	O
inquiries	O
revealed	O
descriptions	O
of	O
vivid	O
consuming	O
events	O
replete	O
with	O
elaborate	O
detail	O
adversely	O
affecting	O
pd	O
patients	B-PERCIEVER
in	O
different	O
ways	O

overt	O
experiences	O
of	O
multisensory	O
hallucinations	O
were	O
also	O
highly	O
variable	O
0480	O
but	O
exceedingly	O
common	O
reported	O
by	O
almost	O
half	O
of	O
the	O
45	O
included	O
prevalence	O
studies	O

there	O
was	O
some	O
evidence	O
for	O
modalityspecific	O
hallucination	O
predictors	O
but	O
this	O
was	O
largely	O
tentative	O
pending	O
robust	O
replication	O

conclusions	O
marked	O
prevalence	O
figures	O
coupled	O
with	O
phenomenological	O
descriptions	O
implicating	O
distress	O
denote	O
that	O
nonvisual	O
and	O
multisensory	O
hallucinations	O
in	O
pd	O
are	O
of	O
clinical	O
significance	O

more	O
direct	O
research	O
and	O
clinical	O
attention	O
need	O
to	O
be	O
devoted	O
to	O
the	O
study	O
and	O
management	O
of	O
such	O
hallucinatory	O
experiences	O

olfactory	O
and	O
cognitive	O
decrements	O
in	O
1991	O
gulf	O
war	O
veterans	O
with	O
gulf	O
war	O
illnesschronic	O
multisymptom	O
illness	O

background	O
gulf	O
war	O
illness	O
gwichronic	O
multisymptom	O
illness	O
cmi	O
is	O
a	O
disorder	O
related	O
to	O
military	O
service	O
in	O
the	O
1991	O
gulf	O
war	O
gw	O

prominent	O
symptoms	O
of	O
gwicmi	O
include	O
fatigue	O
pain	O
and	O
cognitive	O
dysfunction	O

although	O
anosmia	B-OLFACTORY
is	O
not	O
a	O
typical	O
gwicmi	O
symptom	O
anecdotally	O
some	O
gw	O
veterans	O
have	O
reported	O
losing	O
their	O
sense	O
smell	O
shortly	O
after	O
the	O
war	O

because	O
olfactory	O
deficit	O
is	O
a	O
prodromal	O
symptom	O
of	O
neurodegenerative	O
diseases	O
like	O
parkinsons	O
and	O
alzheimers	O
disease	O
and	O
because	O
we	O
previously	O
reported	O
suggestive	O
evidence	O
that	O
deployed	O
gw	O
veterans	O
may	O
be	O
at	O
increased	O
risk	O
for	O
mild	O
cognitive	O
impairment	O
mci	O
and	O
dementia	B-NEURODEGENERATIVE
the	O
current	O
study	O
examined	O
the	O
relationship	O
between	O
olfactory	O
and	O
cognitive	O
function	O
in	O
deployed	O
gw	O
veterans	O

methods	O
eighty	O
deployed	O
gw	O
veterans	O
mean	O
age	O
599	O
70	O
4	O
female	B-PERCIEVER
were	O
tested	O
remotely	O
with	O
the	O
university	O
of	O
pennsylvania	O
smell	O
identification	O
test	O
upsit	B-SMELL_TEST
and	O
the	O
montreal	O
cognitive	O
assessment	O
moca	O

veterans	O
also	O
completed	O
selfreport	O
questionnaires	O
about	O
their	O
health	O
and	O
deploymentrelated	O
exposures	O
and	O
experiences	O

upsit	B-SMELL_TEST
and	O
moca	O
data	O
from	O
healthy	O
control	O
hc	O
participants	B-PERCIEVER
from	O
the	O
parkinsons	O
progression	O
markers	O
initiative	O
ppmi	O
study	O
were	O
downloaded	O
for	O
comparison	O

results	O
gw	O
veterans	O
had	O
a	O
mean	O
upsit	B-SMELL_TEST
score	O
of	O
278	O
63	O
range	O
937	O
and	O
a	O
mean	O
moca	O
score	O
of	O
253	O
28	O
range	O
1930	O

according	O
to	O
age	O
and	O
sexspecific	O
normative	O
data	O
31	O
of	O
gw	O
veterans	O
vs	O
8	O
ppmi	O
hcs	O
had	O
upsit	B-SMELL_TEST
scores	O
below	O
the	O
10th	O
percentile	O

nearly	O
half	O
45	O
of	O
gw	O
veterans	O
vs	O
8	O
ppmi	O
hcs	O
had	O
moca	O
scores	O
below	O
the	O
cutoff	O
for	O
identifying	O
mci	O

among	O
gw	O
veterans	O
but	O
not	O
ppmi	O
hcs	O
there	O
was	O
a	O
positive	O
correlation	O
between	O
upsit	B-SMELL_TEST
and	O
moca	O
scores	O
spearmans	O
rho	O
039	O
p	O
0001	O

there	O
were	O
no	O
significant	O
differences	O
in	O
upsit	B-SMELL_TEST
or	O
moca	O
scores	O
between	O
gw	O
veterans	O
with	O
and	O
without	O
history	O
of	O
covid	O
or	O
between	O
those	O
with	O
and	O
without	O
kansas	O
gwi	O
exclusionary	O
conditions	O

conclusions	O
we	O
found	O
evidence	O
of	O
olfactory	O
and	O
cognitive	O
deficits	O
and	O
a	O
significant	O
correlation	O
between	O
upsit	B-SMELL_TEST
and	O
moca	O
scores	O
in	O
a	O
cohort	O
of	O
80	O
deployed	O
gw	O
veterans	O
99	O
of	O
whom	O
had	O
cmi	O

because	O
impaired	O
olfactory	O
function	O
has	O
been	O
associated	O
with	O
increased	O
risk	O
for	O
mci	O
and	O
dementia	B-NEURODEGENERATIVE
it	O
may	O
be	O
prudent	O
to	O
screen	O
aging	O
deployed	O
gw	O
veterans	O
with	O
smell	O
identification	O
tests	O
so	O
that	O
hypo	O
and	O
anosmic	O
veterans	O
can	O
be	O
followed	O
longitudinally	O
and	O
offered	O
targeted	O
neuroprotective	O
therapies	O
as	O
they	O
become	O
available	O

the	O
anterior	O
olfactory	O
nucleus	O
in	O
parkinsons	O
disease	O

impaired	O
olfaction	O
occurs	O
in	O
patients	B-PERCIEVER
with	O
idiopathic	O
parkinsons	O
disease	O
pd	O
and	O
lewy	O
bodies	O
have	O
been	O
found	O
in	O
the	O
olfactory	O
bulb	O
and	O
tract	O

we	O
now	O
confirm	O
the	O
latter	O
finding	O
and	O
show	O
that	O
this	O
presence	O
of	O
lewy	O
bodies	O
is	O
associated	O
with	O
significant	O
neuronal	O
loss	O

a	O
quantitative	O
study	O
of	O
the	O
anterior	O
olfactory	O
nucleus	O
aon	O
was	O
performed	O
in	O
tissue	O
obtained	O
postmortem	O
from	O
seven	O
patients	B-PERCIEVER
with	O
pd	O
and	O
seven	O
agematched	O
controls	O

neuronal	O
loss	O
was	O
seen	O
in	O
the	O
pd	O
bulb	O
and	O
tracts	O
p	O
001	O
and	O
a	O
strong	O
correlation	O
of	O
neuronal	O
loss	O
with	O
disease	O
duration	O
was	O
detected	O
r	O
087	O

the	O
presence	O
of	O
lewy	O
bodies	O
was	O
confirmed	O
with	O
immunocytochemical	O
staining	O
for	O
ubiquitin	O
in	O
all	O
the	O
pd	O
cases	O

relevance	O
of	O
substantia	O
nigra	O
hyperechogenicity	O
and	O
reduced	O
odor	O
identification	O
in	O
idiopathic	O
rem	O
sleep	O
behavior	O
disorder	O

background	O
substantia	O
nigra	O
sn	O
hyperechogenicity	O
determined	O
by	O
transcranial	O
sonography	O
tcs	O
and	O
olfactory	O
dysfunction	O
are	O
common	O
findings	O
in	O
parkinson	O
disease	O
pd	O
which	O
may	O
reveal	O
a	O
prodromal	O
synucleinopathy	O
in	O
idiopathic	O
rem	O
sleep	O
behavior	O
disorder	O
irbd	O

methods	O
tcs	O
and	O
the	O
odor	O
stick	O
identification	O
test	O
for	O
japanese	O
ositj	O
were	O
performed	O
in	O
34	O
consecutive	O
patients	B-PERCIEVER
with	O
irbd	O
67961years	O
17	O
consecutive	O
patients	B-PERCIEVER
with	O
pd	O
66467years	O
and	O
21	O
control	O
group	O
subjects	B-PERCIEVER
64458years	O

results	O
there	O
was	O
a	O
significantly	O
increased	O
area	O
of	O
echogenicity	O
in	O
the	O
sn	O
in	O
the	O
irbd	O
group	O
020013cm2	O
and	O
pd	O
group	O
022011cm2	O
compared	O
with	O
the	O
control	O
group	O
006006cm2	O

we	O
found	O
pathological	O
sn	O
hyperechogenicity	O
020cm2	O
in	O
412	O
of	O
the	O
irbd	O
group	O
526	O
of	O
the	O
pd	O
group	O
and	O
95	O
of	O
the	O
control	O
group	O

further	O
there	O
were	O
abnormal	O
findings	O
of	O
both	O
pathological	O
sn	O
hyperechogenicity	O
020cm2	O
and	O
functional	O
anosmia	B-OLFACTORY
or	O
hyposmia	B-OLFACTORY
in	O
4	O
118	O
or	O
9	O
265	O
of	O
the	O
irbd	O
group	O
subjects	B-PERCIEVER
respectively	O
and	O
7	O
579	O
or	O
2	O
118	O
of	O
the	O
pd	O
group	O
subjects	B-PERCIEVER
respectively	O

conclusion	O
pathological	O
sn	O
hyperechogenic	O
abnormality	O
and	O
functional	O
anosmia	B-OLFACTORY
in	O
irbd	O
may	O
be	O
a	O
disease	O
state	O
in	O
the	O
transition	O
to	O
a	O
neurodegenerative	O
disease	O

olfactory	O
bulb	O
involvement	O
in	O
neurodegenerative	O
diseases	O

olfactory	O
dysfunction	O
is	O
a	O
common	O
and	O
early	O
symptom	O
of	O
many	O
neurodegenerative	O
diseases	O
particularly	O
of	O
parkinsons	O
disease	O
and	O
other	O
synucleinopathies	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE
and	O
mild	O
cognitive	O
impairment	O
heralding	O
its	O
progression	O
to	O
dementia	B-NEURODEGENERATIVE

the	O
neuropathologic	O
changes	O
of	O
olfactory	O
dysfunction	O
in	O
neurodegenerative	O
diseases	O
may	O
involve	O
the	O
olfactory	O
epithelium	O
olfactory	O
bulbtract	O
primary	O
olfactory	O
cortices	O
and	O
their	O
secondary	O
targets	O

olfactory	O
dysfunction	O
is	O
related	O
to	O
deposition	O
of	O
pathological	O
proteins	O
alphasynuclein	O
hyperphosphorylated	O
tau	O
protein	O
and	O
neurofilament	O
protein	O
in	O
these	O
areas	O
featured	O
by	O
neurofibrillary	O
tangles	O
lewy	O
bodies	O
and	O
neurites	O
inducing	O
a	O
complex	O
cascade	O
of	O
molecular	O
processes	O
including	O
oxidative	O
damage	O
neuroinflammation	O
and	O
cytosolic	O
disruption	O
of	O
cellular	O
processes	O
leading	O
to	O
cell	O
death	O

damage	O
to	O
cholinergic	O
serotonergic	O
and	O
noradrenergic	O
systems	O
is	O
likely	O
involved	O
since	O
such	O
damage	O
is	O
most	O
marked	O
in	O
those	O
diseases	O
with	O
severe	O
anosmia	B-OLFACTORY

recent	O
studies	O
of	O
olfactory	O
dysfunction	O
have	O
focused	O
its	O
potential	O
as	O
an	O
early	O
biomarker	O
for	O
the	O
diagnosis	O
of	O
neurodegenerative	O
disorders	O
and	O
their	O
disease	O
progression	O

here	O
we	O
summarize	O
the	O
current	O
knowledge	O
on	O
neuropathological	O
and	O
pathophysiological	O
changes	O
of	O
the	O
olfactory	O
system	O
in	O
the	O
most	O
frequent	O
neurodegenerative	O
diseases	O
in	O
particular	O
ad	B-NEURODEGENERATIVE
and	O
synucleinopathies	O

we	O
also	O
present	O
neuropathological	O
findings	O
in	O
the	O
olfactory	O
bulb	O
and	O
tract	O
in	O
a	O
large	O
autopsy	O
cohort	O
n	O
536	O
578	O
female	B-PERCIEVER
mean	O
age	O
813	O
years	O

the	O
severity	O
of	O
olfactory	O
bulb	O
hptau	O
abeta	O
and	O
alphasyn	O
pathology	O
correlated	O
and	O
increased	O
significantly	O
p	O
0001	O
with	O
increasing	O
neuritic	O
braak	O
stages	O
thal	O
abeta	O
phases	O
and	O
cerebral	O
lewy	O
body	O
pathology	O
respectively	O

hence	O
further	O
studies	O
are	O
warranted	O
to	O
investigate	O
the	O
potential	O
role	O
of	O
olfactory	O
biopsies	O
possibly	O
restricted	O
to	O
the	O
olfactory	O
epithelium	O
in	O
the	O
diagnostic	O
process	O
of	O
neurodegenerative	O
diseases	O
in	O
particular	O
in	O
clinical	O
drug	O
trials	O
to	O
identify	O
subjects	B-PERCIEVER
showing	O
early	O
preclinical	O
stages	O
of	O
neurodegeneration	O
and	O
to	O
stratify	O
clinically	O
impaired	O
cohorts	O
according	O
to	O
the	O
underlying	O
cerebral	O
neuropathology	O

odor	O
identification	O
test	O
in	O
idiopathic	O
rembehavior	O
disorder	O
and	O
parkinsons	O
disease	O
in	O
china	O

background	O
olfactory	O
dysfunction	O
is	O
common	O
in	O
parkinsons	O
disease	O
pd	O
and	O
idiopathic	O
rapid	O
eye	O
movement	O
sleep	O
behavior	O
disorder	O
irbd	O
which	O
is	O
a	O
risk	O
factor	O
in	O
the	O
development	O
of	O
pd	O

however	O
a	O
few	O
studies	O
have	O
conflicting	O
results	O
when	O
comparing	O
dysosmia	O
in	O
the	O
patients	B-PERCIEVER
with	O
irbd	O
and	O
pd	O

there	O
is	O
no	O
study	O
investigating	O
the	O
olfactory	O
function	O
in	O
chinese	O
patients	B-PERCIEVER
with	O
irbd	O

additionally	O
the	O
sniffin	O
sticks	O
screening	O
12	O
test	O
ss12	O
contains	O
several	O
odors	O
that	O
are	O
not	O
familiar	O
to	O
people	O
in	O
different	O
cultures	O

methods	O
odor	O
identification	O
was	O
evaluated	O
in	O
irbd	O
patients	B-PERCIEVER
n	O
54	O
pd	O
patients	B-PERCIEVER
n	O
54	O
and	O
healthy	O
controls	O
n	O
54	O

with	O
the	O
identification	O
data	O
a	O
brief	O
odor	O
identification	O
test	O
was	O
established	O
and	O
then	O
validated	O
in	O
other	O
subjects	B-PERCIEVER

results	O
odor	O
identification	O
scores	O
in	O
irbd	O
patients	B-PERCIEVER
were	O
significantly	O
higher	O
than	O
those	O
in	O
pd	O
patients	B-PERCIEVER
p0001	O
but	O
lower	O
than	O
those	O
in	O
controls	O
p0001	O

at	O
the	O
cutoff	O
value	O
of	O
75	O
the	O
sniffin	O
sticks	O
clearly	O
differentiated	O
irbd	O
and	O
pd	O
patients	B-PERCIEVER
from	O
the	O
controls	O
and	O
the	O
brief	O
test	O
could	O
increase	O
the	O
specificity	O
in	O
diagnosing	O
pd	O

neither	O
the	O
sniffin	O
sticks	O
nor	O
the	O
brief	O
test	O
could	O
clearly	O
differentiate	O
pd	O
and	O
irbd	O
patients	B-PERCIEVER
from	O
each	O
other	O

conclusions	O
olfaction	O
is	O
more	O
impaired	O
in	O
pd	O
patients	B-PERCIEVER
than	O
in	O
irbd	O
patients	B-PERCIEVER
possibly	O
due	O
to	O
the	O
heterogeneity	O
of	O
irbd	O
patients	B-PERCIEVER

the	O
sniffin	O
sticks	O
could	O
be	O
a	O
useful	O
tool	O
for	O
differentiating	O
irbd	O
patients	B-PERCIEVER
from	O
the	O
healthy	O
population	O
and	O
it	O
could	O
be	O
useful	O
for	O
screening	O
people	O
at	O
highrisk	O
of	O
pd	O
in	O
china	O
especially	O
when	O
combined	O
with	O
polysomnography	O

to	O
reduce	O
the	O
expense	O
and	O
time	O
required	O
for	O
the	O
sniffin	O
sticks	O
test	O
this	O
study	O
shows	O
that	O
a	O
brief	O
test	O
is	O
feasible	O

antioxidant	O
and	O
inflammatory	O
biomarkers	O
for	O
the	O
identification	O
of	O
prodromal	O
parkinsons	O
disease	O

objectives	O
we	O
explored	O
the	O
role	O
of	O
oxidative	O
stress	O
and	O
inflammatory	O
molecules	O
as	O
potential	O
parkinson	O
pd	O
biomarkers	O
and	O
correlated	O
biological	O
with	O
nonmotor	O
abnormalities	O
olfactory	O
impairment	O
and	O
dysautonomia	O
in	O
patients	B-PERCIEVER
with	O
idiopathic	O
rem	O
behavior	O
disorder	O
irbd	O
prodromal	O
pd	O
and	O
established	O
pd	O

methods	O
we	O
recruited	O
11	O
irbd	O
and	O
15	O
patients	B-PERCIEVER
with	O
idiopathic	O
pd	O
hohenyahr	O
13	O
on	O
ldopa	O
and	O
dopamine	O
agonists	O
combination	O
therapy	O
and	O
12	O
age	O
and	O
sexmatched	O
controls	O
ctrl	O

we	O
measured	O
total	O
olfactory	O
score	O
tos	O
autonomic	O
function	O
deep	O
breathing	O
db	O
lying	O
to	O
standing	O
ls	O
and	O
valsalva	O
manoeuvre	O
vm	O
ratios	O
blood	O
reduced	O
glutathione	O
brgsh	O
oxidative	O
stress	O
and	O
inflammatory	O
markers	O
neopterin	O

results	O
anosmia	B-OLFACTORY
was	O
similarly	O
prevalent	O
in	O
irbd	O
36	O
and	O
pd	O
33	O
patients	B-PERCIEVER
but	O
absent	O
in	O
ctrl	O

orthostatic	O
hypotension	O
was	O
more	O
common	O
among	O
irbd	O
73	O
and	O
pd	O
60	O
than	O
in	O
ctrl	O
25	O

by	O
univariable	O
ordinal	O
logistic	O
regression	O
tos	O
brgsh	O
ls	O
and	O
vm	O
ratio	O
worsened	O
from	O
ctrl	O
to	O
irbd	O
and	O
pd	O
groups	O

only	O
reduced	O
brgsh	O
levels	O
p0037	O
or0994	O
95ci	O
09881000	O
were	O
independently	O
associated	O
to	O
pd	O

tos	O
correlated	O
with	O
brgsh	O
r034	O
p0037	O
vm	O
ratio	O
r043	O
p0015	O
and	O
neopterin	O
rho039	O
p0016	O

conclusions	O
reduced	O
systemic	O
antioxidant	O
capacity	O
is	O
found	O
in	O
prodromal	O
and	O
overt	O
pd	O
and	O
may	O
represent	O
in	O
association	O
with	O
olfactory	O
loss	O
and	O
cardiovascular	O
dysautonomia	O
a	O
useful	O
biomarker	O
for	O
an	O
integrative	O
early	O
diagnosis	O
of	O
pd	O

inability	O
to	O
smell	O
peppermint	B-SMELL_SOURCE
is	O
related	O
to	O
cognitive	O
decline	O
a	O
prospective	O
communitybased	O
study	O

background	O
a	O
few	O
studies	O
have	O
demonstrated	O
the	O
association	O
of	O
poorer	O
olfactory	O
identification	O
oi	O
with	O
poorer	O
cognition	O
in	O
populationbased	O
cohorts	O

none	O
of	O
them	O
considered	O
the	O
outcome	O
associated	O
with	O
the	O
inability	O
to	O
smell	O
a	O
certain	O
odor	O

objective	O
to	O
verify	O
the	O
hypothesis	O
that	O
at	O
least	O
one	O
specific	O
odor	O
is	O
associated	O
with	O
incident	O
cognitive	O
decline	O
among	O
older	O
adults	O

methods	O
in	O
the	O
shanghai	O
aging	O
study	O
a	O
subcohort	O
of	O
948	O
dementiafree	O
participants	B-PERCIEVER
who	O
had	O
baseline	O
oi	O
measurements	O
were	O
prospectively	O
followed	O
for	O
5	O
years	O

results	O
an	O
inability	O
to	O
smell	O
peppermint	B-SMELL_SOURCE
beta	O
044	O
p	O
0001	O
rose	O
beta	O
014	O
p	O
0040	O
or	O
coffee	O
beta	O
037	O
p	O
0002	O
was	O
inversely	O
related	O
to	O
the	O
annual	O
rate	O
of	O
change	O
in	O
the	O
mini	O
mental	O
state	O
examination	O
score	O
and	O
an	O
inability	O
to	O
smell	O
peppermint	B-SMELL_SOURCE
was	O
associated	O
with	O
a	O
higher	O
risk	O
for	O
incident	O
dementia	B-NEURODEGENERATIVE
hazard	O
ratio	O
267	O
95	O
ci	O
144496	O
after	O
adjustment	O
for	O
confounders	O

conclusion	O
our	O
study	O
suggests	O
that	O
some	O
odors	O
especially	O
peppermint	B-SMELL_SOURCE
might	O
be	O
considered	O
as	O
a	O
potential	O
predictor	O
for	O
dementia	B-NEURODEGENERATIVE
in	O
older	O
populations	O

olfactory	O
meningiomas	O

the	O
missed	O
diagnosis	O

olfactory	O
meningiomas	O
are	O
benign	O
slowgrowing	O
intracranial	O
tumors	O
arising	O
from	O
the	O
dura	O
along	O
the	O
cribriform	O
plate	O

the	O
first	O
clinical	O
symptom	O
is	O
anosmia	B-OLFACTORY
followed	O
usually	O
after	O
several	O
years	O
by	O
dementia	B-NEURODEGENERATIVE
and	O
visual	O
deterioration	O

a	O
series	O
of	O
36	O
patients	B-PERCIEVER
are	O
presented	O
in	O
all	O
cases	O
but	O
one	O
their	O
conditions	O
were	O
diagnosed	O
late	O
and	O
not	O
until	O
the	O
tumor	O
had	O
reached	O
a	O
very	O
large	O
size	O

by	O
the	O
time	O
the	O
proper	O
diagnosis	O
was	O
made	O
and	O
the	O
tumors	O
were	O
surgically	O
removed	O
mental	O
or	O
visual	O
disability	O
was	O
often	O
irreversible	O

conditions	O
of	O
patients	B-PERCIEVER
initially	O
seen	O
with	O
anosmia	B-OLFACTORY
should	O
be	O
investigated	O
by	O
presently	O
available	O
noninvasive	O
diagnostic	O
methods	O
including	O
computed	O
tomographic	O
scanning	O

impairment	O
of	O
odor	O
recognition	O
in	O
myotonic	O
dystrophy	O
type	O
1	O

there	O
is	O
evidence	O
that	O
impaired	O
human	B-PERCIEVER
cognitive	O
abilities	O
are	O
reflected	O
in	O
loss	O
of	O
olfactory	O
abilities	O

declining	O
olfactory	O
perception	O
may	O
be	O
a	O
biomarker	O
for	O
impairment	O
of	O
cognitive	O
function	O
and	O
of	O
impending	O
illnesses	O
in	O
neurodegenerative	O
disorders	O
such	O
as	O
parkinsons	O
disease	O
pd	O
and	O
alzheimers	O
disease	O
ad	B-NEURODEGENERATIVE

previously	O
we	O
reported	O
that	O
patients	B-PERCIEVER
with	O
myotonic	O
dystrophy	O
type	O
1	O
dm	O
1	O
had	O
lower	O
sensitivity	O
to	O
emotional	O
facial	O
expressions	O
as	O
well	O
as	O
abnormal	O
olfactory	O
threshold	O
or	O
recognition	O
level	O

in	O
dm	O
1	O
pathological	O
studies	O
have	O
reported	O
neurofibrillary	O
tangles	O
in	O
several	O
temporal	O
areas	O
including	O
the	O
entorhinal	O
cortex	O
ent	O
hippocampus	O
hi	O
and	O
the	O
amygdala	O

we	O
observed	O
that	O
patients	B-PERCIEVER
with	O
dm	O
1	O
showed	O
signal	O
abnormalities	O
in	O
the	O
olfactory	O
limbic	O
areas	O
on	O
magnetic	O
resonance	O
imaging	O

our	O
findings	O
underscore	O
the	O
need	O
to	O
pay	O
careful	O
attention	O
to	O
significant	O
decreases	O
in	O
odor	O
identification	O
abilities	O
caused	O
by	O
diverse	O
forms	O
of	O
abnormal	O
brain	O
function	O
especially	O
in	O
the	O
amg	O
ent	O
and	O
hi	O

impaired	O
olfaction	O
is	O
associated	O
with	O
cognitive	O
decline	O
and	O
neurodegeneration	O
in	O
the	O
brain	O

objective	O
we	O
aimed	O
to	O
examine	O
whether	O
impaired	O
olfaction	O
is	O
associated	O
with	O
cognitive	O
decline	O
and	O
indicators	O
of	O
neurodegeneration	O
in	O
the	O
brain	O
of	O
dementiafree	O
older	O
adults	O

methods	O
within	O
the	O
rush	O
memory	O
and	O
aging	O
project	O
380	O
dementiafree	O
participants	B-PERCIEVER
mean	O
age	O
78	O
years	O
were	O
followed	O
for	O
up	O
to	O
15	O
years	O
and	O
underwent	O
mri	O
scans	O

olfactory	O
function	O
was	O
assessed	O
using	O
the	O
brief	O
smell	O
identification	O
test	O
bsit	B-SMELL_TEST
at	O
baseline	O
and	O
categorized	O
as	O
anosmia	B-OLFACTORY
bsit	B-SMELL_TEST
6	O
hyposmia	B-OLFACTORY
bsit	B-SMELL_TEST
610	O
in	O
men	B-PERCIEVER
and	O
61025	O
in	O
women	B-PERCIEVER
and	O
normal	O
bsit	B-SMELL_TEST
102512	O
in	O
men	B-PERCIEVER
and	O
10512	O
in	O
women	B-PERCIEVER

cognitive	O
function	O
was	O
annually	O
assessed	O
with	O
a	O
battery	O
of	O
21	O
tests	O
from	O
which	O
composite	O
scores	O
were	O
derived	O

structural	O
total	O
and	O
regional	O
brain	O
volumes	O
were	O
estimated	O

data	O
were	O
analyzed	O
using	O
linear	O
regression	O
and	O
mixedeffects	O
models	O

results	O
at	O
study	O
entry	O
138	O
363	O
had	O
normal	O
olfactory	O
function	O
213	O
561	O
had	O
hyposmia	B-OLFACTORY
and	O
29	O
76	O
had	O
anosmia	B-OLFACTORY

in	O
multiadjusted	O
mixedeffects	O
models	O
hyposmia	B-OLFACTORY
beta	O
003	O
95	O
confidence	O
interval	O
ci	O
005	O
to	O
002	O
and	O
anosmia	B-OLFACTORY
beta	O
013	O
95	O
ci	O
016	O
to	O
009	O
were	O
associated	O
with	O
faster	O
rate	O
of	O
cognitive	O
decline	O
compared	O
to	O
normal	O
olfaction	O

on	O
mri	O
impaired	O
olfaction	O
hyposmia	B-OLFACTORY
or	O
anosmia	B-OLFACTORY
was	O
related	O
to	O
smaller	O
volumes	O
of	O
the	O
hippocampus	O
beta	O
019	O
95	O
ci	O
033	O
to	O
005	O
and	O
in	O
the	O
entorhinal	O
beta	O
016	O
95	O
ci	O
024	O
to	O
008	O
fusiform	O
beta	O
045	O
95	O
ci	O
078	O
to	O
014	O
and	O
middle	O
temporal	O
beta	O
038	O
95	O
ci	O
072	O
to	O
001	O
cortices	O

conclusion	O
impaired	O
olfaction	O
predicts	O
faster	O
cognitive	O
decline	O
and	O
might	O
indicate	O
neurodegeneration	O
in	O
the	O
brain	O
among	O
dementiafree	O
older	O
adults	O

selective	O
cognitive	O
and	O
psychiatric	O
manifestations	O
in	O
wolfram	O
syndrome	O

background	O
wolfram	O
syndrome	O
wfs	O
is	O
known	O
to	O
involve	O
diabetes	O
mellitus	O
diabetes	O
insipidus	O
optic	O
nerve	O
atrophy	O
vision	O
loss	O
hearing	O
impairment	O
motor	O
abnormalities	O
and	O
neurodegeneration	O
but	O
has	O
been	O
less	O
clearly	O
linked	O
to	O
cognitive	O
sleep	O
and	O
psychiatric	O
abnormalities	O

we	O
sought	O
to	O
determine	O
whether	O
these	O
abnormalities	O
are	O
present	O
in	O
children	O
adolescents	O
and	O
young	O
adults	O
with	O
wfs	O
compared	O
to	O
age	O
and	O
gendermatched	O
individuals	O
with	O
and	O
without	O
type	O
1	O
diabetes	O
using	O
standardized	O
measures	O

methods	O
individuals	O
with	O
geneticallyconfirmed	O
wfs	O
n	O
19	O
ages	O
727	O
were	O
compared	O
to	O
age	O
and	O
gender	O
equivalent	O
groups	O
of	O
individuals	O
with	O
type	O
1	O
diabetes	O
t1dm	O
n	O
25	O
and	O
nondiabetic	O
healthy	O
controls	O
hc	O
n	O
25	O

cognitive	O
performance	O
across	O
multiple	O
domains	O
verbal	O
intelligence	O
spatial	O
reasoning	O
memory	O
attention	O
smell	O
identification	O
was	O
assessed	O
using	O
standardized	O
tests	O

standardized	O
self	O
and	O
parentreport	O
questionnaires	O
on	O
psychiatric	O
symptoms	O
and	O
sleep	O
disturbances	O
were	O
acquired	O
from	O
all	O
groups	O
and	O
an	O
unstructured	O
psychiatric	O
interview	O
was	O
performed	O
within	O
only	O
the	O
wfs	O
group	O

results	O
the	O
three	O
groups	O
were	O
similar	O
demographically	O
age	O
gender	O
ethnicity	O
parental	O
iq	O

wfs	O
and	O
t1dm	O
had	O
similar	O
duration	O
of	O
diabetes	O
but	O
t1dm	O
had	O
higher	O
hba1c	O
levels	O
than	O
wfs	O
and	O
as	O
expected	O
both	O
groups	O
had	O
higher	O
levels	O
than	O
hc	O

the	O
wfs	O
group	O
was	O
impaired	O
on	O
smell	O
identification	O
and	O
reported	O
sleep	O
quality	O
but	O
was	O
not	O
impaired	O
in	O
any	O
other	O
cognitive	O
or	O
selfreported	O
psychiatric	O
domain	O

in	O
fact	O
the	O
wfs	O
group	O
performed	O
better	O
than	O
the	O
other	O
two	O
groups	O
on	O
selected	O
memory	O
and	O
attention	O
tasks	O

however	O
based	O
upon	O
a	O
clinical	O
evaluation	O
of	O
only	O
wfs	O
patients	B-PERCIEVER
we	O
found	O
that	O
psychiatric	O
and	O
behavioral	O
problems	O
were	O
present	O
and	O
consisted	O
primarily	O
of	O
anxiety	O
and	O
hypersomnolence	O

conclusions	O
this	O
study	O
found	O
that	O
cognitive	O
performance	O
and	O
psychological	O
health	O
were	O
relatively	O
preserved	O
wfs	O
patients	B-PERCIEVER
while	O
smell	O
and	O
sleep	O
abnormalities	O
manifested	O
in	O
many	O
of	O
the	O
wfs	O
patients	B-PERCIEVER

these	O
findings	O
contradict	O
past	O
case	O
and	O
retrospective	O
reports	O
indicating	O
significant	O
cognitive	O
and	O
psychiatric	O
impairment	O
in	O
wfs	O

while	O
many	O
of	O
these	O
patients	B-PERCIEVER
were	O
diagnosed	O
with	O
anxiety	O
and	O
hypersomnolence	O
selfreported	O
measures	O
of	O
psychiatric	O
symptoms	O
indicated	O
that	O
the	O
symptoms	O
were	O
not	O
of	O
grave	O
concern	O
to	O
the	O
patients	B-PERCIEVER

it	O
may	O
be	O
that	O
cognitive	O
and	O
psychiatric	O
issues	O
become	O
more	O
prominent	O
later	O
in	O
life	O
andor	O
in	O
later	O
stages	O
of	O
the	O
disease	O
but	O
this	O
requires	O
standardized	O
assessment	O
and	O
larger	O
samples	O
to	O
determine	O

in	O
the	O
relatively	O
early	O
stages	O
of	O
wfs	O
smell	O
and	O
sleeprelated	O
symptoms	O
may	O
be	O
useful	O
biomarkers	O
of	O
disease	O
and	O
should	O
be	O
monitored	O
longitudinally	O
to	O
determine	O
if	O
they	O
are	O
good	O
markers	O
of	O
progression	O
as	O
well	O

trial	O
registration	O
current	O
clinicaltrialsgov	O
trial	O
nct02455414	O

is	O
olfactory	O
impairment	O
associated	O
with	O
10year	O
mortality	O
mediating	O
by	O
neurodegenerative	O
diseases	O
in	O
older	O
adults	O

the	O
fourway	O
decomposition	O
analysis	O

background	O
literature	O
shows	O
that	O
olfactory	O
impairment	O
oi	O
is	O
associated	O
not	O
only	O
with	O
neurodegenerative	O
diseases	O
ndds	O
but	O
also	O
with	O
increased	O
mortality	O

in	O
this	O
study	O
we	O
analyzed	O
data	O
collected	O
from	O
the	O
prospective	O
phase	O
of	O
the	O
10year	O
followup	O
of	O
the	O
shanghai	O
aging	O
study	O
sas	O
to	O
explore	O
the	O
mediation	O
effect	O
of	O
ndds	O
on	O
the	O
oimortality	O
relationship	O

methods	O
we	O
analyzed	O
data	O
collected	O
from	O
the	O
prospective	O
phase	O
of	O
the	O
10year	O
followup	O
of	O
the	O
sas	O

we	O
included	O
1811	O
participants	B-PERCIEVER
aged	O
60	O
years	O
or	O
older	O
who	O
completed	O
both	O
an	O
olfactory	O
identification	O
test	O
and	O
a	O
cognitive	O
assessment	O
at	O
baseline	O
20102011	O

survival	O
status	O
of	O
the	O
participants	B-PERCIEVER
from	O
baseline	O
to	O
december	O
31	O
2019	O
was	O
obtained	O
from	O
the	O
local	O
mortality	O
surveillance	O
system	O

we	O
used	O
the	O
fourway	O
decomposition	O
method	O
to	O
attribute	O
effects	O
to	O
interaction	O
and	O
mediation	O
and	O
to	O
explore	O
the	O
mediation	O
effect	O
of	O
ndds	O
on	O
the	O
oimortality	O
relationship	O

results	O
the	O
fourway	O
decomposition	O
method	O
revealed	O
a	O
statistically	O
significant	O
association	O
of	O
oi	O
with	O
death	O

overall	O
43	O
higher	O
risk	O
for	O
death	O
was	O
associated	O
with	O
oi	O
excess	O
relative	O
risk	O
err	O
043	O
95	O
ci	O
006080	O
p	O
0023	O

excluding	O
the	O
mediation	O
from	O
ndds	O
and	O
interaction	O
between	O
oi	O
and	O
ndds	O
the	O
controlled	O
direct	O
effect	O
of	O
oi	O
on	O
death	O
was	O
even	O
higher	O
in	O
ndds	O
participants	B-PERCIEVER
with	O
an	O
err	O
of	O
77	O
95	O
ci	O
000155	O
p	O
0050	O

statistically	O
significant	O
association	O
was	O
found	O
for	O
failure	O
to	O
identify	O
coffee	O
err	O
077	O
95	O
ci	O
018136	O
p	O
0010	O
and	O
marginally	O
significant	O
associations	O
were	O
found	O
for	O
failure	O
to	O
identify	O
cinnamon	O
err	O
033	O
95	O
ci	O
002068	O
p	O
0068	O
and	O
rose	O
err	O
033	O
95	O
ci	O
001067	O
p	O
0054	O
with	O
death	O

conclusion	O
oi	O
was	O
associated	O
with	O
the	O
longterm	O
mortality	O
in	O
older	O
adults	O
and	O
the	O
association	O
was	O
even	O
stronger	O
in	O
those	O
with	O
ndds	O

failure	O
to	O
identify	O
coffee	O
or	O
rose	O
was	O
associated	O
with	O
a	O
higher	O
mortality	O
risk	O
and	O
the	O
association	O
was	O
mediated	O
by	O
ndds	O

